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ABSTRACT 
 Polycylic aromatic hydrocarbons (PAHs) are a group of chemically-related 
compounds with a well-established body of evidence of adverse human health impacts. 
Additionally, there is a growing area of research on the health outcomes following PAH 
exposure via air pollution, specifically with chronic obstructive pulmonary disorder 
(COPD) and lung cancer. The purpose of this dissertation was to investigate the strength 
of associations among PAHs, COPD, and lung cancer from ambient (outdoor) air 
pollution. The first objective was to determine if there is a potential environmental link 
among PAHs, COPD, and lung cancer occurrence among nonsmokers using data from 
the National Health and Nutrition Examination Survey (NHANES). The second objective 
was to test the hypothesis that a significant association exists among PAHs, COPD, and 
lung cancer deaths in South Carolina (SC) using the National Air Toxics Assessment 
(NATA) models developed by the Environmental Protection Agency (EPA). The third 
and final objective of this research was to utilize the models developed in the previous 
objective and apply it to a large metropolitan context to determine if the same or similar 
associations with COPD and lung cancer deaths were observed. New York City was 
selected as the jurisdiction for this section of the research due to its context of a probable 
interface with a dense population and a variety of known air pollution sources i.e. the port 
of NY/NJ.  
 For the first objective, PAHs were not statistically significant (p=0.4828) in their 
association with COPD occurrence among non-smoking respondents after adjusting
vii 
for known confounders i.e. age, secondhand smoke exposure, former smokers, BMI, etc. 
The results investigating the strength of association between PAHs and lung cancer 
among nonsmokers were unreliable due to the small sample size of lung cancer 
respondents (n=37) in the NHANES dataset and are not included.  
For the second objective, PAHs were significantly associated with COPD deaths 
(p=0.0094 to p<0.0001) at the census tract level in SC, while adjusting for known 
confounders i.e. demographic compositions, smoking prevalence, obesity prevalence, 
primary care provider rates, etc. Additionally, the point estimates for PAHs were 
indicated in the positive direction for each COPD model. Interpreting the rate ratio 
observed from the respective model estimates for PAHs (β=0.1352 to β=0.243) would be 
as follows: for every log unit increase of PAHs in SC, the rate of deaths due to COPD 
increased by 14% to 24% across all models. The lung cancer death model for SC did not 
reveal statistically significant results for PAHs (p=0.0997 to p=0.7776).  
The results for the third objective for New York City were mixed. For both COPD 
and lung cancer death models, there were statistically significant associations with PAHs 
at the census tract level (p<0.0001to p=0.04), however not across all years. Furthermore, 
point estimates for each set of models were also indicated in both positive and negative 
directions.  
In conclusion, taking into account each of the confounders included in the 
analysis for the COPD death model in SC specifically, there are implications for air 
pollution remediation across the state. Additional study is warranted investigating a 
morbidity model using data such as hospitalizations from acute exacerbations of COPD 
(as well as lung cancer or other respiratory-related illnesses, i.e. asthma) and 
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investigating their associations with PAHs at the census tract level. A death model 
includes a longer period of time between dose and response which could be mitigated 
with a morbidity model. Next, other biomarkers for air pollutants, i.e. particulate matter 
<2.5um (PM2.5), are worthy of investigation among the NHANES laboratory sample to 
test for significance with COPD, lung cancer and other known adverse health outcomes 
from pollution. Finally, investigation into environmental justice issues are warranted in 
regards to more localized analyses of PAH exposure and adverse health outcomes among 
populations who reside most proximate to known pollution sources i.e. the neck 
communities of Charleston, SC.  
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CHAPTER 1 
INTRODUCTION 
Overview 
PAHs are a group of chemical compounds that are mostly colorless and made up 
of several hundred related compounds of various sizes and toxicity. They are 
environmentally ubiquitous and identified as persistent organic pollutants (POPs) with 
documented bio-accumulation in numerous flora and fauna (Nadal et al., 2015). Sources 
of PAHs include motor vehicle exhaust, tobacco smoke, coal production, biomass 
burning, or from any context in which organic carbon is being combusted. PAHs bound 
to particulate matter (PM) are of increased importance for ambient (outdoor) air quality, 
especially in regards to the adverse health outcomes linked to PM (Hayakawa et al., 
2017). Additionally, PAHs were one of the first atmospheric pollutants labelled as a 
suspected human carcinogen (Kim et al. 2013). 
Among the associations of PAHs, COPD, and lung cancer, exists is a budding 
area of research when it comes to PAH exposures and direct COPD outcomes. While, the 
scientific literature assessing PAHs and lung cancer is well established (Moorthy et al., 
2015). Additionally, few studies have been devoted to the relationship of all three in the 
context of ambient air pollution and its adverse health effects (Marino et al., 2015; Pauk 
et al., 2013).
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Globally, COPD kills over 3 million people each year (Rabe & Watz, 2017) and 
was the third leading cause of death in 2010 (Burney et al., 2015). According to the 
World Health Organization (WHO), COPD is predicted to be the fifth leading cause of 
disability in the world by 2020 (Viegi et al., 2006). Individuals with COPD have twice 
the risk of developing cancer in the lung (Young et al., 2015), where lung cancer is 
frequently diagnosed as a comorbidity (Schroedl & Kalhan, 2012). The links between 
smoking, lung cancer, and COPD are highly documented, however recent studies have 
demonstrated that some 25 percent of COPD patients are non-smokers and its burden 
among non-smokers is likely underestimated (Zeng et al., 2012). Furthermore, estimates 
of lung cancer deaths in the U.S. among never smokers ranged from 16,000 to 24,000, 
equaling about 10 to 15 percent of total lung cancer deaths (Samet et al., 2009). 
Both acute and chronic exposures to air pollution have been associated with 
COPD death and incidence around the world at levels below air quality guidelines (Liu et 
al., 2016). Impacts from air pollution on COPD are numerous in the scientific literature 
and have been specifically documented in their association with PM, however a small but 
growing number of them have isolated PAHs in their respective mechanisms for 
pathogenesis, and even fewer have isolated how the additional presence of lung cancer 
adds to the overall pathogenic potential (Li et al., 2016, Hamra et al., 2014). The precise 
elements of PM and their associated pathogenesis with COPD were inconclusive prior to 
the work of (Yang et al., 2017a) where the link between PAHs and COPD is of increasing 
importance for investigation vis-a-vis Yang’s proposed biological mechanism and 
pathway. This mechanism and pathway provide promising evidence for the etiology and 
pathogenesis of COPD from PAH exposure. Since this mechanism has significant overlap 
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with lung cancer pathogenesis, its comorbidity with COPD is of increasing interest as 
well. 
Specifically, the impact to public health from PAHs in South Carolina is a salient 
investigation as the city of Charleston, the SC Port Authority, and other relevant 
stakeholders across the state, plan and implement the expansion of the city’s harbor. 
Activities for expansion include dredging to deepen the harbor for greater capacity to 
handle massive container ships traveling from the recently expanded Panama Canal as 
well as a new container terminal in the former Navy base in North Charleston. Dredging 
was set to begin late 2017 and completed by 2020 when the container terminal is set to 
open. Impact assessments and preliminary evaluations have been completed i.e. 
Kimbrough et al. (2015), however an investigation into how PAHs could have both a 
short and long term impact on health in an urban context like Charleston will offer 
greater understanding of the burden to public health with a future that has significant 
increases to air pollution sources.  
 
Specific Aims 
The overall goal of this research was to investigate PAH concentrations from 
ambient air pollution and associations with COPD morbidity and mortality as well as 
lung cancer morbidity and mortality. The focus of the literature review was to provide a 
proof of concept and an evidence base for COPD and lung cancer associations from 
PAHs alone. Additional health outcomes (i.e. heart disease and stroke) could be 
addressed to understand the extent of the public health burden caused by PAHs, however 
this is beyond the scope of the study.    
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The literature review focused on PAHs, their emission sources, known 
transportation routes and fate, and various health impacts. Additionally, a review of the 
current literature was provided on COPD burden, pathogenesis following PAH exposure, 
and relevant environmental-epidemiological studies. Finally, the primary findings from 
the literature of lung cancer comorbidity with COPD from outdoor air pollution exposure 
were summarized in addition to identifying the similarities of their etiopathogenesis.  
Chapter two is a cross-sectional analysis of the association of PAH metabolites 
and the presence of COPD and lung cancer using National Health and Nutrition 
Examination Survey (NHANES) laboratory, examination, and questionnaire data. The 
analytical approach taken was modeled after Shiue (2016) where emphysema, chronic 
bronchitis, and asthma were measured in strength of association with PAH metabolites 
using NHANES data. Additionally, the work of Tilert et al. (2013) used spirometry 
readings from NHANES to determine COPD diagnoses as well as a national COPD 
prevalence estimate. Lastly, a study by Mannino et al., (2003) investigated the association 
between low lung function (spirometry-confirmed COPD) alongside lung cancer 
incidence using NHANES data as well. Essentially, the primary elements mentioned in 
the three studies above (PAH associations, spirometry-confirmed COPD, and lung cancer 
comorbidity) have not been studied altogether with NHANES data. Thus, PAH 
associations with spirometry-confirmed COPD, along with an investigation into 
associations of lung cancer, provide the rationale for chapter two’s contribution to the 
environmental epidemiological literature for PAHs.  
The primary goal of chapter two was to determine whether there is an association 
of PAH levels and spirometry-confirmed COPD as well as lung cancer occurrence from a 
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national perspective as a means to isolate a potential environmental etiology distinct from 
tobacco smoke. Null hypothesis: There is no significant association between PAH levels 
and spirometry-confirmed COPD and lung cancer co-occurrence among non-smokers.  
To investigate this association further, estimates of COPD-lung cancer mortality 
attributable to PAHs in ambient air pollution were assessed. Chapters three and four 
investigated outdoor air quality in two U.S. jurisdictions (the state of South Carolina and 
New York City (NYC)) and the corresponding associations with COPD and lung cancer 
mortality. Investigating South Carolina as a whole provides a logical step following 
chapter two’s NHANES analysis to provide a state-based study of PAHs and COPD-lung 
cancer associations. The rationale for choosing NYC in chapter four’s study was the 
increased amount of transportation and corresponding likelihood of air pollution exposure 
that its port provides. The contribution of motor vehicle exhaust from land and water 
transport in an area that is a significant population center delineates a study area with a 
probable interface between humans and air pollution, specifically PAHs (Rosenbaum et 
al., 2011; Sharma, 2006; Smailys et al., 2007). Additionally, the expansion of the port in 
Charleston made this a worthy study area for improved means of understanding the 
projected burden to public health.  
Thus, chapter three was a state-wide perspective of the health burden from PAHs 
in outdoor air using SC as the study area. Mortality data for COPD and lung cancer were 
acquired from the SC Department of Health and Environmental Control’s Office of Vital 
Statistics (DHEC VS) in five year aggregates between 2002 and 2014. Demographic and 
other relevant confounding variables were acquired from various sources. The full list of 
covariates from the DHEC VS dataset (as well as additional socio-economic and 
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environmental variables) is included in chapter three’s methods. Also, included in the 
methods is the rationale for the identified covariates with supporting literature. Air 
quality data for PAH exposure concentrations was acquired from the U.S. Environmental 
Protection Agency’s (EPA) National Air Toxics Assessment (NATA) dataset that 
provides census track level PAH exposure estimates for years 2002, 2005 and 2014. A 
Poisson regression analysis was carried out to develop two predictive models that 
estimated 1) the proportion of COPD deaths given the amount of PAH exposure 
concentrations in each census tract and 2) the proportion of lung cancer deaths given the 
amount of PAH exposure concentrations in each census tract. Null hypothesis: There is 
no significant association between NATA-derived PAH exposure concentrations and 
mortality from COPD and lung cancer at the census tract level in the state of South 
Carolina. 
Similarly, chapter four investigated the outdoor air quality of PAHs in NYC and 
its associations with COPD and lung cancer mortality. The model developed in chapter 
three was applied in this urban setting to determine whether a significant burden exists in 
the context of increased exposures due to the area’s dense population and proximity to 
known point and non-point sources of PAH pollution such as in and around the port. The 
same dataset for air quality from NATA was used to assess exposures at the census tract 
level as in chapter three for the same years. Census tracts included in the analysis were 
those contained in the five counties that make up New York City – Bronx, Kings, New 
York, Queens, and Richmond counties. Deaths from COPD and lung cancer were 
acquired from New York City’s Vital Statistics Office for the corresponding years of 
available NATA data in five year aggregates between 2002 and 2014. Tests for 
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significance and association were analyzed using a Poisson regression analysis. Models 
were explored to determine the strength of associations to predict the proportion of deaths 
from COPD and lung cancer given the amount of PAH exposure concentrations in each 
census tract of NYC while adjusting for known confounders. Null hypothesis: There is 
no significant association between NATA-derived PAH exposure concentrations and 
mortality from COPD and lung cancer at the census tract level in NYC. 
 
Literature Review 
PAHs – Overview, Sources, Transport, and Fate 
Incomplete combustion of organic materials is characterized by an orange flame, 
while its counterpart of complete combustion is blue. Polycyclic aromatic hydrocarbons 
(PAHs) are organic pollutants resulting from incomplete organic carbon combustion. 
PAHs are arenes (most commonly occurring as benzene rings) and termed aromatic 
compounds since they consist of two or more fused rings (in addition to their aromatic 
quality). They exist in both gaseous and particle phases according to their volatility. 
Gaseous PAHs have a light molecular weight and have two or three aromatic rings, while 
those in the particle phase have a high molecular weight and consist of five or more rings. 
PAHs having three or four rings can occur in both phases (Abdel-Shafy & Mansour, 
2016). Within the various structural formations of PAHs, additional classifications can be 
carried out based on their melting point, vapor pressure, and water solubility. 
PAH sources are petrogenic (hydrocarbons associated with petroleum), pyrogenic 
(hydrocarbons associated with combustion of petroleum, wood, coal, tobacco, etc.), and 
biologic. Primary sources for PAHs typically result from anthropogenic activity such as 
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tobacco smoke, motor vehicle exhaust, residential heating, coal gasification and 
liquefying plants, carbon black, coal-tar pitch and asphalt production, coke and aluminum 
production, as well as catalytic cracking towers and related activities in petroleum 
refineries (Abdel-Shafy & Mansour, 2016). Natural or non-anthropogenic sources for 
PAHs are formed during various biological processes and in other combustion contexts 
such as wildfires and volcanic activity.  
 Lee and Vu (2010) divide PAH emissions into four classes: stationary sources, 
mobile emissions, agricultural activities, and natural sources. Stationary sources include 
both domestic and industrial emissions including biomass burning in the home for 
cooking and heating, as well as gas, oil, and coal burning through much of the 
anthropogenic activities listed above. Additional industrial sources include pyrolysis of 
municipal, medical, and industrial wastes, among other organic-waste materials i.e. 
garbage, scrap tires, etc. (Chen et al., 2007, Lee, et al., 2003). Mobile emissions are 
summarized by those occurring from any vehicle including automobiles (and other motor 
vehicles i.e. motorbikes), trains, airplanes, and ships. Agricultural sources for PAH 
emissions are primarily those resulting from biomass burning such as burning 
brushwood, straw, etc. Finally, natural sources include burning from wildfires caused by 
lightning strikes, volcanic eruptions, and decaying organic matter.   
Long range PAH transmission through the environment takes place primarily 
through atmospheric transport. Various processes disperse PAHs through the air and 
move them through terrestrial and aquatic environments (Abdel-Shafy & Mansour, 
2016).  PAHs are affected by photodegradation as well as other forms of degradation as 
they can react with ambient pollutants such as ozone (O3), sulfur dioxide (SOX), and 
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nitrogen oxides (NOX), ultimately impacting their fate and condition (Lee and Vu, 2010). 
Additionally, the fate and transport of PAHs is determined by their particle and gaseous 
phases as they are partitioned in the atmosphere. This controls the exposure pathway that 
PAHs can enter the human body, among other biota. PAHs are removed from the 
atmosphere through wet and dry deposition processes, which is again, based on their 
original particle or gaseous phases. In this regard, atmospheric deposition is a primary 
source of PAH concentration in soil (Abdel-Shafy & Mansour, 2016). Since PAH 
persistence in the environment is moderate, bio-accumulation has been documented in 
fish, shellfish, and terrestrial vertebrates (Beyer et al., 2010).  
PAHs have been studied significantly as a component of air pollution (Fawole et 
al., 2016, Lewtas, 2007,  Baek et al., 1991). For example, PAHs sorbed to solid particles 
in the air was assessed by Huzlik et al. (2017) to determine their emission/pollution 
sources. The approach to analyzing PAH origins was based on several criteria. These 
included: the size and shape of compounds captured as solid particles; assessment of the 
physical and chemical properties of the captured solids; statistical methods whereby air 
pollutants were modeled based on their concentrations and sources and; measurement of 
certain characteristics in the chemical composition of contaminants attached to solid 
particles. Their findings revealed a significant seasonality to PAH concentrations in the 
air. Specifically, it was suggested that the use of heating stoves that burn organic fuels in 
the winter as well as atmospheric transport were the primary contributors to the PAH 
concentrations that were under investigation according to their specific ratios. 
Conversely, other PAH concentration ratios were observed during the summer months 
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where it was concluded that atmospheric transport alone was the contributor to air 
pollution. 
 Tanaka & Sakata (2002) sought to clarify the effect of photooxidation on two 
primary PAHs, benzo[a]pyrene (BaP), benzo[e]pyrene (BeP), and their respective 
isomers. According to the study, BaP and BeP had different photooxidation rates than 
their isomers. The results revealed that BaP concentrations were reduced by 
photooxidation while the delta(13)C isomer of BaP increased during ultraviolet 
irradiation experiments. Additionally, BeP was not photooxidized and had no change in 
its respective isomer. According to the results, the ratios of BaP/BeP with their respective 
isomers had similar levels during the winter than they had during the summer, in spite of 
photooxidation being less likely to occur during the colder and darker months. Thus, the 
findings support the explanation that BaP was photooxidized during long-range transport 
as it traveled from its sources from the Asian continent prior to reaching the islands of 
Japan, which was the study area.  
Numerous studies and several reviews have assessed the transport and fate of 
PAHs in aquatic environments (Reynaud & Deschaux, 2006; Cerniglia, 1992; Zhang et 
al., 2015). A riverine example, Boonyatumanond et al. (2006) collected sediment samples 
from various waterways in Thailand and analyzed them for PAH concentrations. They 
found concentrations rooted in both petrogenic and pyrogenic sources. Most petrogenic 
profiles of PAHs found were diffuse throughout the country, suggesting a single source 
of automobile contribution. Low levels of pyrogenic PAHs were frequently recorded in 
coastal areas of the Chao Phyara River, suggesting atmospheric transport throughout the 
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country. Mixed profiles of petro-pyrogenic PAHs were recorded as well in middle and 
lower levels of the Phyara River, its mouth, and in the upper Gulf of Thailand.  
In another aquatic study, Feng et al. (2007) analyzed PAH concentrations from 
the Wuhan region of the Yangtze River in China to determine potential sources as well as 
eco-toxicological effects. They found the average PAH concentration in suspended 
particulate matter (SPM) in the water was significantly higher than in the sediment. PAH 
profiles and their specific ratios indicated their primary source in the Yangtze was from 
coal and wood burning atmospheric deposition. PAH concentrations were above drinking 
water standards, however the study concluded that acute biologic effects were not caused 
by PAHs in the sedimentary environment of the Yangtze, although they may pose a 
potential toxic effect from chronic exposure.     
In addition to riverine systems, aquatic transport of PAHs is relevant with 
stormwater. Nielsen et al. (2015) assessed PAH concentrations in stormwater from 
highway runoff. Their rationale, as urbanization and anthropogenic activities increase, 
urban stormwater has turned into a pollution source for receiving waters. A primary 
challenge for stormwater pollution management is pollutants are typically combined with 
colloidal particles which are not effectively removed according to current pollution 
remedial solutions. The results from Nielsen et al. (2015) support this growing area of 
concern with findings such as 45 percent of the PAHs they analyzed in stormwater were 
present in colloidal and dissolved fractions, further demonstrating the persistent and 
ubiquitous quality of PAHs as pollutants.   
Highlighting other areas of PAH fate and transport throughout the environment 
include the pathway of food ingestion. Zelinkova & Wenzl (2015) reviewed 
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epidemiological findings of the occurrence of PAHs in food and the potential threat to 
human health from exposure to PAHs from ingestion. Contamination of food from PAHs 
can occur through the air, soil, water, as well as during cooking and food processing. One 
of the findings presented was a study by the European Scientific Committee on Food 
(SCF) in 2002 investigating the total intake of PAHs from food versus other pathways of 
exposure. They determined food ingestion was the primary source of PAH intake in their 
area of study, which corresponds to the International Association of Research on 
Cancer’s (IARC) major findings of carcinogenic potential of PAHs from ingestion, 
especially BaP (WHO & IARC, 2005).  
Health Effects of PAHs 
 Priority PAHs were determined by the U.S. Environmental Protection Agency 
(EPA) in 1976 to analyze the risks of drinking water on human health. A list of 16 
priority PAHs was developed, leading to a significant body of environmental studies on 
PAH impact and human health (Andersson & Achten, 2015; Keith, 2015). Appendix A 
lists the 16 priority PAHs developed by the EPA. The following section will summarize 
the primary findings of the health impacts of PAHs.  
The U.S. Department of Health and Human Services’ Agency for Toxic 
Substances and Disease Registry (ATSDR) released a public statement in 1995 providing 
an overview of the known health effects of PAHs (ATSDR, 1995b). ATSDR summarized 
the known animal studies demonstrating carcinogenic effects of PAHs as well as the 
human studies leading to cancer. The primary exposure routes of the identified studies 
were inhalation and dermal, which provides a counter-perspective to the SCF findings 
above, albeit one that was released almost seven years prior. Additional findings revealed 
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in the animal studies only, showed harmful effects in immune response and effects to the 
skin and body fluids from both short and long-term exposures (ATSDR, 1995b). These 
animal studies provided the biological basis for adverse health effects of PAHs in regards 
to skin and immune responses in humans. Additional human studies in these areas have 
followed and are mentioned below. 
A seminal review of the carcinogenic effects from PAHs was released by IARC in 
their 2010 monograph evaluating the human cancer risks from PAH exposure. Their 
overall evaluation of carcinogenic potential and strength of evidence for human 
carcinogenicity can be found elsewhere (World Health Organization, International 
Agency for Research on Cancer, 2010). A significant body of epidemiological findings 
was identified by IARC detailing sufficient evidence especially for occupational 
exposures in vocations such as coal gasification, coke production, coal-tar distillation, 
and chimney sweeps, among several others. Documented routes of exposure were 
primarily inhalation and dermal. 
A review of the specific carcinogenic effects of PAHs on the lung was provided 
by Moorthy et al. (2015). Specifically, lung cancer frequently results from excessive 
PAH exposure and is the leading cause of death from cancer for both men and women in 
the United States (Horn et al., 2012). With this focus, the review documented various 
pathways of carcinogenesis including induction of multiple metabolic enzymes via the 
aryl hydrocarbon receptor (AhR). After humans are exposed to PAHs, they can be 
metabolized and formed into carcinogens that lead to DNA adducts which can result in 
mutations, gene alteration, and tumor formation. These effects occur in certain 
demographics more than others, highlighting various susceptibilities among different 
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races/ethnicities, genders, and age groups (Timofeeva et al., 2010; Dong et al., 2012; 
Spitz et al., 2013).  
In addition to carcinogenic effects, other chronic and acute health effects can 
result from PAH exposure. Short term health impacts include eye and skin irritation, 
nausea and vomiting, as well as impaired lung function that can lead to effects on 
asthmatics and thrombosis (blood clots) in people with coronary heart disease (Unwin et 
al., 2006). Long term health effects have been demonstrated in a variety of studies with 
the most prominent findings focusing on occupational exposure (Kim et al., 2013). This 
is of interest for determining chronic health impacts of PAHs beyond cancer alone. 
ATSDR’s toxicological profile identifies PAHs as probable inducers of cataracts and can 
cause kidney and liver damage (ATSDR, 1995a). The inflammatory response to PAHs 
can lead to other forms of cardiopulmonary mortality over time as well (Kuo et al., 2003).  
As mentioned above, COPD effects from PAH exposure is a growing area of 
research. A significant body of this research has its origin in China as COPD is in its top 
five leading causes of death in addition to the increased exposure to air pollution present 
throughout the country (Fang et al., 2011). Although the essential components of PM2.5 
in COPD pathogenesis were previously inconclusive, Yang et al. (2017) provide a novel 
biological basis for their association. The authors’ proposed biological mechanism and 
pathway utilized PAHs bound to PM2.5, showing they were induced by severe oxidative 
stress leading to DNA damage, inflammatory response, and decreased gene expression. 
By this mechanism, risks of COPD were documented during haze events in China. 
Furthermore, it was determined the PAH component of PM2.5 extracts were the specific 
cause of these effects through the AhR pathway.  
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Finally, teratogenic effects have been documented following PAH exposure. 
Animal studies providing the basis for more recent investigation in humans on 
embryotoxic effects include Kristensen et al., (1995) and Wassenberg & Di Giulio 
(2004). Human studies such as those utilizing data from the U.S. Center for Children’s 
Environmental Health (CCEH), demonstrated the linkage between adverse health 
outcomes (i.e. low birthweight, preterm births, and delayed childhood development) with 
prenatal exposure to PAHs (Perera et al., 2005). Additional childhood-related outcomes 
from prenatal PAH exposure include associations with asthma, behavioral problems 
during middle childhood (e.g. ADHD), and low IQ around age three (Edwards et al., 
2010; Perera & Herbstman, 2011; Perera et al., 2014).  
History of PAH Toxicity 
 Andersson & Achten (2015) provide a detailed summary of the history of PAH 
toxicity as well as guidance for what is in store for future research with polycyclic 
aromatic compounds (PACs). From the early 1970’s when the EPA released their list of 
16 priority PAHs there has been targeted focus on this group to study and monitor in the 
environment. This list became the gold standard for overall PAH toxicity with BaP 
serving as the most potent among the PAH class and the most widely studied, especially 
for carcinogenesis. One of the arguments made by Andersson & Achten (2015) however, 
is the recent findings about the potency of other compounds such as dibenzo[a,l]pyrene, 
dibezo[a,i]pyrene and benzo[c]flourene, where they have a carcinogenic potential about 
10 to 20 times that of BaP (Greim, 2008). Thus, expansion to the suite of PAHs as 
priority compounds to consider in regulatory potential and research is warranted.  
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The efficiency of the 16 priority PAHs and their suitability for toxicological study in 
the environment must not be overlooked and revising the list of priority PAHs is not an 
easy undertaking, although there are known PAHs of greater toxicity. For example, in 
contaminated sites that have already undergone cleanup requiring significant investment, 
additional regulatory efforts around a new list of PAHs could invalidate genuine efforts 
from the past and in turn require additional resources. Still, the consensus among PAC 
researchers is the need to expand the list since it is now evident the list is too narrow.  
Air Quality Guidelines for PAHs 
 Guidelines for PAH concentrations in the air is of increasing relevance 
considering the arguments made above by Andersson & Achten (2015) as well as the 
increase in COPD associations with air pollution levels lower than various national and 
international guidelines (Liu et al., 2016).  
Indoor air quality guidelines for PAHs were established by the WHO in 2009 
(Choi et al., 2010). Citing primary epidemiological findings, again and mainly from 
occupational studies, thresholds for PAH exposure were classified according to their 
BaP-equivalence since lung cancer posed the most severe health risk from PAH exposure 
and BaP the most significant carcinogen documented in the epidemiological literature. 
Thus, the indoor air guideline for PAH compounds was estimated at 8.7 x 10-5 per ng/m3 
of BaP. Additionally, the lifetime cancer risk for a lifetime of exposure was generated at 
1/10,000, 1/100,000, and 1/1,000,000 to be 1.2, 0.12, and 0.012 ng/m3 respectively (Choi 
et al., 2010).   
According to the ATSDR, the Occupational Safety and Health Administration 
(OSHA) provides the regulatory guidelines for maximum PAH exposure in the 
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workplace for the U.S. The permissible exposure level (PEL) for PAHs are not 
substance-specific and are regulated primarily under OSHA’s air standards for coal tar 
pitch volatiles (CTPVs) and coke oven emissions (ATSDR, 2009). The PEL for PAHs 
according to OSHA for the workplace is 0.2 mg/m3. This is an eight hour time weighted 
average (TWA) measured from CTPVs. A separate standard exists for coke oven 
emissions (0.15 mg/m3). It is important to note that other federal agencies in the U.S. 
such as the EPA and the National Institute for Occupational Safety and Health (NIOSH) 
have suggested additional thresholds for safe PAH exposure. For example, NIOSH 
recommends the level of safe exposure for PAHs be classified at the lowest detectable 
concentration for CTPVs (0.1 mg/m3). For drinking water, the EPA classified a 
maximum contaminant level (MCL) for BaP specifically at 0.2 parts per billion (ppb). 
Additional MCLs for six other PAHs can be found elsewhere (ATSDR, 2009). 
According to the WHO, outdoor air quality guidelines for PAHs in Europe for 
example are not specifically recommended since many of the compounds are parts of 
complex mixtures. Some are significant carcinogens as they can react with other 
compounds and are attached to particles, i.e. PM. The general recommendation therefore 
from the WHO is that PAH concentrations in the ambient air should be kept as low as 
possible (World Health Organization, 2000). In regards to occupational exposures, the 
WHO refers to the same thresholds offered for indoor air guidelines for BaP (8.7 x 10-5 
per ng/m3). In spite of the limitations of using BaP alone to measure the carcinogenic 
potential of PAHs, the WHO emphasizes that carcinogenic potential will typically be 
underestimated. The advantage of a single indicator however is the opportunity that it 
affords to generate a baseline that is well documented in the literature. Furthermore, since 
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occupational thresholds for BaP are offered, there is evidence for similar risks identified 
from studies of individuals exposed to additional combinations of PAHs (World Health 
Organization, 2000).        
Finally, a review carried out by Liu et al. (2016) on the impacts of air quality 
guidelines on COPD sufferers investigated the short and long-term impacts from air 
pollution on COPD mortality and morbidity from a global perspective. Primary findings 
from the review revealed an association of outdoor air pollution with COPD morbidity 
and mortality including such impacts below air quality guidelines of various jurisdictions 
around the world. Causes for COPD deaths and other areas of morbidity still occur from 
increased levels of incidence in the overall population as well as from exacerbations. 
Thus, additional efforts to amend air quality guidelines are warranted.    
The Public Health Burden of COPD 
 Rabe & Watz (2017) provided a recent review of the epidemiology, causes, 
pathophysiology, comorbidities, and treatment options for COPD. They reported a range 
of global prevalence estimates. The range of results was due to a combination of data 
collection methods (spirometry measures vs. surveys). The most recent findings from the 
2015 Global Burden of Disease study estimated prevalence around 174 million cases 
(GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, 2016) while 
previous estimates from 2010 put global prevalence around 384 million cases when using 
spirometry collection techniques (Adeloye et al., 2015). Regional prevalence rates for 
COPD were reviewed as well. The Americas led with the highest rates at 15 percent in 
2010. Additional areas of increased burden of COPD include the regions where a 
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percentage increase was observed. These include the Americas again, Eastern 
Mediterranean, and Africa (Adeloye et al., 2015).  
COPD is typically underdiagnosed according to Rabe & Watz (2017). This is 
increasingly observed in non-smokers and patients who are younger, have lower 
education, and less severe forms of COPD (Bernd et al., 2015). From a global burden of 
disease perspective, COPD ranks third in the number of annual deaths when adjusted for 
age with around 3.2 million deaths per year (GBD 2015 Mortality and Causes of Death 
Collaborators, 2016). Although COPD is the third leading cause of death, it is often 
observed as a comorbidity with cardiovascular disease (ischemic heart disease and 
cerebrovascular disease are the first two global leading causes of death) where a third of 
the COPD patients die of cardiovascular diseases and a third have limited airflow 
(Anthonisen et al., 2005; Calverley et al., 2007; Franssen et al., 2016; Rabe & Watz, 
2017). Thus, attempts to acquire more accurate estimates of COPD burden are further 
underestimated due to the confluence of comorbidities. Approximately 90 percent of 
COPD deaths occur in low and middle-income countries where the exposure to biomass 
burning for cooking and heating is of increasing relevance from PAH exposure (World 
Health Organization, 2017a).  
COPD is observed more frequently in men than in women (Adeloye et al., 2015), 
however increases in smoking rates among women in various developed countries, as 
well as increases in exposure to biomass combustion in the home for heating and cooking 
have the potential to level out the effects of COPD in both genders (World Health 
Organization, 2017a). Rabe & Watz, (2017) also presented the conclusions from various 
studies that summarize the susceptibility of women to develop respiratory complications 
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such as airflow limitation, which ultimately increases the risk of COPD in women (Han 
et al., 2007; Luoto et al., 2016; Sørheim et al., 2010).  
Tobacco smoking is the primary cause of COPD worldwide with a global 
prevalence around 1.1 billion smokers in 2015 (World Health Organization, 2017b). As 
smoking rates continue to decline, other risk factors for COPD such as indoor and 
outdoor air pollution are increasingly salient (Rabe & Watz, 2017). Furthermore, Salvi & 
Barnes (2009) report that on a global scale more people are exposed to biomass fuel 
burning than they are tobacco smoke.  
An earlier review completed by Mannino & Buist (2007) identified COPD as a 
preventable and treatable disorder, however it is not fully reversible which makes it 
distinct from asthma. According to the GOLD guidelines, COPD is defined as the 
following: “a preventable and treatable disease with some significant extrapulmonary 
effects that may contribute to the severity in individual patients. Its pulmonary 
component is characterized by airflow limitation that is not fully reversible. The airflow 
limitation is usually progressive and associated with an abnormal inflammatory response 
of the lungs to noxious particles or gases”(GOLD, 2017). In regards to reversibility 
specifically, lung function does not fully reverse in response to bronchodilators, anti-
inflammatories, or by some other natural means (GOLD, 2017; Mannino & Buist, 2007).  
Classification of COPD should be made based on its severity and the specific 
characteristics of the individual i.e. genotype, risk factors, etc. Mannino & Buist (2007) 
depict COPD as a heterogeneous disorder with varying degrees of pathology, histories, 
and comorbidities from person to person. Additionally, they report it is a model “gene-
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by-environment disease” with presentations of comorbid complications, poor cellular 
repair, typical response to infections, and growing airway reactivity. 
 Mannino & Buist (2007) also point out that comorbid diseases with COPD can 
add to its prevalence and severity. A variety of diseases that should be considered in the 
differential diagnosis of COPD include asthma, congestive heart failure, bronchiectasis, 
tuberculosis, obliterative bronchiolitis, and diffuse panbronchiolitis (GOLD, 2017). An 
example offered at this point of the review comes from the Burden of Lung Disease 
(BOLD) study where COPD prevalence was assessed in 12 multinational sites. The issue 
related to comorbid diseases and such effects on prevalence and severity comes from the 
BOLD findings where a significantly high COPD prevalence was observed in South 
Africa, which also had a high prevalence of tuberculosis (Amaral et al., 2015). Other 
important disorders of disease overlap include asthma (a standalone risk factor for 
COPD) and popcorn worker’s lung (Kreiss et al., 2002; Lange et al., 1998; Mannino & 
Buist, 2007). In regards to COPD severity, GOLD guidelines for spirometric strength 
have been described elsewhere (Global Initiative for Chronic Obstructive Lung Disease, 
2016). Other factors for COPD severity that were recommended include an overall index 
(called the BODE index) made up of a variety of measures including exercise level, 
dyspnea score, lung function, and body-mass index (Celli et al., 2004). 
Primary risk factors for COPD are controlled by the overlap of environmental 
exposures, genotype, and comorbidities (Mannino & Buist, 2007). Risk factors for COPD 
can be divided into two groups according to Viegi et al. (2006) – exogenous (air 
pollution, tobacco smoke, etc.) and endogenous (genetics, age, gender, etc.). Genetic 
factors impacting COPD include deficiencies in the enzyme serine protease α1 
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antitrypsin, parental lung function as a potential predictor, and several specific genes 
including those that code for microsomal epoxide hydrolase 1, transforming growth 
factor β1, and tumor necrosis factor α (Stoller & Aboussouan, 2005). The largest 
contributor to COPD across the globe is tobacco use. There is genetic variation when it 
comes to COPD and smokers since not all smokers end up developing COPD (Mannino 
& Buist, 2007).  
Occupationally speaking, COPD is caused by a variety of chemicals, fumes, dust, 
and vapors (Trupin et al., 2003). From an indoor air perspective, the main risk factor for 
COPD is exposure to biomass burning for heat and cooking. For example, among low 
and middle income countries, the WHO approximates over a third (35 percent) of COPD 
cases developed from biomass burning indoors (Mathers et al., 2006). Another pollution-
related risk factor, outdoor air pollution has been associated with COPD, however on a 
much smaller level according to Mannino & Buist. Granted, more recent findings reveal 
that outdoor air pollution is of greater significance to COPD than once thought (Liu et al., 
2016; Ogawa & Kishi, 2016; Yang et al., 2017a; Zeng et al., 2012). Earlier estimates 
assessed outdoor urban air pollution contributing to about one percent of COPD cases in 
high income countries and two percent in low and middle income countries (Mathers et 
al., 2006).  
COPD has been associated with increasing age. As global trends in elderly 
populations continue to rise, COPD prevalence, morbidity, and mortality will continue to 
follow suit (Jemal et al., 2005). Infections are an additional risk factor and comorbidity 
associated with COPD that contribute to its pathogenesis as well. A salient area with this 
factor includes infections acquired at a young age which can lead to susceptibilities to 
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airway responsiveness and enlargements in the bronchi (Wedzicha & Seemungal, 2007). 
As mentioned previously, asthma and gender have been associated as risk factors for 
COPD with the latter somewhat controversial in its contribution as tobacco prevalence 
shifts between genders and indoor biomass burning continues to persist. (Mannino & 
Buist, 2007). The final risk factor identified by Mannino & Buist (2007) in their review 
was socioeconomic factors. Poverty alone was identified as a proxy while specific factors 
such as nutrition status, crowding, and access to healthcare were more telling (Antó et al., 
2001; Lawlor et al., 2004; Shohaimi et al., 2004). Furthermore, just as COPD is more 
likely to occur among the poor and less educated, similar findings have been found with 
lung cancer (Punturieri et al., 2009).  
The economic burden of COPD in healthcare costs as well as lost productivity 
have been similarly challenging to estimate as with prevalence since reporting measures 
and data collection methods vary from country to country or jurisdiction to jurisdiction. A 
measure utilized by the WHO, quality-adjusted life years of improvement, assesses the 
cost of individual interventions, in this case for COPD. For the ipratropium inhaler, a 
medication used to open up medium to large airways in the lungs, quality-adjusted life 
years of improvement ranged from $6,700 to $8,900 and $13,400 for other corticosteroid 
inhalers, as well as $238,200 for lung transplants (Mathers et al., 2006). Mannino & Buist 
(2007) indicate that smoking cessation is likely to be highly cost-effective; however 
economic evaluations for this intervention were unknown at the time of their review. 
Direct medical costs for COPD in the U.S. were presented with per patient costs around 
$2,700 to $5,900 for attributable costs and $6,100 to $6,600 for excess costs (Foster et 
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al., 2006). Total costs in the U.S. were estimated at $32.1 billion (direct costs were $18 
billion) (Devine, 2008).  
 Mannino & Buist conclude their review of COPD with a focus on future trends. 
They address improvements in disease classification and treatments as well as the 
continued challenges of prevalence and burden estimates. They reiterate the prediction of 
the impact of smoking prevalence shifts and suggest treatment options such as enhancing 
smoking cessation, improved antioxidant treatments, using biological agents to target 
cellular activity, as well as other interventions to decrease lung hyperinflation. Finally, 
they suggest that population changes with a significantly larger elderly subpopulation 
will make COPD one of the most important chronic diseases of the future and will 
become more prevalent with a greater need for managed care and prevention efforts in a 
potential era of essential resource stewardship (Edward H. Wagner, 2004; E. H. Wagner, 
1998).  
 Patel et al. (2014) assessed the indirect costs of COPD to employers and 
individuals in the U.S. Primary findings indicated COPD generates significant indirect 
costs that are burdensome to employers from lost productivity and for individuals who 
lose income due to disability and absenteeism. Some of the quantitative findings include 
annual sick leave for individuals with COPD ranged from 1.3 to 19.4 days with indirect 
costs of $1,521 to $3,348 per person. Additionally, the percentage of indirect costs out of 
the total costs associated with COPD ranged from 27 to 61 percent (Patel et al., 2014).   
COPD trends for outcomes, financial burden and mortality from acute 
exacerbations was assessed by Jinjuvadia et al. (2017). They found that COPD accounted 
for 3.2 percent of all hospitalizations in 2002 and 3.4 percent in 2010 in the US. Although 
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this was not statistically significant there was a significant increase in secondary 
diagnoses of COPD hospitalizations between 2002 and 2010. Mortality and length of in-
patient hospital stays were observed to decrease during this time period, form 4.8 percent 
to 3.9 percent, and from 6.4 days to 6.0 days respectively. However, in spite of the 
observed decreases, hospitalization cost per patient grew considerably from $22,187 to 
$38,455 (Jinjuvadia et al., 2017).  
Multimorbidity is the presence of two or more chronic conditions and is 
frequently observed in individuals with COPD (Westney et al., 2017). Attempts at 
evaluating the impact of this on the healthcare system have been made since the 
assumption is that a greater burden is placed on state health programs like Medicaid when 
serving a multimorbid population. Specifically, Westney et al. (2017) sought to quantify 
the cost of COPD with additional comorbid diseases among the national Medicaid 
population in the U.S. Some of their findings include an increase in acute care, hospital 
bed stays, and total costs as multimorbidity increased. Interestingly, emergency 
department (ED) visits were less common for COPD than they were for other 
morbidities. Some of the comorbidities identified with COPD were asthma, 
hyperlipidemia, affective disorders, diabetes, and hypertension. Several reasons for ED 
visits for patients with COPD were identified including asthma, congestive heart failure, 
and substance abuse. Finally, females were identified with COPD-associated ED visits 
(as well as non COPD-associated ED visits) (Westney et al., 2017). 
 Ding and Enstone (2016) reviewed the literature on the comorbidity of asthma 
with COPD. Citing the Gold guidelines as well as the Global Initiative for Asthma 
(GINA), they identify that Asthma and COPD Overlap Syndrome (ACOS) is a frequent 
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term used to define such individuals. Other terms used to label patients with this 
comorbidity include mixed COPD-asthma, asthma that complicates COPD, COPD with a 
prominent asthmatic component, and Asthmatic bronchitis (GINA & GOLD, 2015; Louie 
et al., 2013). The significance of ACOS is the understanding of the increased burden this 
syndrome has on patients, the healthcare system, and society in general. ACOS sufferers 
are viewed as having a greater severity in their morbidity which has a corresponding 
impact on healthcare (Louie et al., 2013). Estimates of ACOS prevalence ranged from 12 
to 55 percent and economic burden for Medicaid patients for asthma, COPD, and ACOS 
were $2,307, $4,879, and $14,914 respectively (Ding & Enstone, 2016; Shaya et al., 
2008).  
COPD’s impact to women is a growing disparity observed in the U.S. According 
to Mehari & Gillum (2015), the number of COPD deaths per year is higher in women 
than in men and the mortality rate for African-American women was about half of the 
rate observed in European-American women. Additionally, healthcare utilization for 
COPD was higher for women than for men in emergency room visits and hospitalizations 
(Mehari & Gillum, 2015).  
Biological Pathway of COPD Caused by PAHs 
 Recent studies have demonstrated an increased risk of outdoor air pollution as a 
contributor to COPD. Diaz-Guzman and Mannino (2014) suggest in their review of 
COPD risk factors that indoor air pollution is especially salient for COPD pathogenesis, 
however they contend outdoor air pollution’s contribution is increasingly evident. For 
example, the ESCALA study explored the connection between outdoor air pollution and 
mortality in nine Latin American cities (Romieu et al., 2012). The results revealed a 
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“positive statistically significant association between PM10 and all-natural-cause 
mortality” with COPD having the highest percentage increase in mortality (Romieu et al., 
2012).  
When it comes to outdoor air pollution and PAHs specifically, their association 
with PM2.5 as well as ultrafine particles (UFPs; diameter less than 100nm) has been 
demonstrated to increase the likelihood of COPD occurrence (Gan et al., 2013; Yang et 
al., 2017; Zhang et al., 2017). A longitudinal study to assess the impact of traffic-related 
outdoor air pollution was carried out in Vancouver, Canada assessing exposures to black 
carbon (BC), PM2.5, NO2, NOX, and woodsmoke. The findings revealed a 6 percent and 
7 percent increase for COPD hospitalizations and mortality from BC respectively, and a 
15 percent increase for hospitalizations from woodsmoke after adjusting for known 
potential confounders. Additionally, positive associations with all traffic-related air 
pollution compounds in the study were observed (Gan et al., 2013). Furthermore, it is 
important to note that PAHs are a primary toxic component of woodsmoke as they are 
released from the combustion of organic carbon.  
A recent study completed by Zhang et al. (2017) examined the impact of PM and 
PAHs on diagnosed COPD patients in Peking, China. Specifically, UFPs and PAHs were 
significantly associated with an oxidative stress biomarker in the COPD cases observed 
where interquartile ranges for BC, UFPs, and PAHs had increased associations with the 
biomarker of 87 percent, 69 percent, and 156 percent respectively (Zhang et al., 2017).  
 Viegi et al. (2006) report that air pollution plays a salient role in the pathogenesis 
and exacerbation of COPD and is a significant cause of COPD morbidity and mortality. 
In their review of COPD and air pollution they present several primary studies 
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demonstrating the links between outdoor air pollution and adverse health outcomes 
including COPD. A follow-up study carried out in the U.S. that assessed over 500,000 
people indicated that an increased risk of all-cause mortality, cardiopulmonary, and lung 
cancer mortality were associated with increased elevations of PM2.5 (Pope et al., 2002). 
According to Viegi et al. (2006), additional studies demonstrating an association of 
mortality with outdoor air pollution include (Biggeri et al., 2004; Forastiere et al., 2005; 
Gryparis et al., 2004; Hoek et al., 2002; Künzli et al., 2000) as well as associations with 
morbidity i.e. exacerbations and hospitalizations, to include (Anderson et al., 1997; 
Baldacci et al., 1997; Iversen et al., 2005; Schikowski et al., 2005; Yang et al., 2005). 
The biological mechanism and pathway for COPD as well as lung cancer 
pathogenesis following PAH exposure has been extensively studied when mediated 
through tobacco smoke (DHHS, 2014). Kaur-Knudsen et al. (2012) identify the specific 
role that several genetic factors play in causing adverse health outcomes from PAHs in 
tobacco smoke. Cytochrome P450 1B1 and 2C9 genes are typical metabolizers of PAHs 
which then lead to metabolites that cause tobacco-related disease and more importantly 
when it comes to outdoor air pollution and PAH-related diseases (Kaur-Knudsen et al., 
2012). Pauk et al. (2013) note that PAHs are not directly genotoxic for humans in the 
sense that they must be metabolized first by the cytochrome P450 family. In addition to 
1B1 and 2C9, 1A1 and 1A2 are associated in the carcinogenic pathway to initiate DHA 
adducts leading to potential mutation. 
To evaluate the specific mechanism and pathway in which PAHs from outdoor air 
pollution contribute to COPD pathogenesis, Yang et al. (2017) assessed haze events in 
China and the associations of COPD in the population. They propose the primary avenue 
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for PAHs to initiate the genesis of disease in those exposed occurs through the aryl 
hydrocarbon receptor pathway. The aryl hydrocarbon receptor pathway enables the 
effects of oxidative stress to take place; oxidative stress being a main element in COPD 
pathogenesis and carcinogenesis with lung cancer as well. In their study, Yang and 
colleagues utilized PM2.5 extracts collected during haze events and exposed them to 
human lung epithelial cells. The extracts were observed to induce oxidative stress causing 
DNA damage that lead to inflammation demonstrated by the generation of cytokines 
from BEAS-2B cells in addition to a reduction in α1-antitrypsin expression. Again, the 
main elements of PM2.5 that generated these impacts were primarily those from PAHs, 
specifically those with high BaP-equivalent concentrations (Yang et al., 2017). In 
addition to the genetic investigation carried out, Yang and colleagues assessed individual 
associations with COPD and PAHs. They identified that high BaP-equivalent 
concentrations of PAHs increased the likelihood of COPD.   
Other studies have assessed the impacts of chronic exposures to air pollution with 
COPD as the primary health outcome of investigation. For example, Atkinson et al. 
(2015) evaluated an English cohort of individuals not diagnosed with COPD from 2003 
to 2007. They found inconclusive evidence of chronic associations with COPD from air 
pollution. Conversely, a potential association was found by Andersen et al. (2011) in their 
study of traffic-related air pollution (specific for NOX) and COPD occurrence among a 
Danish cohort of some 57,000 individuals between 1971 and 2006.  
General Comorbidities 
 The following section begins with a summary of COPD comorbidities and their 
effects. Additionally, a specific focus on lung cancer co-occurrence is presented where 
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the bulk of the subsequent sections will include a specific environmental epidemiological 
emphasis on lung cancer as a comorbidity with COPD. 
 According to Corlateanu et al. (2016), the most common comorbidities with 
COPD include “skeletal muscle wasting, cachexia (loss of fat-free mass), lung cancer 
(small cell or non-small cell), pulmonary hypertension, ischemic heart disease, 
hyperlipidemia, congestive heart failure, normocytic anemia, diabetes, metabolic 
syndrome, osteoporosis, obstructive sleep apnea, depression, and arthritis.” The 
interactions among these comorbidities result from a variety of factors such as chronic 
and systemic inflammation, low levels of oxygen (hypoxia), as well as various other 
genotypic and environmental factors.  
 Putcha et al., (2015) report that over 80 percent of individuals with COPD have at 
least one comorbidity and that specific-comorbidity or multimorbidity has only recently 
been considered in treatment management. Findings from Dursunoğlu et al. (2016), 
revealed that about half of all COPD sufferers have three or more comorbidities while 
such comorbidities have a variety of impacts including added complications, reduced 
quality of life, changes in symptomology, treatment/management variations, as well as 
economic impacts i.e. added health care costs and lost productivity.  
Lung Cancer Comorbidity, Prevalence, Mortality, and Demographics 
 The overlap of COPD and lung cancer is well established. Wang (2013) 
summarized that the process of COPD occurrence in an individual is brought about by a 
“series of complex interactions between noxious airborne agents together with a genetic 
predisposition.” Cigarette smoke, air pollution, in addition to infectious agents is 
typically connected with COPD. Much of the same is summarized for lung cancer.  
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According to Putcha et al. (2015), the prevalence of COPD in lung cancer patients 
is around 50 percent while the prevalence of lung cancer in COPD patients is estimated 
around four to eight percent. A study by Skillrud et al., (1986) investigated the risk of 
lung cancer in COPD sufferers with a case control study. They found that approximately 
one percent of patients with COPD acquired lung cancer each year where only 0.2 
percent of non-COPD patients acquired lung cancer annually, indicating a five-fold 
increase of lung cancer among COPD patients. Lung cancer comorbidity was assessed by 
Divo et al. (2012), one of the few prospective studies identifying the links between 
COPD and lung cancer (Wang, 2013). They followed up with COPD patients (N=1,664) 
over the course of four years and identified 79 comorbidities. Lung cancer showed the 
strongest association with nine percent prevalence. 
Putcha and colleagues report several studies demonstrated that lung cancer is a 
significant cause of death among individuals with COPD (Anthonisen et al., 2005a; 
Mannino, Doherty, & Buist, 2006; Mannino, Thorn, Swensen, & Holguin, 2008). 
Additionally, Dursunoğlu et al. (2016) reveal that lung cancer and cardiovascular disease 
have a disproportionate effect on COPD mortality where indices such as the Charlson 
Comorbidity Index and the COPD Specific Comorbidity Index (COTE) have proved 
effective in their predictive power for COPD mortality. Explanations for the excess risk 
of lung cancer mortality in COPD patients include associations with shared genetic loci, 
epigenetic modification of bronchial cells following exposure to tobacco smoke or air 
pollution, or systemic inflammation in sufferers with COPD, which can predispose 
people to lung cancer (Dursunoğlu et al., 2016; Rooney & Sethi, 2011; Wauters et al., 
2011). 
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Demographic application regarding the overlap of COPD and lung cancer reveals 
disproportionate effects in gender. Ben-Zaken Cohen et al., (2007) investigated the 
growing burden of COPD and lung cancer in women, reporting there is a worrying trend 
for both diseases among females. For example, the annual COPD mortality rate increased 
by 291 percent among women in the U.S. between 1980 and 2000, along with a hospital 
rate increasing by 43 percent. Whereas, men in the U.S. had COPD mortality and hospital 
rate increases of 60 percent and 12 percent respectively (Mannino et al., 2002). Lung 
cancer was identified as being no less alarming with the highest mortality rate of cancer 
among women (60 percent more than breast cancer) (Jemal et al., 2005). Additionally, 
the U.S. female mortality rate for lung cancer rose from 38 percent to 41 percent between 
1991 and 2005, while the male rate decreased from 91 percent to 69 percent over the 
same period (Jemal et al., 2009).  
COPD is a standalone risk factor for lung cancer, specifically for squamous cell 
carcinoma (Papi et al., 2004). Additionally, lung cancer is upwards of five times more 
likely in smokers with a chronic airway pathology versus those with no pathology 
(Young & Hopkins, 2010). Wang (2013) identified that COPD is the single most 
important risk factor for lung cancer after adjusting for cigarette smoking when forced 
expiratory volume (FEV1) is used for diagnosis. In a study carried out by Calabrò et al. 
(2010), reduced FEV1 revealed an increased risk from lung cancer where a small 
reduction of 10 percent in FEV1 demonstrated almost a three-fold increase in lung cancer 
probability. Other studies have isolated the risk of lung cancer from COPD independent 
from smoking such as van Gestel et al. (2009) and Rodríguez-Roisin & Soriano (2008). 
Both were cohort studies where van Gestel and colleagues identified significant increases 
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of lung cancer occurrence among COPD patients, where Rodríguez-Roisin & Soriano 
identified increased risks of mortality from lung cancer among COPD patients. 
Oxidative Stress. Inflammation, and Hypoxia Mechanisms 
Proposed mechanisms for the correlation of COPD with lung cancer include 
genetic predispositions to disease and other pathogenic influences in addition to other 
mechanisms such as premature aging (Barnes & Adcock, 2011). COPD and lung cancer 
are closely linked at a molecular level as they share common pathways for activation i.e. 
inflammation (Durham & Adcock, 2015). Most cancerous tissues demonstrate 
inflammation, while a number of inflammatory diseases can lead to cancer (Schetter et 
al., 2010). Tuder et al., (2012) and Caramori et al. (2011) have demonstrated that 
inflammation is causative in both COPD and lung cancer. In an article by Roca et al. 
(2012), the link between COPD and lung cancer is discussed in light of the 
commonalities and co-occurrence of the two diseases. Oxidative stress and inflammation 
are cited as the shared pathogenic mechanisms; however the implications of their 
common risk factors (i.e. smoking) suggest genetic susceptibilities act in concert together 
to initiate biochemical processes for pathogenesis. It is important to note that air pollution 
is an identified risk factor that influences this mechanism for pathogenesis, however it is 
not specified by Roca et al. (2012).  
A historical perspective on the links between COPD and lung cancer is provided 
by Prevot et al. (2012) where prior to the late 1990’s the mechanisms for pathogenesis 
between the two diseases were thought to be unique. As discussed above, the data over 
the past twenty years have demonstrated the commonalities in such mechanisms. Prevot 
et al. (2012) identified that COPD and lung cancer appear to have a genetic basis that 
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predisposes individuals to environmental exposures that can result in the pathogenesis of 
either or both diseases. They expound that the identified commonalities for pathogenesis 
between the two diseases include “genetic and epigenetic abnormalities, mechanical 
factors, and signalization pathways.” 
 Boots et al. (2003) discuss the cyclical effect that oxidative stress and reduced 
antioxidant resources can have on both COPD and lung cancer. They report that several 
indicators of oxidative stress (i.e. hydrogen peroxide exhalation, degraded proteins, etc.) 
are increased among individuals with COPD and what results is reduced antioxidant 
capacity in the individual. Additionally, as this capacity decreases in the blood its effects 
circulate throughout the body indicating a systemic effect. Additional contributors for this 
effect include cell death (apoptosis) and inflammation. As mentioned above, lung cancer 
is influenced through these same pathways of oxidative stress and inflammation.  
According to Vineis & Husgafvel-Pursiainen (2005), PAHs are a significant 
component of PM in air pollution that bring about oxidative stress and subsequent 
damage to DNA. They go on to identify that the basis of evidence from oxidative damage 
to DNA in lymphocytes from air pollution exposure points to one of the major products 
of DNA oxidation, 8-oxo-dG, revealing it as one of the important mutation-causing 
lesions. Additionally, since oxidative stress has been identified as playing a role in COPD 
for some time including the specific role of 8-oxo-dG, the connection of the root causes 
between the two pathologies is further evidenced (Aoshiba et al., 2012; Nemoto et al., 
2014; Yang et al., 2014).  
Specific elements of lung cancer carcinogenesis from PAH exposure include the 
production of DNA adducts (following PAH metabolism), the creation of oxidative harm 
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to DNA, chromosomal shifts, and an involvement in the changes to oncogenes and tumor 
suppressor genes (Farmer et al., 2003; Pauk et al., 2013). In a study carried out by Pauk et 
al. (2013), PAH exposure and its influence on lung carcinogenesis and COPD was 
investigated by looking at PAH induced antibodies in human blood. Their rationale, when 
PAH exposure occurs and DNA adducts are created, antibodies are produced by the 
immune response. The benefit of measuring this is the potential for an additional 
biomarker for PAH exposure in future studies to pinpoint carcinogen-specific antibodies. 
Additionally, if the chronic load of PAH exposure is large enough in cases like tobacco 
smoke and air pollution exposure, the body’s immune response is compromised and anti-
PAH antibodies are less prevalent, therefore creating a context in which the exposed is 
less able to protect against the toxic effects of PAHs from the environment (Pauk et al., 
2013). The study concluded that the genotoxic risk of chronic exposure to PAHs 
increases in settings that have dense concentrations of PAHs from tobacco smoke or 
other forms of PAH pollution. 
The linkage between oxidative stress and inflammation was expounded upon by 
Wang (2013), where air pollutants cause oxidative stress to the lungs giving rise to 
reactive oxygen species (ROSs), which can then overcome antioxidant capacity, as 
mentioned by Boots et al. (2003) above. When this capacity is overrun, ROSs react with 
various elements, such as DNA, to initiate the disease process. In the case of 
inflammation, air pollutants can react with ROSs which then can activate mitogen-
activated protein kinase (MAPK) signaling, which ultimately encourages inflammation. 
For ROSs to occur in the body, inflammatory cells release them (in the lungs in this case) 
leading to increased inflammation, tissue damage, and other harmful impacts. The 
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interaction between inflammation and oxidative stress is highlighted among phagocytes 
as they are activated by particulate matter collecting in the lungs, whereby ROSs are 
released and oxidative stress ensues (Wang, 2013).  
An in vivo study carried out by Karoor et al. (2012) hypothesized that hypoxia in 
the lungs, which is present in COPD patients, can increase the risk of lung cancer 
development. Mice were exposed to hypoxic environments during the study and 
demonstrated an increase in tumor development compared to controls that were exposed 
to normal oxygen levels. They concluded that tumors developed in the hypoxic 
pulmonary context of COPD sufferers, demonstrating amplified growth, angiogenesis 
(blood vessel formation), and survival signaling. What can result from these 
demonstrations is an increased risk of lung cancer among individuals with COPD.   
Genetic Influences 
 Genotype plays a significant role in both COPD and lung cancer. Inherited 
susceptibility to COPD and lung cancer is a primary component to understanding the 
overlap of both diseases. Young et al. (2011) indicate heritability of COPD is between 40 
and 77 percent, where lung cancer heritability is between 15 and 25 percent. The 
presence of COPD comprises an important phenotype that affects a significant portion of 
people with lung cancer as well as an influential impact on lung cancer susceptibility 
(Wang, 2013).  
Specific genes that have been identified in playing a role in lung function and COPD as 
well as those with susceptibility to COPD and lung cancer have been identified in several 
linkage studies (Wang, 2013). Findings from these studies include markers on 
chromosome 6q in regards to lung cancer and abnormal lung function, in addition to 
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chromosome 12 influencing lung cancer, COPD, and lung function. Other genes for 
susceptibility were identified to be influential in “detoxification, immune regulation, 
matrix remodeling, DNA repair, cellular proliferation, and tumor suppression” (Caramori 
et al., 2011; Wang, 2013). 
Expounding on the work of Kaur-Knudsen et al. (2012) and Pauk et al. (2013) 
with cytochrome P450, and delving further into the similarities of the biologic 
mechanisms between lung cancer and COPD, the PAH-metabolizing enzyme - CYP1A1 
(also known as cytochrome P450B1) which is a known aryl hydrocarbon hydroxylase, 
has been isolated in tissues throughout the body including the lungs, skin, intestines, liver 
as well as other cellular material (Wang et al., 2015A). Significant associations between 
the CYP1A1 polymorphism and COPD have been identified with various impacts such as 
susceptibility and overall risk for COPD (Wang et al., 2015B). Moreover, the same 
mechanism and impacts of CYP1A1 have been demonstrated with lung cancer (Lao et 
al., 2014).   
Polymorphisms, specifically single nucleotide polymorphisms (SNPs) can be 
identified in their association with disease susceptibility. Thus, certain genetic variations 
can lead to disease susceptibility if an individual or group of individuals have the same 
genotypes. Matullo et al. (2006) investigated the association of certain polymorphisms 
that occur in DNA repair genes following air pollution and environmental tobacco smoke 
exposure. They provide an example using PAHs (as well as other known air pollution 
carcinogens) where DNA adducts are primary genetic responses to exposure, however 
other responses such as interstrand cross-links and ROSs can lead to lesions resulting in 
mutations and subsequent cancer risk if unrepaired (Vispe et al., 2000). The health 
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outcomes studied by Matullo and colleagues included various cancers (including lung) as 
well as COPD mortality. The results of specific polymorphisms with the corresponding 
health outcomes (including lung cancer and COPD) were inconclusive, indicating there 
were no statistically significant associations among the SNPs and the various health 
outcomes in the study. Adding to the work of Matullo and colleagues includes additional 
null findings found by Kaur-Knudsen et al., (2009). They further expound on 
insignificant associations of polymorphisms with cardiopulmonary diseases and cancer. 
Specifically, they investigated cytochrome P4501B1 (*3 and *4 polymorphisms) and 
found no associations with COPD, various cancers (including overall cancer, tobacco-
related cancer, and female cancer), myocardial infarctions, ischemic heart disease, or 
ischemic cerebrovascular disease.   
The work of Shen et al. (2008) examined SNP associations with COPD in a 
population with significant exposure to indoor smoky coal emissions. They investigated 
18 SNPs in 10 cytokine genes and associated these with COPD risk. They found 
significant associations of 2.4 and 2.7 fold higher risks for the CSF2 117lle allele and the 
AA genotype at IL8 -351 respectively. These findings suggest that the specific 
polymorphisms mentioned above play a role in the pathogenesis of COPD. Furthermore, 
it is important to note that the same population used in this study in China came from one 
of the areas with the highest rates of lung cancer in the country and the same controls that 
matched for COPD cases in this study were used to match to lung cancer cases in a 
separate investigation (Shen et al., 2008). Additionally, the work of Rudisch et al. (2015) 
found similar results with CSF2 and non-small cell lung cancer (NSCLC) associations; 
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specifically where CSF2 played a significant role in the inflammatory pathway of 
NSCLC. 
Lung Comorbidity and Air Pollution 
 A review by Wang (2013) summarized the significant literature linking COPD 
with lung cancer. They report that COPD and lung cancer associations are easily found in 
the literature. Several examples were provided that identified air pollution as an 
environmental factor in the pathogenesis for both diseases, although tobacco smoke was 
the most significant causative factor identified. The mechanisms resulting from air 
pollution that were recognized include oxidative stress and inflammation.  
PAHs, BaP specifically, was mentioned by Wang (2013) for its presence in both 
cigarette smoke and air pollution. Its specific impact on COPD was linked to the increase 
in proliferation of certain lung cancer cells through the epidermal growth factor receptor 
(EGFR). This proliferation can take place as the epithelial cells in the lungs are exposed 
to cigarette smoke leading to chronic EGFR activation where this protracted signaling 
contributes to unrestrained cell growth. In regards to proliferation, it is unclear if this has 
a significant role in the pathogenic potential of COPD. 
Considering air pollution from a broader perspective at a lesser granularity than 
PAHs alone, particulate matter in general has been identified in lung cancer tissue with 
several studies looking at such impacts (Wang, 2013). Caramori et al. (2011) identified 
how increased deposition of PM was present in the major bronchi with the use of 
computer models of the lungs of COPD patients. Additionally, Ling et al. (2011) 
established that PM was present in the lung parenchyma, blood vessel walls, airways, 
lymphoid follicles, and alveolar macrophages. Primary findings here described PM as 
 40 
ubiquitous in the lung tissues of COPD sufferers and that exposure to PM from tobacco 
smoke in particular was associated with PM retention. This is of specific interest for 
disease severity as the lungs of patients with COPD have a decreased capacity to expel 
PM, where this retention could then lead to increased severity. It is important to note this 
latter example from Ling and colleagues did not specify the role of lung cancer resulting 
from PM with specific pulmonary deposition, however this literature can be found 
elsewhere i.e. Saieg et al. (2011) and Tokiwa et al. (1998). 
Although several null findings were briefly touched on previously, the specific 
causal factors associating PAHs with COPD and/or lung cancer has gone through a 
portion of scrutiny with reviews such as Marino et al. (2015) and Connellan (2017), 
especially in regards to chronic exposure. Their conclusions suggest that although there 
are clear toxic effects from hydrocarbon exposure via air pollution, what is required is 
more definitive research to link the effects of longer term and lower exposure detailing 
the specific mechanisms of such toxicity over time. These are valid limitations to a 
portion of the literature mentioned above, however studies such as Pauk et al. (2013), 
Boots et al. (2003), and Vineis & Husgafvel-Pursiainen (2005) provide evidence to the 
contrary detailing the toxic load over time from PAHs, especially when it comes to the 
pathogenic potential from oxidative stress. Furthermore, this is an area the current 
research is proposing to investigate. 
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CHAPTER 2 
ESTIMATING THE STRENGTH OF ASSOCIATION AMONG COPD 
LUNG CANCER ATTRIBUTABLE TO PAHS USING NHANES 
Chapter two assessed the associations of PAHs with COPD and lung cancer to 
isolate an environmental etiology distinct from tobacco smoke. The primary assumption 
of this investigation was PAH exposure occurring from air pollution. However, in light of 
the environmentally ubiquitous quality of PAHs  in the soil, food sources, water, etc., air 
pollution exposure could not be isolated as the sole source. The next section outlines the 
evidence base for using the National Health Assessment and Nutrition Examination 
Survey (NHANES) to associate PAHs and health outcomes, including the presence of 
COPD or lung cancer. Afterward, the methodology for the analysis is provided, and 
finally the results are presented. 
PAH Metabolite Analysis Justification 
 The biological basis for using PAH metabolites to assess associations with health 
outcomes is well defined in the literature. This is demonstrated specifically with studies 
utilizing NHANES laboratory, examination, and questionnaire data. Numerous 
investigations have explored the health effects and various associations with PAH 
metabolites using NHANES i.e. Alshaarawy et al. (2014); Farzan et al. (2016); Kim et al. 
(2014); Liu et al. (2016); Scinicariello & Buser. (2014); Xu et al. (2010), etc.
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While the studies above were not all intentionally assessing ambient air pollution 
exposure using PAH metabolites as a biomarker, additional studies assessing routes of 
exposure from PM2.5/PAHs and resulting PAH metabolites in the urine include (Bekki et 
al., 2012; Hayakawa et al., 2011, 2017; Motoyama et al., 2009). Specifically, Hayakawa 
et al. (2017) reviewed the recent studies investigating PAH metabolites, their oxidative 
potential from air pollution, and the resulting health impacts such as the production of 
ROSs. They discuss the importance of these studies in regards to the growing health 
concerns from PM2.5 and summarize the established literature on exposure pathways and 
biological mechanisms for PAH metabolites.   
Earlier work in this area includes Lee & Kang (2008) where they investigated a 
particular urinary PAH metabolite, Urinary 2-napthol, and summarized its usage as a 
biomarker of ambient particulate matter exposure and specific associations with COPD 
and lung cancer. Further investigations of theirs tested the stability of Urinary 2-napthol 
as a biomarker for air pollution exposure indicating its strong utility in epidemiological 
studies in the realm of PAH exposure from air pollution and resulting COPD and lung 
cancer associations.  
 Zhou et al. (2016) expound on the nuance between general exposure to ambient 
PAHs and associations with respiratory pathologies versus the association with PAH 
metabolites and respective pathologies. They investigated this difference by assessing a 
sample of the general Chinese population and the relationships between urinary PAH 
metabolites and corresponding lung function. Specifically, they measured 12 urinary 
PAH metabolites in 2,747 participants and analyzed associations using mixed linear 
models. Their findings revealed significant associations with PAH metabolite 
concentrations and reduced lung function using forced expiratory volume after one 
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second (FEV1) as the primary measure. The significant PAH metabolites they assessed 
included 2-hydroxynaphthalene, 9-hydroxyfluorene, 2-hydroxyfluorene, 4-
hydroxyphenanthrene, 9-hydroxyphenanthrene, 3-hydroxyphenanthrene, 1-
hydroxyphenanthrene, 2- hydroxyphenanthrene, and 1-hydroxypyrene. The largest 
individual PAH metabolite associations leading to reduced lung function included 2-
hydroxyfluorene, 4-hydroxyphenanthrene, and 1-hydroxyphenanthrene (41.76-, 36.87- 
and 39.53- ml reduction in FEV1 respectively). The total urinary PAH metabolite 
influence on lung function was 37.13-ml reduction in FEV1. Additional areas of inquiry 
in the study included traffic exposure time and dietary PAH exposure, which both 
revealed positive associations to urinary PAH metabolite concentrations.  
In light of these various studies as well as the ones mentioned in the introduction 
in regards to NHANES investigations with COPD, lung cancer, and PAHs, there has not 
been an investigation into spirometry-confirmed COPD associations with PAHs, nor has 
there been an investigation into the overlap of all three of these areas within NHANES. 
Furthermore, there have been no cross-sectional studies of this size that analyzed the 
associations of all three. As such, the following methodology is proposed using the 
various analytical approaches of Mannino et al., (2003); Shiue, (2016); and Tilert et al., 
(2013).  
 
Methods 
 The foundation for chapter two’s analysis was based on the analytical approach 
identified by Shiue (2016). The focus of the study used the two principal disease 
categories of chronic bronchitis and emphysema for COPD and then analyzed 
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associations with urinary PAHs from NHANES laboratory data. For the analysis, data 
was obtained from CDC’s NHANES data portal 
(https://www.cdc.gov/nchs/nhanes/index.htm) for years 2007, 2009, and 2011. While 
PAH laboratory data as well as medical condition data like chronic 
bronchitis/emphysema have been collected more recently and even prior to 2007, these 
years correspond to the most recent survey iterations when spirometry measures were 
collected. The NHANES web tutorial was followed for downloading NHANES data as 
SAS transport files, appending, merging, cleaning and recoding, formatting and labeling, 
and saving data sets. 
Mirroring Shiue’s study, the statistical procedures employed in the analysis 
included chi square tests for independence and logistic regression. Log transformation 
was used since urinary PAH concentrations from NHANES were highly skewed (Shiue, 
2016). Primary covariates understood as potential confounders included age, sex, ratio of 
family income to poverty (socio-economic proxy), BMI, education, urinary creatinine, 
serum cotinine (tobacco biomarker), alcohol consumption, and physical activity level.  
It is important to reiterate that Shiue (2016)’s study did not incorporate the use of 
spirometry as a confirmation of COPD diagnosis nor was COPD addressed in the study in 
general, although chronic bronchitis and emphysema are the two primary types of COPD 
categories, yet COPD as a term has been used since the 1960s (CDC, 2016; Petty, 2006). 
Additionally, COPD as a classification within NHANES was not explicitly asked on the 
questionnaire portion of the survey until 2013.  Finally, Shiue did not include covariates 
for secondhand smoke exposure or former smokers, which were additional covariates 
included in this study. 
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The first objective of this chapter was a synthesis of the methodologies of the 
studies mentioned above to measure the association between PAHs and COPD. 
Specifically, urine samples measuring PAH levels from NHANES were analyzed 
alongside participants’ spirometry readings at levels indicating a COPD diagnosis 
according to the GOLD spirometry test guidelines (Global Initiative for Chronic 
Obstructive Lung Disease, 2016). Spirometry data were utilized as a continuous variable 
and were analyzed alongside PAH measures (also continuous variables) to investigate 
whether a significant association was present. Self-reported COPD was also included in 
an overall COPD measure that was combined with the spirometry-confirmed COPD 
variable and was used in the model as the primary dependent variable.  
The second objective for this chapter was to measure the association between 
PAHs and COPD occurrence among smokers versus non-smokers. 
The third and final objective: isolate a distinct environmental etiology from PAH 
exposure using COPD and lung cancer comorbidity as the outcomes. 
Finally, no funding was required for this analysis as NHANES data is public 
access and the analysis software (SAS 9.4) was acquired in-kind. Although IRB approval 
was not required by the CDC to gain access to the NHANES data portal, the University 
of South Carolina IRB review process was followed including completing the 
Collaborative Institutional Training Initiative’s (CITI) web-based human research course 
titled Social and Behavioral Researchers (and subsequent certification) as well as 
completing an expedited IRB review and approval due to the data’s secondary and de-
identified nature.  
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Methodology Summary 
Goal: To determine whether there is an association of PAHs and spirometry-
confirmed COPD and/or  lung cancer as a means to determine a potential environmental 
etiology distinct from tobacco smoke. 
Objective 1: Synthesis of the methodologies of Mannino et al., (2003); Shiue, 
(2016); and Tilert et al., (2013) to determine if there is a significant association between 
PAHs and COPD. 
Objective 2: Measure the associations between PAHs and COPD occurrence 
among smokers versus non-smokers to assess statistical significance in COPD prevalence 
among non-smokers specifically. 
Objective 3: Measure the associations between PAHs and lung cancer occurrence 
among smokers versus non-smokers to assess statistical significance in lung cancer 
prevalence among non-smokers. 
Null hypothesis: There is no significant association between PAH levels and 
spirometry-confirmed COPD and lung cancer co-occurrence among non-smokers. 
Alternative Hypothesis: There is a significant association between PAH levels and 
spirometry-confirmed COPD and lung cancer co-occurrence among non-smokers.  
 
Results 
Sample Size and Descriptive Statistics 
 The overall NHANES sample from combined years between 2007 and 2012 was 
30,442 respondents. The laboratory sub-sample provided 23,337 serum cotinine 
responses. Additional laboratory sub-sampling for PAHs had respective sample sizes 
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ranging from 7,735 (1-hydroxynaphthalene) to 7,846 (9 hydroxyflourene). The 
spirometry sub-sample consisted of 20,050 responses. Descriptive statistics for the 
categorical and continuous variables utilized in the analysis are included in Tables 2.1 
and 2.2.  
Frequencies for the dependent variables of COPD and lung cancer were as 
follows. The number of respondents indicating a medical professional had previously 
diagnosed the respondent with COPD was 1,229. It is important to note these were self-
reported. The frequency for spirometry-confirmed COPD was 518 with a combined 
sample size for self-reported COPD and spirometry-confirmed COPD of 1,690 cases 
(adjusted for duplicates). The self-reported lung cancer frequency was 37 cases and thus 
was not powerful enough to generate any reliable estimates from a regression analysis 
after adjusting for confounders. Finally, smoking was defined as having a serum cotinine 
level >13.7 ng/ml, which resulted in a frequency of 4,291 overall smokers in the sample. 
Cross tabulations of smoking status by overall COPD, spirometry-confirmed COPD, and 
lung cancer frequencies are included in Table 2.3. 
Principal Components Analysis  
 A principle component analysis (PCA) allows for the reduction in the number of 
covariates utilized in a multivariate analysis while still accounting for most of the 
variance in the observed variables (Abdi & Williams, 2010). To reduce the number of 
PAH covariates tested in the logistic regression, a PCA was performed on the nine PAH 
log transformed covariates included in the NHANES laboratory sub-sample. It is 
important to note additional PAHs are available for certain years of the Continuous 
NHANES sample, however only those available across all the three iterations (2007, 
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2009, and 2011) of these NHANES years are included. One factor from the PCA resulted 
to be significant with an eigenvalue greater than one as well as the results of the scree 
plot with significant distance between this factor and the rest of the factors (Cattell, 
1966). Table 2.4 provides a summary of the respective eigenvalues of each factor and 
figure 2.1, the scree plot of each eigenvalue.  
Model 1: Regression Stratified by Age Alone  
Two logistic regression models were generated to carry out the objectives described 
above.  Model 1 stratified by age alone and Model 2 stratified by adult smoking status. 
Adults 20 years and above comprised the portion of the sample tested in the first model. 
Degrees of freedom (DF) for the logistic regression were set to infinity. Classes for the 
categorical variables were set as those with probable healthy effects i.e. gender = female, 
race = Caucasian, smoker = no, education = high school diploma or more, etc. The 
weight variable employed in the model was derived from the laboratory sub-sample for 
PAHs where the rationale for employment of various NHANES weight variables is 
dependent upon the smallest sub-sample utilized in the analysis (National Center for 
Health Statistics, 2006). Thus, the weight for the PAH sub-sample was utilized since it 
was the smallest sub-sample included in the overall dataset. Additionally, stratum and 
cluster variables were used according to NHANES analytic and reporting guidelines. 
Urinary creatinine was included in the model since other urinary sampling biomarkers 
(PAHs) were also used in the model. Creatinine provides for an adjustment effect on the 
urinary sample to account for variable dilutions (Barr et al., 2005).  
The number of observations used in Model 1 was 2,308. 219 cases for overall COPD 
(self-report and spirometry-confirmed COPD) and 2,089 non-COPD cases were included 
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in the response profile of the model. Statistically significant covariates were defined as 
those with a p-value < 0.05. According to the analysis of maximum likelihood estimates, 
the significant covariates identified in the model were “Other” Race (p=0.0012), Smokers 
(p<0.0001), Former Smokers (p=0.0348), Secondhand Smoke Exposure in the Home 
(p=0.0092), Age (p<0.0001), BMI (p=0.0029), and PAHs (Factor1) (p=0.0098). Table 
2.5 provides a summary of the maximum likelihood estimates of all of the covariates 
included in the model. The respective odds ratios for the significant covariates were 
“Other” Race 0.491 (0.319, 0.756), Smokers 2.314 (1.536, 3.485), Former Smokers 1.482 
(1.028, 2.135), Secondhand Smoke Exposure in the Home 1.722 (1.144, 2.592), Age 
1.039 (1.026, 1.053), BMI 1.037 (1.013, 1.062), and PAHs (Factor1) 1.295 (1.064, 
1.575). Odds ratios for all covariates included in the model are summarized in Table 2.6. 
The only odds ratio with a negative correlation/protective effect for COPD was “Other” 
Race which included Hispanics as well as various other races. All other statistically 
significant odds ratios had positive correlations/non-protective effects, including PAHs.  
Model 2: Regression Stratifying by Smoking Status 
 To further investigate a potential environmental link between PAHs and COPD, a 
logistic regression analysis was carried out to isolate the effects of PAHs on COPD from 
smoking. Thus, a model was generated stratifying the sample by smoking status. All 
specifications for degrees of freedom, weighting, stratum, cluster, and classes were 
repeated as in model 1. The domain specified in the model was adults 20 years and above 
who were positive for serum cotinine at 13.7 ng/ml or above (smoking biomarker). The 
following results were generated in the model among the non-smoking cohort of the 
NHANES sample.   
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The number of observations read and used in the model were 30,442 and 2,260, 
respectively. 90 cases for overall COPD (self-report and spirometry-confirmed COPD) 
and 1,360 non-COPD cases were included in the response profile of the model for non-
smoking adults. Three statistically significant covariates were identified in the analysis, 
Age (p<0.0001), BMI (p=0.0393), and Alcohol Consumption (p=0.0347). PAHs 
(Factor1) had a non-significant estimate (p=0.4828). All statistically significant 
covariates had positive correlations/non-protective effects with COPD cases. Table 2.7 
includes a summary of all covariates including the Chi Square tests of their respective 
estimates. Odds ratios for all covariates are included in Table 2.8. Specifically, the odds 
ratio for PAHs (Factor1) was 1.120 (0.816, 1.537). 
It is important to note a third model was carried out to explore any additional 
statistical significance among PAHs and COPD. This model included all Continuous 
NHANES iterations from 2003 to 2014 (n=61,087) where PAHs were collected in the 
laboratory sub-sample (PAHs were not collected in 2015 NHANES and 2017 NHANES 
is still undergoing data collection). When stratifying for smoking status among these 
years, this additional logistic regression analysis did not yield any statistically significant 
results among the non-smokers for PAHs (p=0.4276), in spite of a significantly larger 
sample size for self-reported COPD cases (n=2,355). It is also of interest that the lung 
cancer cohort (positive cases) during this range of years was still not powerful enough to 
include in its own regression analysis (n=84).  
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Discussion 
Previous evidence associating PAHs with adverse respiratory outcomes like COPD is 
well-documented (Pauk et al., 2013; L. Yang et al., 2017; Y. Zhang et al., 2017). 
Utilizing a nationally representative human sample that collects PAH biomarkers affords 
the analytical opportunity to further investigate these associations on a large scale. 
Consistent with the findings from (Shiue, 2016), model one’s results are discussed below, 
which are then compared with inconsistent findings from model two.  
Model one was a general analysis testing for significance between PAHs and 
COPD by stratifying by adults 20 years and above, while adjusting for known 
confounders i.e. smoking. A significant association between PAHs with combined self-
reported COPD and spirometry-confirmed COPD was found (p=0.0098). The odds ratio 
for PAHs in model one demonstrated a non-protective effect on COPD with a value 
greater than one (1.295) and a confidence interval that did not include one (1.064, 1.575). 
The Chi-squared test for smoking (p<.0001) was significant with COPD in addition to an 
odds ratio above one as well (2.314 (1.536, 3.485)). Thus, the need to further isolate the 
effect of PAH exposure from smoking to investigate a probable environmental source 
was warranted. Since PAH exposure is generated from smoking (Department of Health 
and Human Services, 2014), the PAH biomarkers in urine metabolites would be expected 
to be elevated. Thus, a model that stratified by smoking status would allow for a more 
precise understanding of a potential environmental link (i.e. air pollution) between PAHs 
and COPD by separating out the contribution of smoking on PAH exposure. It is 
important to note that other statistically significant covariates were found during the 
analysis (as identified in the results) in model one and are included in Table 2.5.  
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 Model two stratified by smoking status and tested the significance of PAHs on 
COPD among the non-smoking cohort. PAHs were not statistically significant among the 
non-smokers (p=0.4828) in model two. The odds ratio for PAHs was 1.12 with a 
confidence interval that included one (0.816, 1.537). Thus, the null hypothesis was 
supported and the alternative was rejected; where PAHs were not significantly associated 
with COPD among non-smokers, while adjusting for known confounders. Other 
statistically significant covariates that are important to note for model two include Age 
(p=<.0001), BMI (p=0.0393), and alcohol consumption (p=0.0347). The respective odds 
ratios for each of these confounders were all above one, demonstrating a non-protective 
effect on COPD occurrence (Table 2.8).  
 The findings from model one support the results generated by Shiue’s study 
investigating PAH associations with emphysema, chronic bronchitis, and asthma while 
using an NHANES sample. Shiue found significant associations among several 
individual PAHs with chronic bronchitis and emphysema, however no significant 
associations were found with asthma or other infections that were assessed i.e. hay fever. 
The analysis carried out by (Shiue, 2016) did not include additional covariates related to 
other smoking measures i.e. former smokers and secondhand smoke exposure. The 
advantage of the current study was the inclusion of these two additional confounders, a 
larger sample size of six years of data (rather than a single iteration of two years), as well 
as the inclusion of spirometry-confirmed COPD as a dependent variable.  
 In contrast, the next step of the analysis with model two did not support Shiue’s 
overall findings when stratifying by smoking status. As individuals who smoke (as well 
as former smokers and those exposed to secondhand smoke) are exposed to PAHs 
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resulting from the combustion of tobacco, PAHs are released into the surrounding air and 
such individuals are subsequently inhaling these compounds. Therefore, to adequately 
investigate whether a nationally representative human sample like NHANES has 
significant associations of PAHs with COPD to make the case for air pollution as a 
potential source, such a model must include stratification by smoking status. Shiue did 
not stratify by smoking status in the original study, or at least no mention of this type of 
investigation was made.  
 The findings from both models warrant additional study into the health effects of 
PAHs with adverse respiratory outcomes like COPD. Possible explanations for the lack 
of significance of PAHs with COPD in model two may be related to the omission of BaP 
as a PAH collected in the NHANES sample, lag time between dose and response from 
something like air pollution where exposure levels have decreased, in addition to other 
confounding factors not included in the model i.e. potential biomarkers for PM2.5, etc. It 
is important to note the additional smoking-related covariates (Former Smokers and 
Second Smoke Exposure) could be included in the stratification with overall smokers, 
which may have an impact on the strength of association of PAHs in the new model. 
Thus, additional modeling with other air pollution-related covariates e.g. PM2.5 
biomarkers, as well as adjusting the stratification for additional smoking covariates may 
exhibit new results.  
Additionally, the work of Alshaarawy, Elbaz, & Andrew (2016) investigated the 
association of urinary PAHs with cardiovascular diseases (CVD - stroke, heart attacks, 
angina, and coronary heart disease) using an NHANES sample (2001 to 2010). The 
pathogenic pathway between oxidative stress, inflammation, and atherosclerosis are well-
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documented (Curfs et al., 2005; Jeng et al., 2011) and provide a biological mechanism for 
their analysis’ rationale. Alshaarawy et al. (2016) stratified a multivariate model by 
smoking status (former, never, and recently active) using structural equation modeling 
and revealed statistically significant findings with PAHs and CVD. Thus, novel 
approaches to investigating the role of PAHs on a host of chronic diseases from a known 
environmental source like air pollution is warranted in addition to employing similar 
statistical techniques like structural equation modeling as proposed by Alshaarawy and 
colleagues. 
Strengths and limitations 
 The strength of this study comes in the form of utilizing various biomarkers as 
covariates as well as a standardized clinical diagnostic test to generate a dependent 
variable with improved precision to test in a multivariate logistic regression model. The 
power of the sample was significant using multiple years from NHANES, a nationally 
representative sample for human health. Stratification among the non-smoking cohort of 
the sample in addition to including several other smoking-related covariates was an 
improvement based on a previous study investigating a similar research question. Again, 
this was essential to make a stronger case for a potential environmental source of adverse 
outcomes related to PAH exposure beyond the influence of individual smoking or 
environmental tobacco smoke exposure.  
The limitations of the study are related to the cross-sectional nature of NHANES. 
Causality was not possible to assess between PAH exposure as a type of dose and COPD 
as its response. Next, various other covariates including known biomarkers for air 
pollution or other environmental hazards were not pursued in the study as other forms of 
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confounders. Specifically, since BaP is not included in the suite of PAHs collected in the 
NHANES sample, yet this primary PAH is the most widely studied PAH for its health 
effects. Furthermore, BaP specifically has been identified in the pathogenesis with both 
COPD and lung cancer (DHHS, 2014; Yang et al., 2017) yet was unfortunately not 
possible to test. Finally, the size of the lung cancer sample was not robust enough to test 
for significance with PAHs while adjusting for confounders. This may be due to the high 
mortality rate related to lung cancer in addition to the increased severity of symptoms that 
lung cancer patients endure; which would make them ineligible for participating in each 
of the assessments carried out according to the NHANES data collection methodology. 
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Table 2.1 Descriptive statistics of NHANES categorical variables used in the logistic 
regression analysis (2007-2012 NHANES).a 
 
Frequency % Cumulative 
Frequency 
Cumulative 
% 
Gender 
Male 15,177 49.9 15,177 49.86 
Female 15,265 50.1 30,442 100 
Race 
Caucasian 11,508 37.8 11,508 37.8 
African American 6,851 22.5 18,359 60.31 
Other 12,083 39.7 30,442 100 
2nd Hand Smoke Exposure (home) 
No 27,804 91.3 27,804 91.33 
Yes 2,638 8.67 30,442 100 
Former Smoker 
No 26,181 86 26,181 86 
Yes 4,261 14 30,442 100 
Routine Physical Activity 
No 17,895 83.7 21,381 100 
Yes 3,486 16.3 3,486 16.3 
Some High School or Less 
No 12,717 71.9 12,717 71.9 
Yes 4,969 28.1 17,686 100 
aAll frequencies are un-weighted. 
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Table 2.2 Descriptive statistics of NHANES continuous variables used in the logistic 
regression analysis (2007-2012 NHANES).a 
Variable Label N N 
Miss. 
Mean Std. 
Dev. 
Min. Max. 
Factor1 Principal 
Component 
of logPAHs 
7,347 23,095 2.53E-16 1 -
2.8172 
4.4073 
Age Age at 
Screening 
Adjudicate
d - Recode 
30,442 0 32.3387 25.0055 0 80 
BMI Body Mass 
Index 
(kg/m**2) 
26,875 3567 25.6651 7.6921 12.4 84.87 
Alcohol  Avg # 
alcoholic 
drinks/day -
past 12 mos 
10,305 20137 2.9646 3.1137 1 83 
URXUC
R 
Urinary 
creatinine 
7,907 22535 123.252
6 
79.0192 4 800 
aAll frequencies are un-weighted. 
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Table 2.3 Cross tabulations of overall COPD (self-reported COPD and spirometry-
confirmed COPD), spirometry-confirmed COPD, and lung cancer by smoking status 
(2007-2012 NHANES).a,b 
 
 Smoker - No Smoker - Yes Total 
Overall COPD - No 8,034 (63.53%) 3,288 (26%) 11,322 
(89.53%) 
Overall COPD - Yes 672 (5.31%) 652 (5.16%) 1,324 (10.47%) 
Total 8,706 (68.84%) 3,940 (31.16%) 12,646 (100%) 
 
Spirometry-
confirmed COPD - 
No 
550 (46.53%) 217 (18.36%) 767 (64.89%) 
Spirometry-
confirmed COPD - 
Yes 
185 (15.65%)  230 (19.46%)  415 (35.11%) 
Total 735 (62.18%) 447 (37.82%) 1,182 (100%) 
    
Lung Cancer - No 763 (71.85%) 278 (26.18%) 1,041 (98.02%) 
Lung Cancer - Yes 17 (1.60%) 4 (0.38%) 21 (1.98%) 
Total 780 (73.45%) 282 (26.55%)  1,062 (100%) 
aAll frequencies are un-weighted. 
bPercentages are overall percentages. 
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Table 2.4 Eigenvalues from the principal component analysis of the log transformed 
PAHs (2007-2012 NHANES). 
Eigenvalues of the correlation matrix:  
Total = 9 Average = 1 
 
Eigenvalue Difference Proportion Cumulative 
1 6.81091393 6.0910945 0.7568 0.7568 
2 0.71981946 0.2592624 0.08 0.8367 
3 0.46055711 0.1064763 0.0512 0.8879 
4 0.3540808 0.0728273 0.0393 0.9273 
5 0.28125353 0.1307852 0.0313 0.9585 
6 0.15046834 0.0458525 0.0167 0.9752 
7 0.1046158 0.0178218 0.0116 0.9869 
8 0.08679403 0.055297 0.0096 0.9965 
9 0.031497 
 
0.0035 1.0000 
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Figure 2.1 Scree plot of Eigenvalues from principal components analysis of log 
transformed PAHs (2007-2012 NHANES). 
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Table 2.5 Point estimates and p-values for all variables in model one (2007-2012 
NHANES).   
Parameter 
 
Estimate Standard 
Error 
Wald Chi-
Square 
Pr > ChiSq 
Intercept 
 
-5.5473 0.5627 97.1937 <.0001 
Gender 1 0.2918 0.1725 2.8614 0.0907 
Race 2 -0.3451 0.2239 2.3759 0.1232 
Race 3 -0.7114 0.2202 10.432 0.0012 
Smoker 1 0.839 0.209 16.1199 <.0001 
Former Smok 1 0.3933 0.1863 4.4547 0.0348 
HomSmokExp 1 0.5432 0.2087 6.7761 0.0092 
Some HS or 
less 
1 0.029 0.1999 0.021 0.8848 
Age 
 
0.0386 0.00644 35.8265 <.0001 
BMI 
 
0.0364 0.0122 8.8867 0.0029 
Alcohol 
 
0.0296 0.0309 0.9172 0.3382 
Creatinine 
 
-0.00292 0.00182 2.5681 0.109 
PAHs (all) 
 
0.2584 0.1 6.6772 0.0098 
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Table 2.6 Odds ratio estimates for model one (2007-2012 NHANES).   
Effect Point 
Estimate 
95% Wald Confidence 
Limits 
Gender 1 vs 2 1.339 0.955 1.877 
Race 2 vs 1 0.708 0.457 1.098 
Race 3 vs 1 0.491 0.319 0.756 
Smoker 1 vs 0 2.314 1.536 3.485 
FormSmok 1 vs 0 1.482 1.028 2.135 
HomSmokExp  
1 vs 0 
1.722 1.144 2.592 
Some HS or less 
1 vs 0 
1.029 0.696 1.523 
Age 1.039 1.026 1.053 
BMI 1.037 1.013 1.062 
Alcohol 1.03 0.969 1.094 
Creatinine 0.997 0.994 1.001 
PAHs (all) 1.295 1.064 1.575 
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Table 2.7 Point estimates and p-values for all variables in model two (2007-2012 
NHANES).a   
Parameter 
 
Estimate Standard 
Error 
Wald Chi-
Square 
Pr > ChiSq 
Intercept 
 
-6.1678 0.8236 56.0773 <.0001 
Gender 1 0.1703 0.3491 0.238 0.6256 
Race 2 -0.0591 0.3376 0.0307 0.861 
Race 3 -0.6022 0.3216 3.5056 0.0612 
FormSmok 1 0.4451 0.2403 3.431 0.064 
HomSmokExp 1 0.1988 0.5388 0.1361 0.7122 
Some HS or 
less 
1 -0.2753 0.3551 0.6011 0.4381 
Age 
 
0.0386 0.00774 24.8602 <.0001 
BMI 
 
0.0382 0.0185 4.2479 0.0393 
Alcohol 
 
0.0928 0.0439 4.458 0.0347 
Creatinine 
 
0.00101 0.00234 0.1853 0.6668 
PAHs (all) 
 
0.1133 0.1614 0.4925 0.4828 
 aModel estimates are reported for the non-smoking sub-sample.  
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Table 2.8 Odds ratio estimates for model two (2007-2012 NHANES).a   
Effect Point 
Estimate 
95% Wald Confidence 
Limits 
Gender 1 vs 2 1.186 0.598 2.35 
Race 2 vs 1 0.943 0.486 1.827 
Race 3 vs 1 0.548 0.292 1.029 
FormSmok 1 vs 0 1.561 0.974 2.499 
HomSmokExp  
1 vs 0 
1.22 0.424 3.507 
Some HS or less 
1 vs 0 
0.759 0.379 1.523 
Age 1.039 1.024 1.055 
BMI 1.039 1.002 1.077 
Alcohol 1.097 1.007 1.196 
Creatinine 1.001 0.996 1.006 
PAHs (all) 1.12 0.816 1.537 
 aModel estimates are reported for the non-smoking sub-sample.  
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Table 2.9 Point estimates and p-values of individual PAHs from model one (2007-2012 
NHANES).a 
Parameter DF Estimate Standard 
 
Error 
Wald 
 
Chi-Square  
Pr > ChiSq 
1-napthol 1 0.1398 0.0497 7.9316 0.0049 
2-napthol 1 0.1047 0.0848 1.5272 0.2165 
3-fluorene 1 0.1417 0.0834 2.8874 0.0893 
2-fluorene 1 0.2288 0.0873 6.8756 0.0087 
3-phenanthrene 1 0.1538 0.0808 3.6287 0.0568 
1-phenanthrene 1 0.1192 0.0874 1.8629 0.1723 
2-phenanthrene 1 0.1792 0.0789 5.1621 0.0231 
1-pyrene 1 0.0835 0.0668 1.5609 0.2115 
aCovariates for model one were included in the analysis but are not reported.  
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Table 2.10 Odds ratio estimates for individual PAHs in model one (2007-2012 
NHANES).a   
Effect Point Estimate 95% Wald 
 
Confidence Limits  
1-napthol 1.150 1.043 1.268 
2-napthol 1.110 0.940 1.311 
3-fluorene 1.152 0.978 1.357 
2-fluorene 1.257 1.059 1.492 
3-phenanthrene 1.166 0.996 1.366 
1-phenanthrene 1.127 0.949 1.337 
2-phenanthrene 1.196 1.025 1.396 
1-pyrene 1.087 0.954 1.239 
aCovariates for model one were included in the analysis but are not reported. 
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Table 2.11 Point estimates and p-values of individual PAHs from model two (2007-2012 
NHANES).a,b 
Parameter DF Estimate Standard 
 
Error 
Wald 
 
Chi-Square  
Pr > ChiSq 
1-napthol 1 0.0956 0.0751 1.6173 0.2035 
2-napthol 1 -0.1382 0.1080 1.6383 0.2006 
3-fluorene 1 -0.0430 0.1191 0.1306 0.7178 
2-fluorene 1 0.0544 0.1055 0.2659 0.6061 
3-phenanthrene 1 0.0350 0.1200 0.0850 0.7706 
1-phenanthrene 1 0.0178 0.1009 0.0310 0.8603 
2-phenanthrene 1 -0.0574 0.1007 0.3251 0.5686 
1-pyrene 1 -0.0721 0.0864 0.6958 0.4042 
aCovariates for model two were included in the analysis but are not reported.  
bEstimates are reported for the non-smoking sub-sample. 
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Table 2.12 Odds ratio estimates for individual PAHs in model two (2007-2012 
NHANES).a   
Effect Point Estimate 95% Wald 
 
Confidence Limits  
1-napthol 1.100 0.950 1.275 
2-napthol 0.871 0.705 1.076 
3-fluorene 0.958 0.758 1.210 
2-fluorene 1.056 0.859 1.298 
3-phenanthrene 1.036 0.819 1.310 
1-phenanthrene 1.018 0.835 1.241 
2-phenanthrene 0.944 0.775 1.150 
1-pyrene 0.930 0.786 1.102 
aModel estimates are reported for the non-smoking sub-sample. 
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CHAPTER 3 
ESTIMATING THE STRENGTH OF ASSOCIATION AMONG COPD 
AND LUNG CANCER DEATHS ATTRIBUTABLE TO PAHS IN SOUTH 
CAROLINA 
Overview 
The scope of the investigation for chapter three was a state-wide population-based 
ecological study of PAH exposure concentrations in South Carolina. It sought to test the 
strength of PAH associations with deaths from COPD and lung cancer. In other words, 
this population-based ecological study assessed annual PAH exposure concentrations and 
to what extent they contribute to mortality from the two diseases. 
The rates of COPD mortality and morbidity in SC rank among the highest in the 
nation. COPD prevalence among South Carolinians ranked 15th in the nation (within the 
highest quartile) in 2016 with an age-adjusted prevalence of 7.1% (Centers for Disease 
Control and Prevention, National Center for Chronic Disease Prevention and Health 
Promotion, Division of Population Health, 2016). Additionally, COPD is the fourth 
leading cause of death in SC and SC had the 12th highest mortality rate from COPD in the 
nation in 2017 (Centers for Disease Control and Prevention, National Center for Health 
Statistics, 2017). In regards to lung cancer, South Carolina ranks 17th in age-adjusted 
incidence (64.2 cases/100,000 people in 2014), and 18th for age-adjusted mortality (46.6 
deaths/100,000 in 2014) (U.S. Cancer Statistics Working Group, 2017).  
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A significant proportion of COPD and lung cancer cases are attributable to smoking both 
nationally as well as in SC (DHHS, 2014; McLain et al., 2017). This was an important 
investigation from a state-wide perspective to assess what
proportion of these diseases can be attributed to an exposure hazard beyond that of 
tobacco smoke. Additionally, the connection of this study to the port expansion in 
Charleston speaks to the importance of estimating the influence of a new context of 
ambient air pollution for the state.  
The main research question of chapter three was whether there exists a significant 
association between deaths from COPD/lung cancer given the annual exposure 
concentrations of PAHs at the census tract level. The primary hypothesis to test was 
whether environmental exposure to ambient PAHs significantly contributes to mortality 
from the two diseases. It is important to note that although a significant section of the 
literature review was devoted to the etiopathogenesis of COPD-lung cancer from PAHs, 
it was beyond the scope of this investigation to determine whether ambient PAH 
exposures caused the deaths from COPD or lung cancer in the study population. 
Estimating attributable mortality to PAHs was the scope of the study’s investigation. 
Finally, two primary data sources were used to test the hypothesis referenced 
above. The first was the EPA’s National Air Toxics Assessment (NATA) datasets for 
years 2002, 2005, and 2014. The rationale for employing this source in the study is 
addressed below. The second primary dataset employed was mortality data for South 
Carolina, provided in five year aggregates between 2002 and 2014. The source for this 
data was the SC Department of Health and Environmental Control’s Office of Vital 
Statistics (DHEC VS).  
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Study Rationale 
Numerous air pollution studies assessing adverse health outcomes (i.e. mortality) 
used approaches similar to the one outlined in this chapter. Additionally, one of the most 
relevant studies identified in chapter one, the ESCALA study, assessed daily air pollution 
concentrations and the effect on mortality in nine Latin American cities (Romieu et al., 
2012). In it, COPD was identified to have significant mortality effects from daily air 
pollution concentrations. While daily concentrations are not assessed by EPA within 
NATA, studies utilizing annual concentrations are of significant importance to build an 
evidence-base to justify the proposed study, and are summarized below.  
 Numerous investigations were identified in the literature that used annual air 
pollution concentrations to assess the contribution to adverse health outcomes. In this 
respect, annual concentrations of air pollutants were most commonly referred to as long 
term exposure assessments (vs. short-term or daily assessments) in the identified studies. 
The most common air pollutants identified in the literature included PM10, PM2.5, NO2, 
SO2, NOx, and O3. Two significant studies assessed lung cancer mortality using annual 
ambient air quality data, Hwang, Lee, Jung, Lim, & Kwon (2007) and Sifaki-Pistolla et 
al. (2017). Hwang et al., (2007) utilized a Poisson model to analyze annual ambient air 
quality data with standardized mortality ratios (SMRs) and standardized incidence ratios 
(SIRs) from national cause of death statistics in seven South Korean cities. They found 
significant associations with PM10 and lung cancer mortality among females. Sifaki-
Pistolla et al. (2017) carried out a lung cancer mortality and incidence study in Greece 
that used annual concentrations of air pollutants and matched these to mortality rates and 
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age-adjusted incidence from the national cancer registry. A significant association was 
found between ambient air pollutants and lung cancer mortality, with the highest risk 
found in major urban centers.  
An additional study that used a similar approach was carried out by Cao et al. 
(2011). In their investigation, a cohort of middle-aged men and women (N=70,947) were 
followed up after 10 years to assess mortality. They matched national hypertension 
survey data with fixed-site monitor data using resident zip codes. Their findings showed 
similar results from above with statistically significant associations of SO2 and NOx with 
cardiopulmonary and lung cancer mortalities. Additional studies using annual 
concentrations of hazardous air pollutants (HAPs) to assess mortality and other adverse 
outcomes include Yorifuji et al. (2013), Orru, Laukaitienė, & Zurlytė (2012), Elliott, 
Shaddick, Wakefield, de Hoogh, & Briggs (2007), Chiu et al. (2006), Jiřík et al. (2016), 
Gholampour et al. (2014), and Nasser et al. (2015).  
Modeling air quality exposures has precedence in epidemiological studies such as 
Carey et al. (2013), Bentayeb et al. (2015), and Thurston et al. (2016). Specifically, Carey 
et al. (2013) was an English cohort study that used annual pollution concentrations 
(PM10, PM2.5, NO2, O3, & SO2) and emissions-based models to match with death 
certificates at the postcode level. Bentayeb et al. (2015) was a French cohort mortality 
study and used a chem-transport model to estimate annual pollution exposures of PM10, 
PM2.5, NO2, O3, and SO2. Finally, Thurston et al. (2016) was a large U.S. cohort 
mortality study (N=517,041 men and women) that used annual exposure estimates 
derived from EPA’s Air Quality System (AQS) to generate census tract level estimates of 
PM2.5.  
 73 
The use of NATA exposure concentrations of various HAPs is well documented 
in the epidemiological literature. Many of them have focused on the early childhood 
impacts of various ambient air pollutants. Perhaps one of the most relevant studies to the 
proposed research was the work of  Grineski & Collins (2018). They used NATA data to 
assess environmental justice issues of neurotoxicants in U.S. public schools. Their most 
significant findings revealed that Metropolitan New York public schools (EPA Region 2) 
were identified as the most burdened from ambient neurotoxicants in the country 
(Metropolitan New York is the study area of chapter four’s analysis). Additional studies 
using NATA’s annual ambient exposure concentrations include Lupo et al. (2010), 
Stingone, McVeigh, & Claudio (2017), Dickerson et al. (2016), Woodruff, Wells, Holt, 
Burgin, & Axelrad (2007), and Windham, Zhang, Gunier, Croen, & Grether (2006).  
By proposing the use of NATA’s modeled approach to include in a new model to 
regress ambient PAH contributions with COPD and lung cancer death in South Carolina 
(as well as in New York City), there is an inherent limitation that models upon models 
add to the overall noise or uncertainty of overall estimates. As demonstrated above, this 
has not been a deterrent to utilizing NATA in epidemiological studies as a reliable data 
source to assess the adverse health outcomes from hazardous environmental exposures 
previously. Given this potential limitation however, there is documented literature of 
NATA’s sensitivity analyses. Touma, Isakov, Ching, & Seigneur (2006) provide a 
general overview of NATA by summarizing its strengths and applications while 
addressing its limitations. They point out that model-to-monitor comparison of NATA’s 
ambient concentration estimates that were modeled, performed within a factor of two at 
most sites. Dominici, Zeger, & Samet (2000) indicate that personal exposure assessment 
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reveals that pollutant monitors aren’t enough. Thus, quality personal exposure considers 
both indoor and outdoor sources for exposures. Payne-Sturges, Burke, Breysse, Diener-
West, & Buckley (2004) add to this with their sensitivity study using a NATA model 
while comparing it to personal exposure monitoring efforts. Their rationale for this study 
indicated that human exposure research has consistently shown personal exposures can 
be significantly different from outdoor air concentrations. Thus, risk assessments using 
such sources can over or under-estimate risk. Their results revealed that NATA’s related 
model was reasonably accurate as a surrogate for personal exposures when it came to 
mobile sources and background sources. In other areas, it estimated lower exposures. 
When this was extrapolated for lifetime cancer risk for example, there was a three-fold 
greater estimate than that of what NATA estimated. The authors continued here on the 
importance of considering indoor sources for personal exposure, which when accounting 
for indoor secondhand smoke exposure, would most likely assume a significant 
proportion of HAP exposure.   
EPA NATA Overview and Methodology 
 Assessment of the PAH exposure concentration amounts at the census tract level 
over the course of a given year are based on the EPA’s hybrid model used to develop this 
respective variable in the National Air Toxics Assessment (NATA) dataset. The rest of 
the section below is devoted to providing a summary of the methodology used to develop 
the exposure concentration variable.  
Before summarizing how population exposures are estimated within NATA, it is 
important to identify the larger methodology EPA carried out to generate the overall 
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dataset. There are four primary analytical steps taken to complete each iteration of 
NATA: 
• Compile National Emissions Inventory (NEI); 
• Estimate ambient concentrations of air toxics across the U.S; 
• Estimate population exposures; and 
• Characterize potential public health risks from inhalation.  
The current study was interested in the first three steps identified above and 
completed its own investigation of the public health risks associated with estimated 
exposures. The bulk of this current section will summarize the hybrid model used to 
generate population exposure estimates, while briefly touching upon the first step 
identified above to provide a basic foundation of the overall NATA methodology.  
The NEI provides the basis for which NATA emissions are assessed, where the 
methodology for its collection has been described elsewhere (Environmental Protection 
Agency Office of Air Quality, Planning, and Standards, 2016). The approach taken 
within NATA is to systematically compile a nationwide inventory of air toxic emissions 
with NEI as its primary source. Quality assurance and reviews were conducted by state 
and local agencies as well as reviewers to make changes while the NATA emissions 
inventory was in development. To process the NEI data, certain steps took place such as 
placing individual chemicals into groups as well as adjusting emission rates of metal 
compounds based on the molecular weights of toxic metal proportions found within it 
(Environmental Protection Agency Office of Air Quality, Planning, and Standards, 2015). 
NATA includes the following emission source types and estimates from NEI: 
• Point sources/Major Stationary Sources i.e. factories, large waste incinerators, etc; 
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• Nonpoint sources/area and smaller stationary sources i.e. small manufacturers, dry 
cleaners; 
• On-road and non-road mobile sources i.e. trucks, cars, boats, etc; 
• Fires and biogenic sources; 
• Estimates for background emissions from natural and anthropogenic toxics 
persisting from previous emission years as well as those transported from distant 
sources; 
• Estimates for secondarily formed emissions i.e. photochemical reactions in the 
atmosphere producing formaldehyde, acrolein, etc.  
NEI data sources for HAPs used to develop NATA emissions have been described 
elsewhere. A full description of the first analytical step in the NATA methodology of 
compiling NEI emissions data can be accessed in the NATA Technical Support 
Document (TSD) found at: https://www.epa.gov/national-air-toxics-assessment/2011-
nata-technical-support-document).  
Each iteration of the NATA dataset (1996, 1999, 2002, 2005, 2011 and 2014) 
included improvements in their air quality and exposure modeling. The latest 
methodology from 2014 will be covered below and areas where the previous iterations of 
the methodology were improved upon will be addressed where appropriate.  
A hybrid approach was used by the EPA to generate census tract-level air quality 
concentrations of air toxics within NATA. The two models used during this analytical 
step were the AERMOD dispersion model (American Meteorological 
Society/Environmental Protection Agency Regulatory Model - a component of the 
Human Exposure Model version 3; HEM-3) and a chemical transport model, CMAQ (the 
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Community Multiscale Air Quality Modeling System). Both were utilized within NATA 
to capitalize on their individual strengths.  
CMAQ’s function as a model is to carry out urban and regional scale simulations 
of multiple air quality issues (Environmental Protection Agency Office of Air Quality, 
Planning, and Standards, 2015). Its novel technique brings together both physical and 
chemical purposes connected to air pollutants at various scales and how they are 
transported and dispersed. The resolution of the grid used by CMAQ to generate ambient 
air concentrations was 12 km x 12 km. Primary abilities of the CMAQ model that are 
considered strengths include conservation of mass (accounts for pollutants leaving an 
area and its contribution to the new area), consideration of long range transport of 
pollutants, and estimated concentrations of secondarily-formed pollutants. A total of 40 
HAPs are modeled in CMAQ and its uniqueness in comparison to AERMOD is its 
inclusion of fires and biogenic emissions as well as the secondary formation of pollutants. 
Neither of these were included in AERMOD. 
AERMOD is the EPA’s preferred air quality model used for regulatory purposes. 
It has the ability to estimate ambient concentrations at a low geographic granularity. 
During the analysis, AERMOD was run within the larger HEM-3 model (specifics of the 
HEM-3 can be accessed in the TSD). According to the NATA Technical Support 
Document, the AERMOD receptor locations used during the modeling were based on 
three primary elements: centroid of populated census blocks, monitoring site positions, 
and five evenly distributed points within each 12 km x 12 km CMAQ grid cell. The 
concentrations for each census block were then weighted according to population size to 
develop census tract concentrations. Again, the differences between AERMOD and 
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CMAQ were with fires and background estimates only being addressed by CMAQ. 
However, AERMOD did include all of the other emission source types. The final output 
of AERMOD provides ambient air concentrations for each receptor.  
The hybrid approach of both models entailed capitalizing on the low geographic 
granularity of pollution sources from AERMOD with the contribution of the chemistry 
and transport provided by CMAQ. It is important to note that AERMOD as a model does 
not treat pollutant species as chemically reactive. Therefore, the data from emissions and 
meteorology used in CMAQ were taken an additional step to align AERMOD inputs with 
that of CMAQ. The EPA suggests that the novelty of this hybrid approach to modeling 
“attempts to optimize characterization of non-reactive and reactive species across 
multiple spatial scales” (Environmental Protection Agency Office of Air Quality, 
Planning, and Standards, 2015 p.81). The advantage of this approach compared to the 
modeling carried out in 2005 is the capability to “anchor” the AERMOD receptor 
concentrations to the CMAQ grid concentrations. Without such an approach, mass is not 
conserved and double counting can take place to create redundancies, which was a 
limitation in 2005’s model.  
Background estimates of ambient air toxics is an important consideration 
accounted for within NATA. Background concentrations considered were those from 
natural sources, emissions of persistent chemicals occurring from the previous year, and 
long-range transport from distant sources. These are treated separate from anthropogenic 
emissions of the same pollutants for a given year. The modeling carried out by CMAQ 
included background concentrations while a spatially uniform remote background 
concentration was calculated for the AERMOD-only pollutants and added to the overall 
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model concentrations. The final output from the hybrid model estimates ambient 
concentrations at every census block receptor which was then weighted according to the 
block’s population to generate a population-weighted average across the respective 
census tract. 
NATA used an additional model to assess human exposure to ambient 
concentrations at the census tract level called, HAPEM7. This next analytical step in 
NATA’s methodology is imperative as the concentration of a pollutant that a human 
breathes could be higher or lower than the ambient concentration of a fixed location, in 
this case estimated for census tracts (Environmental Protection Agency Office of Air 
Quality, Planning, and Standards, 2015). Additionally, both AERMOD and CMAQ do 
not directly address this level of human exposure in their respective models. Thus, 
HAPEM7 utilized the ambient concentrations of census tracts estimated from the hybrid 
approach as inputs in for its model, which is termed a screening-level inhalation exposure 
model.  
Alongside ambient concentrations, HAPEM7 used a series of inputs from a 
variety of sources to generate estimates for human exposure. Sources include census data, 
human activity pattern data, ambient air quality levels, climate data, and indoor/outdoor 
concentration relationships. What is then estimated at this point in the analysis is an 
expected range of inhalation exposure concentrations for groups of individuals. Then, for 
the best estimate of exposure, the estimate is derived for a hypothetical person for the 
respective census tract.  
It is important to note that the analyses in the 2002 and 2005 NATA datasets 
employed the HAPEM simulation generated in 1999 while the 2011 and 2014 NATA 
 80 
used a combination of new updates with the original model. These new simulations were 
carried out for a variety of pollutants which included generic PAHs – of primary interest 
for chapter three’s investigation. 41 HAPS and diesel PM were estimated in 2011, while 
51 HAPS and diesel PM were estimated in 2014. 
Again, additional analytical detail for estimating population exposures is provided 
in the NATA TSD. Background for the HAPEM7 model can be found at the following 
weblink: (https://www.epa.gov/fera/human-exposure-modeling-hazardous-air-pollutant-
exposure-model-hapem). Finally, it is important to note that various other approaches to 
modeling within NATA were carried out in previous iterations of the assessment system. 
According to the Environmental Protection Agency Office of Air Quality, Planning, and 
Standards (2015), a series of changes made to modeling ambient concentrations as well 
as exposure estimates vary across each iteration. Additionally, the final step of estimating 
health risks within NATA is not expounded upon here as it does not pertain to the current 
study since that is the scope of this analysis.   
 
Methods 
Again, chapter three is an investigation in the association of COPD and lung 
cancer deaths with PAHs from outdoor air using South Carolina as the study area. The 
primary statistical procedure used for this analysis was a Poisson regression model since 
its focus was modeling using counts of which census tract mortality aggregates were 
analyzed. Two models were developed, one for COPD and another for lung cancer. As 
was used in chapter two, SAS 9.4 was the primary statistical software utilized to run the 
analysis. 
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Air Quality data for PAH exposure concentrations were acquired from the EPA’s 
National Air Toxics Assessment (NATA) data portal for the following years: 2002, 2005, 
and 2014. Although 2011 NATA was available for use and was assessed in the analysis 
for the 2010-2014 models for lung cancer and COPD, only the 2014 results are presented 
since they are the most recent. Additionally, no significant differences were observed 
between the two iterations in the 2010-2014 models.  Next, although earlier years of 
NATA were available for 1996 and 1999, EPA did not model annual PAH exposure 
concentrations at the census tract level during these two first iterations. Finally, NATA 
datasets are public domain and require no payment to download.  
Mortality data for COPD and lung cancer were acquired from DHEC VS and 
were provided in five-year aggregates of mortality frequencies for the above diseases in 
each census tract across the state. A data request was completed to acquire mortality data 
from DHEC VS according to agency protocol. A concurrent proposal was submitted 
through the University of South Carolina’s Office of Research eIRB portal acquiring IRB 
approval to satisfy institutional review of the study. ICD-10 codes requested from DHEC 
Vital Statistics included J40-J44 and J47 for COPD and C34.82, C34.90, and C34.91 for 
lung cancer.  
Various other data sources were utilized to carry-out the modeling in the study. 
These sources and the justification for testing in the Poisson models for each disease are 
addressed in the next section. All data were matched at the census tract level in an 
attempt to acquire the same geographic comparisons, where available. Variables available 
at the county level as the lowest level of geographic granularity are indicated in the 
following section as well. Years of all covariates/independent variables matched with the 
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dependent variable of COPD and lung cancer deaths were analyzed where available 
among the years between 2002 and 2014.  
COPD Model Covariates 
Specific covariates for deaths related to COPD and lung cancer vary, thus the 
need for two distinct Poisson models. To isolate the associated significance of PAH 
exposure concentrations with COPD/lung cancer mortalities, adjustment of confounding 
factors were carried out by including a variety of covariates into the model.  
 Schembri et al. (2009) developed a predictive model for COPD hospital 
admissions and deaths assessing numerous explanatory variables including gender, age, 
smoking status, BMI, respiratory symptoms (spirometry, dyspnea score, mobility, airway 
questionnaire, etc.), and past medical history (oxygen use, inhaler technique, steroid use, 
antibiotic use, and vaccination status). Additionally, a review by Celli (2010) reported 
primary predictors of COPD mortality such as Forced Expiratory Volume in one second 
(FEV1), dyspnea, exercise capacity, and BMI.  
Several studies have assessed the causes of mortality in COPD. For example, the 
Lung Health Study carried out a randomized clinical trial (RCT) among smokers aged 35 
- 60 using cessation treatments as well as bronchodilator therapy. Mortality rates were 
low (12% among the cohort), however the leading causes of death during the 14-year 
follow-up were cancer (33%), cardiovascular disease (22%), and respiratory disease (8%) 
(Anthonisen et al., 2005b). Another study among more severe cases of COPD revealed 
different results. Among patients with  COPD where inhaled corticosteroids and a 
placebo were used for treatment, a pooled analysis of RCTs demonstrated that during a 
follow-up period of 26 months, the leading causes of death included respiratory disease 
 83 
(34%), cardiovascular disease (30%), cancer (21%) and other causes (15%) (Sin et al., 
2005). 
Given these predictors of COPD mortality were primarily focused on individual 
medical histories, it is a known limitation for an ecological study like the one outlined 
above that relies on population data to adequately predict COPD deaths from PAHs 
without access to direct medical records where variables like FEV1, BMI, comorbidities, 
oxygen use, etc. could be assessed for inclusion into a predictive model. However, since 
this is a population-based study, the following variables will be relied upon. With this 
ecological approach, covariates will be socio-economic (census-sourced) and 
environmentally focused. Furthermore, there is substantial public and population health 
evidence for such statistical modeling with support from frameworks like the social 
determinants of health and conceptual frameworks that link population with elements like 
primary health care service (Levene, Bankart, Khunti, & Baker, 2012; Singh et al., 2017). 
Several studies have assessed socio-economic and environmental factors for 
COPD mortality at the population level. Levene et al., (2012) carried out a mortality 
study for various chronic diseases investigating primary care centers. The main predictors 
for mortality in the study were age and low socio-economic status (SES). In regards to 
access to medical care, a 1% increase in the proportion of patients recalling better able to 
see their preferred doctor was associated with reductions in COPD mortality by 0.7% (CI 
0.2-2.0%, p=0.02). Gershon, Dolmage, Stephenson, & Jackson (2012) carried out a 
review of the most significant determinants of health for COPD outcomes with a specific 
focus on socio-economic status. Specific findings suggested that COPD sufferers of the 
lowest SES bracket were twice as likely to have poor outcomes when compared to the 
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highest bracket. They conclude that social and economic disadvantage has a consistent 
and significant effect on both mortality and morbidity from COPD.  
The primary data source that was used to assess SES-related covariates in the 
COPD-Poisson model was the American Community Survey (ACS) and 2000/2010 
census results found on the American Fact Finder web portal 
(https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml). ACS covariates were 
accessed using census tract geographies and linked with the NATA-PAH and DHEC VS-
COPD mortality datasets (also outlined for census tract counts). Age, race/ethnicity, 
gender, educational attainment, employment status, median household income , and 
poverty status in the past 12 months were covariates acquired from ACS/census.  
Environmental or ecological predictors of mortality can be construed from a 
broad lens in public and population health; however, classical environmental domains 
would consider covariates from air, water, and soil sources. Thus, the NATA-PAH 
dataset was the primary source for air to be assessed in the model. County-level smoking 
prevalence was included using BRFSS five year moving averages available from the 
Robert Wood Johnson County Health Rankings.   
A primary climate-related variable included in one of the short-term/daily air 
pollution studies addressed above, included temperature as a statistically significant 
covariate (Romieu et al., 2012). From a long-term investigative approach using annual 
ambient concentration exposures matched with annual mortalities, the overall sample size 
of temperature on a yearly frequency was assumed to be too small for significance for 
inclusion in the model. Thus, accommodation was pursued by other means by 
aggregating the number of temperature related events in a given year by using National 
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Oceanic Atmospheric Administration (NOAA) 30-year averages for the number of 
heating and cooling days.  
Offering evidence for which environmental covariates (i.e. temperature) to test in 
the model is the work of Chan, Weinhold, Thomas, Gohlke, & Portier (2015). They 
tested the environmental predictors for mortalities related to cardiopulmonary and 
cardiovascular diseases across all counties in the U.S. including COPD and lung cancer. 
Primary climate-related data utilized by Chan et al. (2015) include monthly averages of 
three primary determinants of weather: temperature, precipitation, total heating degree 
days and total cooling degree days. The U.S. National Oceanic and Atmospheric 
Administration’s Comparative Climatic Data was used as the source for this data. Also 
included were air quality concentrations of NOx, SOx, PM2.5, PM10, Volatile Organic 
Carbons (VOCs), NH3, CO, and O3 that came from a variety of EPA sources. Another 
air quality measure included was diesel emissions which was acquired directly from 
NATA.  Socio-economic data tested in their model included social capital data derived by 
Rupasingha, Goetz, & Freshwater (2006). They used 14 county-level social capital-
related indicators which were assessed and merged into five components e.g. community 
organizational life, engagement in public affairs, social trust, etc. These were used by 
Chan et al. (2015) to generate a total of 16 social capital indicators that were tested in 
their analysis. Also included were risk factor data on exercise, few fruits and vegetables, 
obesity, hypertension, smoking, and diabetes, which were acquired from the U.S. 
Department of Health and Human Services’ Community Health Status Indicators. 
Finally, demographic and economic-related data was sourced from the Census Bureau 
including poverty level, educational level, number of primary care physicians per 10,000 
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population, number of dentists per 10,000 population, racial composition, median ages 
for each sex, combination of both sexes, median household income, median family 
income, county per capita income, crime characteristics, housing characteristics, and 
employment by industry.  
The results from Chan et al. (2015) for all-causes mortality revealed only two 
statistically significant predictors across all groups. These were percentage of single 
parent households and percentage of people aged 16-64 years with physical disability. 
Among four of the groups, percentage of votes cast for president, percentage of Hispanic 
or Latino, percentage of adults reporting no exercise, and total suicide deaths per 100,000 
population were significant. Finally, the only significant environmental variable was O3. 
When modeling COPD mortality, no covariate was universal across all quintiles, 
however percentage single parent households, percentage of people aged 16-64 years 
with physical disability, and percentage Black or African American was found across 
four of the quintile groups. Among the environmental pollutant data, none were 
significant for COPD mortality alone, however ozone was the only environmental 
pollutant that showed significance in a combination analysis of cardiovascular diseases, 
cancers, and COPD. Thus, it will be pertinent to test the significance of PAHs with the 
proposed study.  
Given the evidence mentioned above for inclusion of such covariates, Table 1 
provides a summary of the covariates that were tested in the COPD Poisson model. 
Finally, it should be noted that a variety of soil, water, and other ambient air pollution 
covariates could be included that have not been expounded upon or discussed for 
consideration into the model. However, since the goal of this research was to first test the 
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strength of PAHs in a regression of COPD/lung cancer mortalities, pursuit of additional 
air, water, and soil data sources could be considered by follow-up studies, especially 
considering the uniqueness and expenditure of resources that acquiring this type of data 
entails.  
Lung Cancer Model Covariates 
 Many of the proposed covariates for COPD will be utilized in the lung cancer 
model as well, especially considering the framework provided by Chan et al. (2015). 
However, to explore whether unique covariates for lung cancer mortality exist, a review 
of the lung cancer mortality literature among population-based studies was carried out.  
The first item to consider in this review was what Chan et al. (2015) identified in their 
regression parameters when assessing cancer mortality in the U.S. The only covariate 
with significant results for all of the quintiles was percentage of people aged 16-64 years 
with physical disability. One additional covariate had significance among four of the 
quintiles – percentage Hispanic or Latino. Ozone was the only environmental pollutant 
that showed significance in a combination analysis of cardiovascular diseases, cancers, 
and COPD; as well as cardiovascular diseases, cancers, and reductions in life expectancy.  
A follow-up study assessing the ABO phenotypes and inflammation-related 
predictors of lung cancer mortality was carried out by Suadicani, Hein, & Gyntelberg 
(2007). Among the various phenotypes assessed, significant predictors included tobacco 
consumption, high salt intake, long-term occupational dust exposure, high fat intake, and 
consumption of alcohol. Thus, dietary factors and inflammation-related factors like 
hypertension as was discussed by Chan et al. (2015), should be considered with the lung 
cancer model as well. As phenotype is mentioned at this juncture, it is important to note 
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that genetic covariates to be tested in the proposed regression study are outside of the 
scope of this analysis, due again to its ecological design without the benefit of individual 
medical records.  
Future directions in lung cancer epidemiology were addressed by Alberg, Brock, 
& Samet (2005). They focused on the pandemic of lung cancer over the 20th century 
largely in part due to smoking and admit that smoking rates are in decline and thus lung 
cancer should be in decline over the next decade and will begin to level off around 2030. 
They admit that unless greater reductions are made in smoking prevalence however, the 
burden of lung cancer will continue to persist. Thus, it is imperative to assess the 
contribution that both smoking and air pollution have on lung cancer mortality.  
Socio-economic predictors of lung cancer mortality were tested by Mazza et al. 
(1999). Low income and rural environment were both significant predictors identified in 
their double cohort study when compared to subjects living in an industrial town. They 
conclude that smoking, alcohol consumption, and poor living conditions can increase 
cancer mortality even when other protective environmental conditions like rural 
Mediterranean life are present.  
 Kanarek, Fitzek, Su, Brower, & Jia (2008) explored the ecological predictors of 
lung cancer mortality at the county level by use of decision tree analysis with the 
intended benefit of targeting public health practitioners. They determined significant 
predictors included smoking, prior coronary heart disease mortality, poverty, and 
National Air Toxics Assessment excess cancer deaths estimates provided by the EPA in 
the NATA datasets. 
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Supporting the inclusion of secondhand tobacco smoke into a risk model includes 
the work of Burnett et al. (2014). They created a global burden of disease risk function 
attributable to fine particulate matter (PM2.5). The significant covariates determined in 
their analysis included ambient air pollution, secondhand smoke, household solid cooking 
fuel, and active smoking. The population attributable fractions for ambient air pollution 
exposure for COPD and lung cancer was < 1 to 21 and < 1 to 25 respectively. 
Methodology Summary 
Goal: To assess annual PAH exposure concentrations in South Carolina and to 
what extent they contribute to mortality from COPD and lung cancer. 
Objective: Investigate the strength of association between NATA-derived census 
tract PAH exposure concentrations and deaths from COPD and lung cancer using Poisson 
regression modeling. 
Null hypothesis: There is no significant association between NATA-derived PAH 
exposure concentrations and mortality from COPD and lung cancer at the census tract 
level.  
Alternative Hypothesis: There is a significant association between NATA-derived 
PAH exposure concentrations and mortality from COPD and lung cancer at the census 
tract level.  
 
Results 
The analysis completed for chapter three focused on census tract comparisons of 
COPD and lung cancer deaths in South Carolina. Census tract death counts of COPD and 
lung cancer were utilized as the dependent variables in respective Poisson regression 
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models while adjusting for known confounders. Four models were carried out for COPD 
and lung cancer deaths each. Eight total analyses were completed using five-year death 
aggregates for both diseases for the following year ranges: 2002-2006, 2004-2008, 2006-
2010, and 2010-2014. It is important to reiterate that 2011 NATA data was assessed 
using the 2010-2014 models and no significant differences were observed among the 
PAH associations with the outcome variables, and the results have not been included. 
Again, the 2014 NATA data used for the 2010-2014 models and the results are included 
below. 
The primary datasets utilized in the analysis included vital statistics mortality data 
from DHEC PHSIS (as described above), EPA’s NATA data for years 2002, 2005, and 
2014, U.S. Census data for 2000 and 2010, Robert Wood John Foundation’s County 
Health Rankings (CHR) 2010, CDC’s Community Health Status Indicators (CHSI) 2010, 
and NOAA’s Annual Climate Normals from 1981 to 2010. Additionally, water quality 
data for a PAH proxy (benzoapyrene- BaP) was provided by DHEC’s Drinking Water 
Compliance Monitoring Program for 2002 to 2017. However, no data was generated for 
these years as BaP concentrations have never been detected by the program’s monitoring 
thresholds. Covariates tested in the model are summarized in Table 3.1 according to their 
data source, spatiality (census tract or county), and temporality (years available).  
EPA NATA data was utilized in each model for the nearest year available. Thus, 
model one (2002-2006) utilized 2002 NATA data, models two and three (2004-2008 and 
2006-2010) used the 2005 NATA, and model four (2010-2014) used the 2014 NATA. All 
NATA data were available at the census tract level. 2000 U.S. Census covariates were 
utilized for the first three models (2002-2006, 2004-2008, and 2006-2010) and 2010 
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Census covariates were utilized for model four (2010-2014). All Census data were 
available at the census tract level. County Health Rankings and Community Health Status 
Indicators were available for only as early as 2010 and only as low as the county level. 
Thus, their respective county-level covariates were utilized for all models. Original 
sources and documentation for CHR and CHSI have been described elsewhere (Centers 
for Disease Control and Prevention, 2010; County Health Rankings, 2018)  
NOAA Climate Normals were utilized for their summary of 30 year aggregates of 
heating and cooling days. Heating and cooling days were averaged over this period and 
included as an annual average in each of the models. NOAA provided Climate Normals 
at the county level which were applied to each census tract in the merged dataset for the 
respective county they reside in. A small number of counties did not have Climate 
Normals data. Thus, cities with available Climate Normals were utilized as a county 
proxy for the respective census tracts in the merged dataset.  
Each dataset was provided in an original CSV file. They were cleaned for missing 
variables, merged, and the rest of the analysis was completed using SAS 9.4. Missing 
deaths in the vital statistics dataset were actual zeroes and not missing. Thus, the dataset 
was adjusted accordingly. The overall sample sizes for models one through three were 
874 census tracts, and model four had a sample size of 1,103 census tracts. Average 
counts for lung cancer and COPD deaths at the census track ranged from 12.78 to 13.37 
and 9.8 to 11.73, respectively. It is important to note that average lung cancer deaths at 
the census tract level decreased from 2002 to 2014, however average COPD deaths 
increased during this same time period. A summary of the descriptive statistics of all 
covariates used in each model is included in Appendix B (Table B.1-B.4).  
 92 
Model 1: Regression of COPD and Lung Cancer Deaths (2002-2006) 
Model one consisted of two analyses – a Poisson regression each for COPD 
deaths (Model 1.a) and lung cancer deaths (Model 1.b). All covariates included in the 
models were proportions i.e. percentage of females per census tract, percentage of 
African Americans per census tract, percentage of smokers per county, average number 
of heating days per county, etc. An offset statement was used in the model which 
transformed death counts (dependent variable) into rates. This was carried out since the 
dependent variables were originally available in five-year aggregates. Census tract 
population counts were log transformed and then included as the new variable for the 
offset. The models carried out were multi-level regressions as they included both census 
tract and county-based covariates.  
The number of observations read in model one were 602. Statistical significance 
was defined as those estimates with a p-value < 0.05. In Model 1.a, covariates identified 
as those with statistically significant estimates included Percent Hispanic (p= 0.0408), 
Median Household Income (p= 0.0482), Percent with Education of Some High School or 
Less (p<0.0001), Adults 65 and Over (p<0.0001), Percent Female (p<0.0001), and PAHs 
(p= 0.0048). All statistically significant covariates had point estimates in the positive 
direction (with the exception of Percent Hispanic β= -0.0264) indicating a positive 
correlation with COPD deaths. It is important to note that Smoking was not statistically 
significant (p= 0.8542). A summary of the analysis of the maximum likelihood parameter 
estimates from the Poisson regression can be found in Table 3.2.   
In model 1.b, statistically significant covariates identified were Construction 
Occupation Prevalence (p= 0.0279), Percent with Education of some High School or Less 
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(p= 0.0038), Percent Adults 65 and Over (p<0.0001), Percent Female (p= 0.0269), and 
Number of Heating Days (p= 0.0377). It is important to note that Smoking (p= 0.0624) 
and PAHs were not statistically significant (p= 0.0624, p=0.1074, respectively) for lung 
cancer deaths in model 1.b. Table 3.3 provides a summary of the maximum likelihood 
parameter estimates. 
Model 2: Regression of COPD and Lung Cancer Deaths (2004-2008) 
The methodology utilized in model one was kept the same for models two 
through four. 874 observations were read and 602 observations were used in model two. 
Statistically significant covariates were the same as in model 1.a (COPD deaths) with the 
addition of Percent African American (p=0.0216) and Construction Occupation 
Prevalence (p= 0.0285). The point estimates for the significant racial covariates however 
were negative (β= -0.0323 and -0.0268, respectively) indicating a negative correlation or 
protective effect on COPD deaths. All other covariates were positive, indicating a non-
protective effect on COPD deaths. Again, PAHs were statistically significant (p= 0.0001) 
with an estimate in the positive direction (β= 0.1648). It is important to note there was no 
significance again with Smoking in model 2.a.  
Statistically significant results for model 2.b (Lung cancer deaths) were the same 
as in model 1.b with the addition of Hispanic composition (p= 0.032) and Percent Poverty 
(p= 0.0165). Hispanic composition and Percent Poverty had negative point estimates  
(β= -0.0225 and -0.0093, respectively) indicating a protective effect on lung cancer 
deaths. All other covariates had positive point estimates indicating a non-protective effect 
on lung cancer deaths. Again, PAHs and smoking were not statistically significant  
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(p= 0.2129 and 0.1776).  The results of the regression analysis for models 2.a and 2.b can 
be located in Appendix B (Tables B.5 and B.6). 
Model 3: Regression of COPD and Lung Cancer Deaths (2006-2010) 
 874 observations were read and 602 were used in model three. Model 3.a (COPD 
deaths) resulted in statistically significant covariates that remained the same with model 
2.a with the exception of the removal of Percent African American (p= 0.1884). PAHs 
remained significant with a p-value < 0.0001 and a positive point estimate (β= 0.1941). 
Again, statistical significance was not found with Smoking.  
 In model 3.b (Lung cancer deaths), statistically significant covariates remained 
the same as in model 2.b with the exception of the removal of Percent Female (p= 
0.0714) and the addition of Smoking (p= 0.0433). Again, PAHs were not statistically 
significant (p= 0.7776) with lung cancer deaths. The results of the regression analysis for 
models 3.a and 3.b can be located in Appendix B (Tables B.7 and B.8). 
Model 4: Regression of COPD and Lung Cancer Deaths (2010-2014) 
 The number of observations read and used in model four were 1,104 and 1,081, 
respectively. Model 4.a (COPD deaths) resulted in statistically significant covariates that 
remained the same as in model 3.a, with the addition of Percent Caucasian (p= 0.0463), 
Smoking (p= <0.0001), and Number of Heating Days (p= 0.0028). Hispanic composition 
was not statistically significant (p= 0.0545). Percent Caucasian, Smoking, and Number of 
Heating Days all had positive point estimates (β= 0.0097, 2.5644, and 0.0039, 
respectively). PAHs remained significant (p< 0.0094) with a positive point estimate (β= 
0. 0.2342).   
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 For model 4.b, statistically significant covariates remained the same with the 
exception of the removal of Percent Hispanic (p= 0.0918), and the addition of Percent 
Caucasian (p= 0.0068) and Percent Female (p= 0.0004). The point estimates for Percent 
Caucasian and Percent Female were both positive (β= 0.0115 and 0.0114, respectively), 
indicating a positive correlation with a non-protective effect. The results of the regression  
analysis for models 4.a and 4.b can be located in Appendix B (Tables B.9 and B.10).    
Finally, Table 3.4 provides a summary of the salient findings from each model for 
PAHs. It is important to note that obesity, hypertension, and low physical activity 
compositions from CHSI were not statistically significant covariates in any of the 
models. Thus, they were removed from the model statements as they did not add any 
significance, and are not specified in the tables below.   
Application of Model Four to Charleston, SC 
To explore the significance of the previous models, model four was applied at a 
smaller geographic level to Charleston County.  The merged dataset for model four was 
stratified at the county-level and selected by Charleston. A new dataset was created and 
run using the same covariates as discussed above. Results generated by the model were 
unreliable. County-level covariates were kept constant during the analysis as they each 
had only one value. Therefore, an application at a large metropolitan level to test the 
models’ utility with an area including more than one county is a logical next step to 
study. The next chapter will explore this study objective.  
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Discussion 
The primary research question investigated in this study was whether PAHs were 
significantly associated with COPD and/or lung cancer mortality. The rationale for a 
mortality investigation from air pollution is supported by works such as (Elliott et al., 
2007; Romieu et al., 2012; Yorifuji et al., 2013), etc. Additionally, modeling hazardous 
air pollution exposures and assessing epidemiological outcomes is also documented  in 
the literature (Bentayeb et al., 2015; Carey et al., 2013; Thurston et al., 2016). Finally, the 
biological mechanism described by (Yang et al., 2017)  provides a reliable explanation of 
the pathogenesis between PAH exposure and COPD occurrence. 
Overall, the findings from models one through four support the alternative 
hypothesis set forth in this chapter; there is a statistically significance associated with 
PAH exposure and COPD/lung cancer mortality. Specifically, PAH exposures 
concentrations were found to be significant with COPD mortality while adjusting for 
known confounders; however, they were not significantly associated with lung cancer 
mortality. The evidence supporting the significant association of PAH exposure 
concentrations with COPD mortality achieved a degree of reliability as it was repeated 
across four separate models. Future investigation should be carried out to stratify the 
analysis by various demographic variables to test for significance in regards to lung 
cancer mortalities i.e. whether PAH associations are observed with lung cancer deaths 
among females. This is of interest given the findings of Hwang et al. (2007) among 
others. Additional discussion on this is addressed below. 
 Point estimates for PAHs from each model were exponentiated for interpretation. 
Thus, based on the analysis carried out in models one through four, the rate of deaths 
 97 
from COPD increased by 14%, 18%, 22%, and 23%, respectively for every log unit 
increase in PAH exposure. These findings are generally consistent with several 
occupational studies as well as various animal studies assessing chronic PAH exposures 
and subsequent mortality (Brown, Bailey, Oliveri, Levin, & Di Giulio, 2016; Miller, 
Doust, Cherrie, & Hurley, 2013; Randem et al., 2003) Specifically, Randem et al. (2003) 
assessed non-malignant disease mortality associated with asphalt workers. Increased 
mortality from respiratory diseases was identified among workers in the study. The 
authors concluded there was evidence of a dose-response relationship with both PAH 
exposure and bitumen fume as coal tar was identified as the source of PAHs. This 
adverse impact on respiratory health supports the conclusion of inhalation as the primary 
route of PAH exposure.  
 Additional covariates of interest that resulted in statistically significant 
associations and positive estimates with COPD deaths include education level, age, 
gender, and heating days. Percent Caucasian was also positively associated and 
statistically significant with COPD deaths in model 4.a. These confounders provide 
further evidence for their role in overall environmental epidemiological studies assessing 
mortality from various hazards. Specifically, the statistically significant findings 
associating Percent Females with COPD mortality is supported by the findings from other 
epidemiological studies i.e. (Ben-Zaken Cohen, Paré, Man, & Sin, 2007; and Westney et 
al., 2017). In detail, Westney et al. (2017) investigated comorbidity associations with 
COPD emergency department visits and found that females were identified with COPD-
associated ED visits. Ben-Zaken Cohen et al. (2007) suggests there is a worrying trend 
among females with both COPD and lung cancer. They go on to elaborate that annual 
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COPD mortality rates increased by 291 percent among U.S. women between 1980 and 
2000, in addition to a hospital admission rate increase of 43 percent. This dwarfed the 
male rates which were 60 percent and 12 percent, respectively. Thus, further 
investigation is warranted to test the significance of PAH exposure and COPD/lung 
cancer deaths to assess a potentially disproportionate effect on females.  
 The significance of heating days as a confounder with both COPD and lung 
cancer mortality is important to note. Its rationale for inclusion in the model was based on 
the work of  Chan, Weinhold, Thomas, Gohlke, & Portier (2015). Specifically, Osman et 
al. (2008) report that poorer respiratory health status among COPD patients is associated 
with days when heating was not adequately kept in residences. Thus, colder months 
demonstrate a seasonal influence on COPD severity. Additionally, there is a potential link 
of heating days with increased PAH exposure where the number of days in which heating 
is required for residences would be associated with an increased load of combustion of 
fossil fuels for heat whether burning a coal stove, electrically derived heat, or combustion 
of natural gas. Natural gas combustion and electrically sourced heat are further along the 
spectrum of complete combustion in jurisdictions with power and gas grids, which would 
emit fewer PAHs into the ambient air. Thus, an environmental explanation such as this 
would be more probable in contexts where biomass burning for heating and cooking are 
highly utilized (Sana, Somda, Meda, & Bouland, 2018).  
Strengths and Limitations 
This is the first ecological study of its kind to employ NATA data at the census 
tract level to assess state-wide associations of PAHs with respiratory-related mortalities. 
The state-wide assessment provided a significant sample size of census-tract observations 
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to test the strength of associations among COPD, lung cancer, and PAHs while adjusting 
for known confounders. It employed a comprehensive set of confounders to attempt to 
eliminate potential bias from known sources. Finally, the biological mechanism 
establishing the pathogenesis between PAH exposure and COPD (and lung cancer) is 
significantly documented with investigations like Yang et al. (2017). The mortality 
models detailed in this study provide additional evidence beyond the association of initial 
COPD occurrence, and point to further required research to investigate the increased 
burden from COPD mortality.  
The limitations of the study include cross-level bias (true with any ecological 
investigation), in addition to several covariates that were expected to demonstrate 
statistical significance, however they did not (i.e. smoking and primary care provider 
rates). Additionally, Percent Poverty had mixed results that showed significance with 
three out of the four lung cancer models but insignificance with COPD’s models. Cross-
level bias was inherent in this study due to the availability of covariate data. Thus, a 
multi-level model was carried out as certain covariates were only available at the county 
level. Additionally, mortality data was provided by DHEC for years 2002-2010 using 
2010 census tract delineations. This created over 200 missing data points for deaths 
during the merging process with the other datasets, which were created using year 2000 
census tracts. Death data for model four did not have this issue as it utilized 2010 census 
tracts along with its respective merged covariate datasets. Along with this spatial 
limitation, temporality was a limitation as well since a variety of the covariates were only 
available at certain years. Thus, covariate rates pertaining to year ranges in each model 
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were applied as a single year, if only provided for a single year, e.g. NATA’s modeling 
years for PAHs.  
Additionally, smoking is a known and robust confounder in most epidemiological 
studies. Its application with epidemiological air pollution studies is well documented as 
mentioned above. Thus, possible explanations for smoking not demonstrating statistical 
significance with COPD deaths in models one through three is a counterintuitive finding 
(it was not statistically significant for lung cancer deaths in models 1.b and 2.b). It is 
important to note the year of smoking’s covariate data source. County Health Ranking’s 
smoking prevalence estimates were aggregated using data from the Behavioral Risk 
Factor Surveillance System (BRFSS) (County Health Rankings, 2018). The earliest year 
this data is available in the County Health Rankings data portal is 2010. Thus, a possible 
explanation for smoking’s non-statistical significance for COPD deaths in models one 
through three is the length of time in which the covariate was modeled and then which 
year range the model was applied. Aggregates for BRFSS smoking were acquired prior to 
2010 to generate a valid estimate at the county level, however there is an element of 
cross-level bias here due to the availability of the data and the extent to which it was 
applied to earlier models. Additionally, secondhand smoke was not controlled for due to 
the unavailability of any census tract or even county-level data during the study periods 
of each model. This is a limitation especially in regards to indoor air exposures. Thus, 
additional investigation should be carried out with a secondhand smoke exposure 
covariate as this data becomes available.   
Next, the lag time between exposure and chronic disease mortality is lengthy, 
where utilizing a single year estimate for PAH concentrations would be somewhat 
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erroneous to associate with deaths in the same year, as it takes years/decades for chronic 
exposure to have an adverse effect on health. This type of attributable mortality approach 
however is not without precedence in epidemiological assessments. The Smoking 
Attributable Morbidity Mortality and Economic Costs (SAMMEC) modeling developed 
by the CDC used this type of single year of smoking prevalence approach to generate 
mortality estimates for the same year (Centers for Disease Control and Prevention, 2009). 
Additionally, as smoking initiates most often during teen years, individuals are exposed 
to PAHs beginning in their early years as well. Since COPD and lung cancer mortality 
were highly associated with Percent Population 65 years and above, these estimates were 
most likely originated in the older age groups. Thus, the association was modeled not 
based on individual dose and response, but with the PAH levels (much like smoking 
prevalence) and its correlation with mortality rates. This explanation does not completely 
satisfy those investigating an exact dose and response relationship between PAHs and 
respiratory-related mortality however. Thus, additional investigation using a protracted 
longitudinal study design is warranted to assess mortality impacts based on dosage. 
Finally, a shortened study period between exposure and adverse respiratory 
outcomes would provide for less variability with something like a morbidity study 
design, i.e. regressing hospitalizations from acute exacerbated COPD with NATA-
derived exposure concentrations of PAHs at the census tract level. This type of study 
would be a logical area to investigate to further validate the current study’s findings.   
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Table 3.1 Covariate summary for South Carolina Poisson models. 
Name Source Spatiality Temporality 
Age Census/ACS Census Tract 2000 & 2010 
Race Census/ACS Census Tract 2001 & 2010 
Sex Census/ACS Census Tract 2002 & 2010 
Median HH Income Census/ACS Census Tract 2003 & 2010 
Education Census/ACS Census Tract 2004 & 2010 
Poverty Census/ACS Census Tract 2005 & 2010 
Occupation by Industry Census/ACS Census Tract 2000 & 2010 
PAHs EPA Census Tract 2002, 2005, & 
2011 
Lung Cancer Deaths Vital Stats Census Tract 2002-2014  
COPD Deaths Vital Stats Census Tract 2002-2014 
Total Heating Days NOAA County 1981-2010  
Total Cooling Days NOAA County 1981-2010  
Hypertension CHSI County 2010 
No Exercise CHSI County 2010 
Smoking RWJ County 2010 
Obesity RWJ County 2010 
Primary Care 
Physicians 
RWJ County 2010 
Binge Drinking RWJ County 2010 
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Table 3.2 Model 1.a: Point estimates and p-values, South Carolina COPD deaths (2002-
2006).a 
Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -7.5582 1.5529 -10.601 -4.514 23.69 <.0001 
Caucasian -0.0114 0.0136 -0.038 0.0153 0.7 0.4026 
Hispanic -0.0264 0.0129 -0.0516 -0.001 4.18 0.0408 
African_American -0.0203 0.0135 -0.0467 0.0061 2.26 0.1325 
Percent_Poverty 0.0038 0.0045 -0.005 0.0127 0.72 0.3948 
MedianHHIncome 0 0 0 0 3.9 0.0482 
Construction_Occu 0.0087 0.0068 -0.0046 0.022 1.65 0.1995 
SomeHSorLess 0.0004 0.0001 0.0003 0.0006 35.2 <.0001 
Adults65nOver 0.045 0.0046 0.036 0.054 95.51 <.0001 
Female 0.0448 0.0114 0.0224 0.0672 15.37 <.0001 
logPAHPOM 0.1352 0.0479 0.0413 0.2292 7.97 0.0048 
Smoke -0.1565 0.8511 -1.8247 1.5118 0.03 0.8542 
LogPCP -0.0088 0.058 -0.1225 0.1049 0.02 0.8791 
Heat_Days 0.0036 0.0018 0 0.0072 3.83 0.0505 
BingeDrink 1.5348 0.9682 -0.3629 3.4325 2.51 0.1129 
Scale 1.6112 0 1.6112 1.6112 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
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Table 3.3 Model 1.b: Point estimates and p-values, South Carolina lung cancer deaths 
(2002-2006).a 
Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -6.4844 1.2218 -8.8791 -4.0898 28.17 <.0001 
Caucasian -0.0094 0.0109 -0.0308 0.012 0.74 0.3889 
Hispanic -0.0189 0.0101 -0.0388 0.001 3.47 0.0625 
African_American -0.011 0.0108 -0.0322 0.0101 1.04 0.3074 
Percent_Poverty -0.0045 0.0037 -0.0118 0.0028 1.44 0.2304 
MedianHHIncome 0 0 0 0 3.43 0.064 
Construction_Occu 0.0119 0.0054 0.0013 0.0225 4.83 0.0279 
SomeHSorLess 0.0002 0.0001 0.0001 0.0003 8.37 0.0038 
Adults65nOver 0.0424 0.0037 0.0351 0.0498 128.58 <.0001 
Female 0.0184 0.0083 0.0021 0.0347 4.9 0.0269 
logPAHPOM 0.064 0.0389 -0.0122 0.1403 2.71 0.0997 
Smoke 1.2629 0.6776 -0.0652 2.591 3.47 0.0624 
LogPCP 0.0103 0.0463 -0.0804 0.101 0.05 0.824 
Heat_Days 0.0031 0.0015 0.0002 0.0059 4.32 0.0377 
BingeDrink 0.8371 0.7681 -0.6685 2.3426 1.19 0.2758 
Scale 1.5251 0 1.5251 1.5251 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
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Table 3.4 Point estimates and p-values for overall PAHs in models 1-4, South Carolina 
(2002-2014). 
Model Point Estimate P-Value 
Model 1.a 
COPD Deaths 2002-2006 
0.1352  0.0048 
Model 1.b 
Lung Cancer Deaths 2002-2006 
0.064 0.0997 
Model 2.a 
COPD Deaths 2004-2008 
0.1648  0.0001 
Model 2.b 
Lung Cancer Deaths 2004-2008 
0.0454 0.2223 
Model 3.a 
COPD Deaths 2006-2010 
0.1998  <.0001 
Model 3.b 
Lung Cancer Deaths 2006-2010 
0.0104 0.7776 
Model 4.a 
COPD Deaths 2010-2014 
0.2342 0.0094 
Model 4.b 
Lung Cancer Deaths 2010-2014 
-0.0388 0.6204 
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Figure 3.1 South Carolina county names and locations. 
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Figure 3.2 PAH total exposure concentrations by census tract in South Carolina 
(2002). 
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Figure 3.3 PAH total exposure concentrations by census tract in South Carolina 
(2005). 
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Figure 3.4 PAH total exposure concentrations by census tract in South Carolina 
(2014). 
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CHAPTER 4 
ESTIMATING THE STRENGTH OF ASSOCIATION AMONG COPD 
AND LUNG CANCER DEATHS ATTRIBUTABLE TO PAHS IN NEW 
YORK CITY 
Overview 
Chapter four was an application of the models derived in chapter three’s 
investigation in the context of New York City. The five counties of NYC included in the 
analysis were Bronx, Kings, New York, Queens, and Richmond counties. The intent for 
this application was an attempt at predictive analysis to demonstrate the health effects of 
pollution in a population-dense context in regards to PAH load from multiple point and 
non-point sources. The connection of this application was to estimate the outcomes of 
pollution increases as to what may be anticipated for the port expansion in Charleston.  
The burden of COPD and lung cancer in New York City is significant. The 
prevalence of COPD in the City was estimated at 5.5 percent according to the state’s 
2014 BRFSS surveillance (New York State Department of Health, 2014). Mortality from 
COPD in New York City was identified to be 20.0 per 100,000 population in 2014 (New 
York City Department of Health Vital Statistics, 2018). The average annual incidence of 
lung cancer cases between 2010-2014 for men and women was 60.3 per 100,000 males 
and 57.2 per 100,000 females respectively. Mortality rates for lung cancer were 41.5 per 
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100,000 males and 25.0 per 100,000 females for the same time period (New York State 
Department of Health, 2018)  
Methods 
 The same data sources for covariates and PAHs were applied in chapter four. 
Mortality data was acquired from the New York City Department of Health Vital 
Statistics Office and used as the dependent variable. 
Census tract mortality datasets from COPD and lung cancer were acquired in five 
year aggregates from NYC Vital Statistics for the following yearly ranges: 2002-2006, 
2004-2008, 2006-2010, and 2010-2014. Modeling using these year ranges with 
concentrations for census tract PAHs derived in chapter three were utilized to regress 
with the above mortality data. Again, PAH estimates at the census tract level were 
acquired from EPA’s website for NATA estimates for the years 2002, 2005, and 2014.  
Methodology Summary 
Goal: To apply the model derived in chapter three to assess annual PAH exposure 
concentrations in New York City and to what extent they contribute to mortality from 
COPD and lung cancer. 
Objective 1: Investigate the strength of association between NATA-derived 
census tract PAH exposure concentrations and deaths from COPD  
Objective 2: Investigate the strength of association between NATA-derived 
census tract PAH exposure concentrations and deaths from COPD 
Null hypothesis: There is no significant association between NATA-derived PAH 
exposure concentrations and mortality from COPD and lung cancer at the census tract 
level in New York City.  
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Alternative Hypothesis: There is a significant association between NATA-derived 
PAH exposure concentrations and mortality from COPD and lung cancer at the census 
tract level in New York City.  
 
Results 
Chapter four’s analysis mimicked that of chapter three with the exception of a different 
study jurisdiction. Five counties pertaining to greater New York City were included in the 
study area. These counties were selected based on the New York City Department of 
Health’s regulation authority including where their public health surveillance is 
monitored. Thus, the counties included in the analysis were those identified in the 
methods (Figure 4.1).   
 The primary datasets utilized in the analysis were the same as in chapter three 
with the exception of the mortality data. As was addressed in the methods, NYC Vital 
Statistics provided this data in the same year ranges as chapter three (2002-2006, 2004-
2008, 2006-2010, and 2010-2014).  
 NOAA Climate Normals were applied for each county where available. Data for 
heating and cooling days from New York County were utilized for Kings and Richmond 
Counties since this was the next closest location with available data. Bronx and Queens 
Counties had their own respective data for heating and cooling days. 
 The same covariates tested in chapter three’s models were utilized in chapter four 
and are summarized in Table 3.1 according to their source, spatiality, and temporality. 
Four models were generated for each respective iteration of the five-year mortality 
aggregates of COPD and lung cancer. SAS 9.4 was used to run the analysis including 
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merging all datasets. The overall sample size for models one and two was 2,217 census 
tracts. Model three had a sample size of 2,218 and model four had a sample size of 2,168 
census tracts.  
A significant number of missing values for COPD and lung cancer deaths were 
observed due to the suppression threshold delineated by NYC Vital Statistics (deaths 
suppressed if n < 5). Thus, death counts were set equal to 4 (5/√2) if missing, to account 
for suppression. This was an ad-hoc single data imputation adjustment carried out to 
accommodate the issue of left censored data due to the lower limit detection that NYC 
Vital Statistics uses for mortality data suppression in their census tract datasets. 
Descriptive statistics for each model are included in Appendix C (Tables C.1-C.4). 
Statistical significance was defined as those estimates with a p-value < 0.05.  
Model 1: Regression of COPD and Lung Cancer Deaths (2002-2006) 
 Model one consisted of two analyses – a Poisson regression each for COPD 
deaths (Model 1.a) and lung cancer deaths (Model 1.b). All model statements from 
chapter three were repeated for chapter four’s models, i.e. the offset was set as the log of 
the census tract population.  
 The number of observations used and read in model one were 2,217 and 2,159, 
respectively. Six statistically significant covariates were identified in the analysis for 
model 1.a: Percent Caucasian (p=0.0242), Percent African American (p<0.0001), Median 
Household Income (p<0.0001), Construction Occupation Prevalence (p= 0.001), Percent 
with Education of Some High School (p=0.0049), Percent Adults 65 and over 
(p<0.0001), and Percent Male (p<0.0001). All significant covariates had point estimates 
that were positive, indicating a positive correlation or non-protective effect with COPD 
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deaths. PAHs were not statistically significant (p= 0.1549) and had a negative point 
estimate (β= -0.0772). A summary of the analysis of the maximum likelihood parameter 
estimates from the Poisson regression can be found in Table 4.1. 
 Nine covariates were statistically significant with lung cancer deaths in model 1.b: 
Percent Caucasian (p<0.0001), Percent Hispanic (p<0.0001), Percent African American 
(p<0.0001), Construction Occupation Prevalence (p=0.0046), Percent with Education of 
Some High School (p=0.0005), Percent Adults 65 and Over (p<0.0001), Percent Male 
(p<0.0001), Smoking (p<0.0001), and Number of Cooling Days (p=0.0478). All 
significant covariates had point estimates in the positive direction indicating a positive 
correlation or non-protective effect on lung cancer deaths, with the exception of Percent 
Hispanic (β= -0.0033). PAHs were not statistically significant (p= 0.2741) and had a 
positive point estimate (β= 0.0479). A summary of the analysis of the maximum 
likelihood parameter estimates can be found in Table 4.2. 
Model 2: Regression of COPD and Lung Cancer Deaths (2004-2008) 
 The methodology for model one was repeated for models two through four. The 
number of observations used and read in model two were 2,217 and 2,159, respectively. 
The significant covariates identified in model 2.a were: Percent African American 
(p<0.0001), Median Household Education (p<0.0001), Construction Occupation 
Prevalence (p= 0.0032), Percent with Education of Some High School (p= 0.0055), 
Adults 65 and over (p<0.0001), Percent Male (p<0.0001). All significant covariates had 
point estimates that were positive, indicating a positive correlation or non-protective 
effect with COPD deaths. PAHs were not statistically significant (p= 0.7167) and had a 
negative point estimate (β= -0.0209).  
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 The statistically significant covariates identified in model 2.b were: Percent 
Caucasian (p=0.0003), Percent Hispanic (p<0.0001), Percent African American 
(p=0.0003), Construction Occupation Prevalence (p= 0.0039), Percent with Education of 
Some High School (p<.0001), Adults 65 and Over (p<0.0001), Percent Male (p<0.0001), 
PAHs (p=0.0174), Percent Who Smoke (p<0.0001), and Number of Cooling Days 
(p=0.0297). All significant covariates had point estimates in the positive direction 
indicating a positive correlation or non-protective effect on lung cancer deaths, with the 
exception of Percent Hispanic (β= -0.0038). PAHs were statistically significant with a 
positive point estimate (β= 0.1135). A summary of the analysis of the maximum 
likelihood parameter estimates for both models can be found in Appendix C (Tables C.5 
and C.6). 
Model 3: Regression of COPD and Lung Cancer Deaths (2006-2010) 
 The number of observations used and read in model three were 2,218 and 2,159, 
respectively. The statistically significant covariates identified in model 3.a were: Percent 
African American (p<0.0001), Median Household Income (p<0.0001), Construction 
Occupation Prevalence (p= 0.0043), Percent with Education of Some High School 
(p=0.0003), Adults 65 and over (p<0.0001), and Percent Male (p<0.0001). All significant 
covariates had point estimates that were positive, indicating a positive correlation or non-
protective effect with COPD deaths. Again, PAHs were not statistically significant 
(p=0.5878) and had a negative point estimate (β= -0.0312).  
The statistically significant covariates identified in model 3.b were: Percent 
Caucasian (p=0.0015), Percent Hispanic (p<0.0001), Construction Occupation 
Prevalence (p=0.0002), Percent with Education of Some High School (p=0.0001), Adults 
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65 and Over (p<0.0001), Percent Male (p<0.0001), PAHs (p= 0.04), and Smoking 
(p<0.0001). All significant covariates had point estimates in the positive direction 
indicating a positive correlation or non-protective effect on lung cancer deaths, with the 
exception of Percent Hispanic (β= -0.0038). Again, PAHs were significant with a positive 
point estimate (β= 0.0972). A summary of the analysis of the maximum likelihood 
parameter estimates for both models can be found in Appendix C (Table C.7 and C.8). 
Model 4: Regression of COPD and Lung Cancer Deaths (2010-2014) 
 The numbers of observations read and used in model 4 were 2,129 and 2,107, 
respectively. Statistically significant covariates in model 4.a (COPD deaths) were: 
Percent Caucasian (p= 0.0250), Percent African American (p<0.0001), Adults 65 and 
over (p<0.0001), Percent Male (p<0.0001), and PAHs (p<0.0001). All significant point 
estimates were indicated in the positive direction with the exception of PAHs (β= -
0.3115).  
The statistically significant covariates identified in model 4.b (lung cancer deaths) 
were: Percent Caucasian (p <.0001), Percent Hispanic (p<0.0001), Percent African 
American (p= 0.0003). Percent Median Household Income (p=0.0032), Construction 
Occupation Prevalence (p= 0.0059), Percent with Education of Some High School or less 
(p=0.0002), Adults 65 and Over (p<0.0001), Male (p= 0.0486), and Smoking (p=0.0025). 
All significant covariates had point estimates in the positive direction indicating a 
positive correlation or non-protective effect on lung cancer deaths, with the exception of 
Percent Hispanic (β= -0.0035). A summary of the analysis of the maximum likelihood 
parameter estimates for both models can be found in Appendix C (Tables C.9 and C.10). 
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Finally, Table 4.3 provides a summary of the salient findings from each model for 
PAHs. Elaboration on some of the other statistically significant covariates identified in 
the analysis is included below.  
 
Discussion 
As discussed in chapter three, the evidence for mortality associations with air 
pollution is supported by various epidemiological studies. Additionally, utilizing modeled 
air pollutant concentrations for health studies has precedence in the epidemiological 
literature. Finally, the pathogenic potential of PAHs with COPD and lung cancer is 
supported by biological mechanisms such as what was proposed by Yang et al. (2017). 
Overall, the findings from models one through four do not support either the null 
or alternative hypotheses set forth in this chapter. Specifically, PAH exposure 
concentrations were found to be significant with lung cancer mortality (a positive 
correlation in models two and three β= 0.1135, 0.0972), while adjusting for known 
confounders. Conversely, PAH exposure concentrations were not significantly associated 
with COPD mortality in three out of the four models, and were negatively associated with 
a statistical significance in model four (p= 0.0007, β= -0.3115), while adjusting for 
known confounders. The mixed results generated by comparing the first three models 
with model four in either case of lung cancer or COPD mortality gives rise to a degree of 
reduced reliability with the overall findings.  
The findings from chapter four’s analysis are not consistent with the findings 
from chapter three due to the mixed results and negative correlations with both COPD 
and lung cancer in each model. Models two and three did however demonstrate statistical 
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significance with PAHs and lung cancer deaths. This is inconsistent with the findings 
from the lung cancer models in chapter three, however consistent with occupational 
studies such as Miller, Doust, Cherrie, & Hurley (2013). These inconsistencies are 
possibly related to the change in jurisdiction where the variability of known confounders 
modified the effect on mortality, especially among the county-level confounders.  
Another explanation for the inconsistent findings is related to the suppression 
threshold NYC Vital Statistics applied to their datasets that transforms death counts less 
than five into missing values. A large number of missing values can add bias and reduce 
representativeness of a sample; where imputation can reduce such effects (Enders, 2010). 
Adjustment was made for this in the analysis. It is possible this reduced the amount of 
precision and could have yielded different conclusions based on potential other methods 
that could have been used (Asselineau, Thiébaut, Perez, Pinganaud, & Chêne, 2007). The 
negative correlations identified in model four still suggest however that another issue(s) 
was influencing the results.   
Figures 4.2, 4.3, and 4.4 depict the total exposure concentrations by census tract 
in NYC across three iterations of NATA (2002, 2005, and 2011). As Figure X depicts, 
the exposure concentrations in 2011 were significantly reduced compared to the previous 
iterations of NATA. It is unclear if this was related to the modeling changes between 
2005 and 2011 or if this was related to what was actually occurring in situ. This reduction 
in concentrations exhibited by EPA’s modeling was also depicted for South Carolina in 
between 2005 and 2011. Findings for COPD deaths were still found to be positively 
correlated with statistical significance in South Carolina for 2011 however. This suggests 
the likelihood that a smaller geographic jurisdiction such as NYC exhibited exaggerated 
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results when compared to the state-wide analysis in chapter three, possibly due to the lack 
of variability of the effect of a reduced application of county-level covariates on a smaller 
jurisdiction. This, in addition to the smaller PAH concentration estimates provide likely 
explanations of these inconsistencies.  
Strengths and Limitations 
 The large sample size of census tracts that make up greater New York City 
provided for an increased number of observations compared to the state-based study in 
chapter three. By applying a greater number of observations to a smaller geographic area, 
the probable interface between a dense population and pollution exposures was increased. 
The variability of county-level covariates was greatly reduced compared to chapter three 
however, which had 46 separate counties to compare. Chapter four included a total of 
five counties with respective county-level covariates exhibiting a much smaller number 
of variability in county-level data to be regressed. Again, this may have exaggerated the 
effects of the county-level covariates in chapter four’s models.  
 Additional analyses from both state-wide as well as more localized regions (other 
large metropolitan areas) are warranted to further explore the findings from chapters three 
and four. If an analysis is attempted on a smaller geographic area, adjusting the model to 
account for the county-level covariate variability must be explored with procedures such 
as multiple imputation. It is important to note the analysis carried out in chapter three to 
apply the fourth model to Charleston County, SC, exhibited similar limitations as NYC. 
Unreliable findings were generated due to the invariability of the county-based 
covariates. Thus, a state-wide assessment is recommended with the proposed models that 
are depicted in chapters three and four.  
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Table 4.1 Model 1.a: Point estimates and p-values, NYC COPD deaths (2002-2006).a 
Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -11.612 2.4234 -16.361 -6.862 22.96 <.0001 
Caucasian 0.0026 0.0011 0.0003 0.0048 5.08 0.0242 
Hispanic 0.0016 0.001 -0.0003 0.0036 2.67 0.1022 
African_American 0.0068 0.0011 0.0048 0.0089 41.4 <.0001 
Percent_Poverty 0.0027 0.002 -0.0012 0.0067 1.85 0.1743 
MedianHHIncome 0 0 0 0 31.89 <.0001 
Construction_Occu 0.0132 0.004 0.0054 0.0211 10.86 0.001 
SomeHighSchool 0.0088 0.0031 0.0027 0.015 7.93 0.0049 
Adults65nOver 0.0439 0.0023 0.0395 0.0483 377.61 <.0001 
Male 0.0389 0.0043 0.0305 0.0474 81.7 <.0001 
logPAHPOM -0.0772 0.0543 -0.1837 0.0292 2.02 0.1549 
Smoke 2.8389 1.641 -0.3773 6.0552 2.99 0.0836 
LogPCP 0.0089 0.2881 -0.5558 0.5736 0 0.9754 
Cool_Days 0.0115 0.0468 -0.0802 0.1031 0.06 0.806 
BingeDrink -0.4126 3.3351 -6.9493 6.1241 0.02 0.9015 
Scale 1.2827 0 1.2827 1.2827 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
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Table 4.2 Model 1.b: Point estimates and p-values, NYC lung cancer deaths (2002-
2006).a 
Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -13.2031 1.9439 -17.013 -9.393 46.13 <.0001 
Caucasian 0.0038 0.0009 0.002 0.0056 17.55 <.0001 
Hispanic -0.0033 0.0008 -0.0049 -0.001 15.83 <.0001 
African_American 0.0038 0.0009 0.0021 0.0055 19.43 <.0001 
Percent_Poverty -0.0007 0.0017 -0.0041 0.0026 0.18 0.6705 
MedianHHIncome 0 0 0 0 0.26 0.6104 
Construction_Occu 0.0096 0.0034 0.003 0.0163 8.01 0.0046 
SomeHighSchool 0.0092 0.0026 0.0041 0.0144 12.28 0.0005 
Adults65nOver 0.0336 0.0019 0.0299 0.0373 316.59 <.0001 
Male 0.0212 0.0038 0.0137 0.0287 30.73 <.0001 
logPAHPOM 0.0479 0.0438 -0.0379 0.1336 1.2 0.2741 
Smoke 5.897 1.2795 3.3892 8.4048 21.24 <.0001 
LogPCP 0.3339 0.233 -0.1227 0.7905 2.05 0.1518 
Cool_Days 0.0741 0.0374 0.0007 0.1474 3.92 0.0478 
BingeDrink -1.6035 2.6979 -6.8914 3.6843 0.35 0.5523 
Scale 1.229 0 1.229 1.229 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
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Table 4.3 Point estimates and p-values for overall PAHs across all models, NYC (2002-
2014). 
Model Point Estimate P-Value 
Model 1.a 
COPD Deaths 2002-2006 
-0.0772 0.1549 
Model 1.b 
Lung Cancer Deaths 2002-2006 
0.0479 0.2741 
Model 2.a  
COPD Deaths 2004-2008 
-0.0209 0.7167 
Model 2.b 
Lung Cancer Deaths 2004-2008 
0.1135  0.0174 
Model 3.a  
COPD Deaths 2006-2010 
-0.0312 0.5878 
Model 3.b 
Lung Cancer Deaths 2006-2010 
0.0972 0.04 
Model 4.a 
COPD Deaths 2010-2014 
-0.3115 0.0007 
Model 4.b 
Lung Cancer Deaths 2010-2014 
-0.0839 0.2899 
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Figure 4.1 Greater New York City (NYC) county names and locations. 
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 Figure 4.2 PAH total exposure concentrations by census tract in New York City (2002). 
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Figure 4.3 PAH total exposure concentrations by census tract in New York City (2005). 
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Figure 4.4 PAH total exposure concentrations by census tract in New York City (2014). 
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CHAPTER 5 
CONCLUSIONS 
The body of this work sought to investigate the connection between PAHs 
sourced from ambient air pollution and adverse respiratory health outcomes, in addition 
to testing the strength of such connections through several population-based and 
ecological studies. The primary research question tested was whether there was a 
statistically significant association between PAHs and adverse respiratory health 
outcomes.  
In the first chapter, a variety of studies and literature were summarized, specifying 
the biological pathway between PAH exposure and subsequent outcomes such as COPD 
and lung cancer. The role of the aryl hydrocarbon receptor in oxidative stress in addition 
to the impact of chronic inflammation, highlight key elements in the pathogenesis of 
COPD and lung cancer. Additionally, PAHs, inflammation, and oxidative stress are 
connections made with other chronic diseases as well i.e. CVD (Alshaarawy et al., 2016; 
Curfs et al., 2005). Specifically, the work of Yang et al. (2017) was a cogent study 
detailing the pathogenesis between PAHs from ambient air pollution and COPD-related 
outcomes.  
The scope of work in chapter two was based on the urinary metabolites of 
respective PAHs collected through NHANES and correlating these biomarkers with 
COPD and lung cancer. As a nationally representative sample investigating human 
health, NHANES enables extensive investigation into the associations with various health 
 128 
outcomes, a host of biomarkers, while including a comprehensive suite of potential 
confounders. The findings from chapter two supported the null hypothesis where no 
statistical significance was associated with PAH metabolites and COPD among non-
smokers at the national level. The overall model completed in chapter two identified 
significant associations with PAHs and COPD prevalence; however when the sample was 
stratified by smoking status, no statistical association was identified between the two. The 
sample size for the lung cancer cohort was too small to generate any reliable conclusions. 
Possible explanations for the lack of significance in the stratified model in spite of the 
supporting literature of likely associations, includes the omission of BaP as a primary 
PAH, which is not collected via NHANES. Additionally, other biomarkers related to air 
pollution i.e. PM2.5 were not explored as potential variables contained within the overall 
dataset to further explore the role of air pollution on such health outcomes. Thus, 
additional studies using NHANES are warranted to investigate the associations with 
PAHs and respiratory health outcomes.  
 Chapter three was a state-wide population-based ecological study that used the 
EPA’s NATA models to investigate the strength of associations with PAH exposure and 
COPD and lung cancer mortality in South Carolina. Exploring the public health burden 
related to PAHs by investigating a death model was the rationale for first testing whether 
a significant environmental health issue exists with PAHs sourced from air pollution in 
South Carolina. It is important to note that mortality investigations comprise a significant 
portion of public health burden assessments (López-Campos, Tan, & Soriano, 2016). 
Overall, the alternative hypothesis was supported by the findings generated by chapter 
three’s analysis where a statistically significant and positive association was observed 
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between PAH exposure concentrations from air pollution and COPD mortality, while 
adjusting for known confounders. All four models generated during the analysis 
demonstrated overall reliability as each one identified a positive significance between 
PAHs and COPD mortality. No significant associations were observed between PAH 
exposures and lung cancer deaths.   
 Finally, chapter four sought to apply the models developed in the previous chapter 
to a smaller jurisdiction to explore their utility at a smaller geographic granularity. 
Specifically, chapter four sought to investigate such associations in NYC, a study area 
with a dense population and a context known for increased exposures to air pollution 
from PAH sources (Jung et al., 2014). The findings generated during the analysis did not 
support either the null or alternative hypotheses. Statistically significant associations 
were found among PAHs and COPD/lung cancer deaths, however they were not 
significant across all models, nor were their point estimates all indicated in the same 
direction (positive or negative). The results indicated a degree of unreliability compared 
to chapter three’s models when applied to a smaller geographic area. The primary 
explanation for this inconsistency was due to the amount of county-level covariates 
utilized in the analysis. Since a multi-level Poisson regression procedure was employed 
in the models, the number of county-level covariates possibly skewed the results when 
fewer counties were included in the study area for the models’ application. Thus, 
application of these models is optimum at the state-level and unreliable among large 
metropolitan areas that include only a small number of counties. Exploring more granular 
geographic estimates for confounders (zip code or census tract), especially for a powerful 
confounder such as smoking, would be important advancements in small area estimation 
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procedures (McLain et al., 2017) and environmental epidemiological studies to better 
assess risk.  
Implications and Future Directions 
 Increased study focus is warranted with PAHs and COPD morbidity and 
mortality. The findings from chapter three have significance for South Carolina, 
especially as the state considers the future public health implications of growing its 
economic initiatives with projects like the expansion of the Port of Charleston and the 
development of the new container terminal in the former Navy base of North Charleston. 
The increased loads of air pollution projected from this growing transportation hub have 
created a significant concern for the surrounding communities near the port (and terminal 
facility) as they are added to the various other pollution sources already present in the 
area i.e. industrial waste, underground storage tanks, etc. Svendsen et al. (2014) report 
that due to the port expansion, traffic increases to the neck communities of the Charleston 
peninsula are expected to increase by at least 7,000 diesel truck trips per day, which 
equates to a near 70 percent increase from the current daily average. The neck 
communities of Charleston will be disproportionately affected by not only the trucks 
coming into and out of the area, but also those related to train and container ship 
transport. Applying the models generated in chapter three, for every log unit increase 
from PAH exposure related to the new transport from the expansion, deaths from COPD 
will increase by anywhere between 14 to 24 percent.  
 Thus, air quality monitoring in Charleston in addition to epidemiological 
surveillance are essential elements for vested stakeholders in the port’s expansion. 
Furthermore, environmental justice issues for communities like those of the neck area of 
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Charleston are undergirded by the findings from this research. Additional policy issues, 
mitigation efforts, and air pollution remediation elements are essential considerations for 
communities most proximate to PAH pollution sources, especially those with significant 
increases expected in the near future. Further study is also necessitated to investigate 
morbidity models to assess the acute impact of short-term exposure to PAHs and effects 
on COPD and lung cancer hospitalizations, along with other related diseases, i.e CVD, 
asthma, etc.   
 Finally, it was anticipated a significant association among PAH exposure, COPD 
mortality, and lung cancer mortality would be observed in NYC. By establishing this 
evidence, a framework for environmental justice that has emerged in other urban centers 
(Chakraborty, 2009; Gee & Payne-Sturges, 2004; J. Maantay, 2002; J. Maantay, 2007; 
Schweitzer & Stephenson, 2007) would be an important exhibit to consider for 
application in the neck communities of Charleston as they attempt to mitigate the impacts 
from increased loads of air pollution, especially from non-point sources. Thus, additional 
investigation is required in both South Carolina and NYC to assess not only the morbidity 
impacts from PAHs but smaller area applications of the the mortality models at the 
county or city level and their implications for environmental justice.  
In conclusion, the evidence demonstrated by the South Carolina models for 
COPD mortality establishes a link between PAH exposure and respiratory-related deaths. 
This provides additional scientific evidence to the already large body of literature that is 
quite contrary to the latest federal administration’s moves to lessen automobile emission 
standards. The findings provided above warrant more restriction on emissions regulated 
by the EPA, not less. More must be done in South Carolina specifically to prevent, 
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mitigate, and remediate the increased loads of pollution from the Charleston expansion, 
especially on those populations who are most proximate to the sources as well as those 
who have less capacity to protect themselves from ambient air toxins. The economic 
gains from Charleston’s growing transportation hub must not come at the cost of the 
nearby population. The perpetuation of environmental injustice predicted from the 
Charleston port is consistent with numerous other injustices nationally as well as globally 
where economic progress overruns public health.  
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APPENDIX A – 16 PRIORITY PAHS DEVELOPED BY THE EPA 
1. Acenaphthene 
2. Naphthalene 
3. Fluoranthene 
4. Benz(a)anthracene 
5. Benzo(a)pyrene 
6. Benzo(b)fluoranthene 
7 Benzo(k)fluoranthene 
8. Chrysene 
9. Dibenz(a,h)anthracene 
10. Indeno(1,2,3-c,d)pyrene 
11. Acenaphthalene 
12. Fluorene 
13. Phenanthrene 
14. Anthracene 
15. Benzo(ghi)perylene 
16. Pyrene 
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APPENDIX B  
SUPPLEMENTARY TABLES ASSOCIATED WITH CHAPTER 3 
Table B.1. Model 1 descriptive statistics for South Carolina (2002-2006) 
Variable N N Miss Minimum Maximum Mean 
GEO_id2 874 0 4.5E+10 4.51E+10 4.5E+10 
Caucasian 874 0 0.4 99.3 64.37 
Hispanic 874 0 0.1 38.3 2.4 
African_American 874 0 0 98.8 32.43 
Percent_Poverty 871 3 0 100 15.86 
MedianHHIncome 874 0 0 200001 36667.29 
Construction_Occu 870 4 0 33.1 11.43 
Production_Occu 870 4 0 47.6 19.82 
SomeHSorLess 874 0 0 3162 719.35 
Adults18nOver 874 0 55.6 99.9 75.54 
Adults65nOver 874 0 0 41 12.75 
Male 874 0 25.2 100 48.58 
Female 874 0 0 74.8 51.42 
logPAHPOM 858 16 -6.91 -3.63 -5.33 
logTotalConc 858 16 -6.73 -3.05 -4.95 
Smoke 871 3 0.15 0.33 0.23 
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LogPCP 874 0 -9.21 -6.34 -7.17 
LC_Death 619 255 0 121 13.25 
COPD_Death 619 255 0 62 9.8 
SmokingDeath 619 255 0 104 11.94 
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Table B.2 Model 2 descriptive statistics for South Carolina (2004-2008) 
Variable N N Miss Minimum Maximum Mean 
GEO_id2 874 0 4.5E+10 4.51E+10 4.5E+10 
Caucasian 874 0 0.4 99.3 64.37 
Hispanic 874 0 0.1 38.3 2.4 
African_American 874 0 0 98.8 32.43 
Percent_Poverty 871 3 0 100 15.86 
MedianHHIncome 874 0 0 200001 36667.29 
Construction_Occu 870 4 0 33.1 11.43 
Production_Occu 870 4 0 47.6 19.82 
SomeHSorLess 874 0 0 3162 719.35 
Adults18nOver 874 0 55.6 99.9 75.54 
Adults65nOver 874 0 0 41 12.75 
Male 874 0 25.2 100 48.58 
Female 874 0 0 74.8 51.42 
logPAHPOM 858 16 -7.03 -3.07 -5.45 
logTotalConc 858 16 -6.87 -3.12 -5.04 
Smoke 871 3 0.15 0.33 0.23 
LogPCP 874 0 -9.21 -6.34 -7.17 
LC_Death 619 255 0 125 13.37 
COPD_Death 619 255 0 62 10.19 
SmokingDeath 619 255 0 201 23.05 
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Table B.3 Model 3 descriptive statistics for South Carolina (2006-2010) 
Variable N N Miss Minimum Maximum Mean 
GEO_id2 874 0 4.5E+10 4.51E+10 4.5E+10 
Caucasian 874 0 0.4 99.3 64.37 
Hispanic 874 0 0.1 38.3 2.4 
African_American 874 0 0 98.8 32.43 
Percent_Poverty 871 3 0 100 15.86 
MedianHHIncome 874 0 0 200001 36667.29 
Construction_Occu 870 4 0 33.1 11.43 
Production_Occu 870 4 0 47.6 19.82 
SomeHSorLess 874 0 0 3162 719.35 
Adults18nOver 874 0 55.6 99.9 75.54 
Adults65nOver 874 0 0 41 12.75 
Male 874 0 25.2 100 48.58 
Female 874 0 0 74.8 51.42 
logPAHPOM 858 16 -7.03 -3.07 -5.45 
logTotalConc 858 16 -6.87 -3.12 -5.04 
Smoke 871 3 0.15 0.33 0.23 
LogPCP 874 0 -9.21 -6.34 -7.17 
LC_Death 619 255 0 97 13.35 
COPD_Death 619 255 0 62 10.93 
SmokingDeath 619 255 0 229 27.94 
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Table B.4 Model 4 descriptive statistics for South Carolina (2010-2014) 
Variable N N Miss Minimum Maximum Mean 
GEO_id2 1104 0 4.5E+10 4.51E+10 4.5E+10 
Caucasian 1089 15 0 100 66.52 
Hispanic 1089 15 0 57.6 4.45 
African_American 1089 15 0 100 29.1 
Percent_Poverty 1087 17 0 100 17.55 
MedianHHIncome 1084 20 8828 173636 44903.22 
Construction_Occu 1085 19 0 37.1 10.96 
Production_Occu 1085 19 0 50.8 15.69 
SomeHSorLess 1084 20 9074 173636 45206.03 
Adults18nOver 1089 15 45.5 100 76.92 
Adults65nOver 1089 15 0 64.2 13.7 
Male 1089 15 16.9 100 48.68 
Female 1089 15 0 83.1 51.32 
logPAHPOM 1092 12 -7.02 -5.24 -6.48 
Smoke 1100 4 0.15 0.33 0.23 
LogPCP 1103 1 -9.21 -6.34 -7.18 
LC_Death 1090 14 0 111 12.78 
COPD_Death 1090 14 0 57 11.53 
SmokingDeath 1090 14 0 234 25.7 
 
 
 165 
Table B.5 Model 2.a: Analysis of maximum likelihood estimates South Carolina COPD 
deaths (2004-2008).a 
Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -6.1183 1.475 -9.0092 -3.2273 17.21 <.0001 
Caucasian -0.0193 0.0127 -0.0442 0.0055 2.33 0.1271 
Hispanic -0.0323 0.0125 -0.0568 -0.0079 6.73 0.0095 
African_American -0.0268 0.0126 -0.0514 -0.0022 4.55 0.0329 
Percent_Poverty -0.0019 0.0045 -0.0108 0.0069 0.18 0.6723 
MedianHHIncome 0 0 0 0 4.36 0.0368 
Construction_Occu 0.0143 0.0065 0.0015 0.0271 4.8 0.0285 
SomeHSorLess 0.0004 0.0001 0.0002 0.0005 26.88 <.0001 
Adults65nOver 0.0406 0.0046 0.0316 0.0495 79.05 <.0001 
Female 0.0367 0.0109 0.0153 0.058 11.35 0.0008 
logPAHPOM 0.1648 0.0434 0.0797 0.25 14.4 0.0001 
Smoke 0.6377 0.8234 -0.9761 2.2515 0.6 0.4386 
LogPCP -0.0116 0.0563 -0.1219 0.0988 0.04 0.8371 
Heat_Days 0.0032 0.0018 -0.0004 0.0067 3.1 0.0783 
BingeDrink 0.8982 0.943 -0.9501 2.7465 0.91 0.3409 
Scale 1.6007 0 1.6007 1.6007 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
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Table B.6 Model 2.b: Analysis of maximum likelihood estimates South Carolina lung 
cancer deaths (2004-2008).a 
Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -6.1872 1.2532 -8.6434 -3.731 24.38 <.0001 
Caucasian -0.0101 0.0111 -0.0317 0.0116 0.83 0.363 
Hispanic -0.0225 0.0105 -0.043 -0.0019 4.6 0.032 
African_American -0.0109 0.0109 -0.0324 0.0105 1 0.3179 
Percent_Poverty -0.0093 0.0039 -0.0169 -0.0017 5.75 0.0165 
MedianHHIncome 0 0 0 0 3.03 0.0817 
Construction_Occu 0.0151 0.0055 0.0043 0.0259 7.51 0.0061 
SomeHSorLess 0.0002 0.0001 0.0001 0.0003 11.92 0.0006 
Adults65nOver 0.0373 0.0039 0.0296 0.0449 91.84 <.0001 
Female 0.0193 0.0085 0.0026 0.036 5.14 0.0234 
logPAHPOM 0.0454 0.0372 -0.0275 0.1183 1.49 0.2223 
Smoke 0.9369 0.695 -0.4252 2.299 1.82 0.1776 
LogPCP 0.0337 0.0473 -0.0589 0.1264 0.51 0.4754 
Heat_Days 0.0034 0.0015 0.0004 0.0063 4.93 0.0264 
BingeDrink 0.1542 0.7865 -1.3872 1.6956 0.04 0.8446 
Scale 1.5612 0 1.5612 1.5612 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
 
 
 167 
Table B.7 Model 3.a: Analysis of maximum likelihood estimates South Carolina COPD 
deaths (2006-2010).a 
Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -6.4149 1.4415 -9.2403 -3.5895 19.8 <.0001 
Caucasian -0.0086 0.0126 -0.0332 0.0161 0.46 0.4973 
Hispanic -0.0244 0.0121 -0.0481 -0.0008 4.1 0.0428 
African_American -0.0164 0.0125 -0.0409 0.008 1.73 0.1884 
Percent_Poverty -0.0045 0.0045 -0.0133 0.0042 1.03 0.3093 
MedianHHIncome 0 0 0 0 9.36 0.0022 
Construction_Occu 0.0156 0.0063 0.0033 0.028 6.17 0.013 
SomeHSorLess 0.0003 0.0001 0.0002 0.0005 22.52 <.0001 
Adults65nOver 0.0384 0.0045 0.0296 0.0472 73.27 <.0001 
Female 0.0278 0.0102 0.0077 0.0478 7.39 0.0066 
logPAHPOM 0.1998 0.0415 0.1185 0.2812 23.18 <.0001 
Smoke 1.4951 0.7887 -0.0508 3.041 3.59 0.058 
LogPCP -0.0338 0.0541 -0.1397 0.0722 0.39 0.5325 
Heat_Days 0.0018 0.0017 -0.0016 0.0052 1.11 0.2927 
BingeDrink 0.5016 0.9096 -1.2813 2.2844 0.3 0.5814 
Scale 1.6107 0 1.6107 1.6107 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
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Table B.8 Model 3.b: Analysis of maximum likelihood estimates South Carolina lung 
cancer deaths (2006-2010).a 
Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -5.9885 1.2334 -8.4059 -3.5711 23.57 <.0001 
Caucasian -0.0104 0.0109 -0.0318 0.0109 0.92 0.3383 
Hispanic -0.0256 0.0105 -0.0461 -0.0051 6.01 0.0143 
African_American -0.0115 0.0108 -0.0327 0.0096 1.14 0.2862 
Percent_Poverty -0.0097 0.0039 -0.0173 -0.0021 6.22 0.0127 
MedianHHIncome 0 0 0 0 4.37 0.0366 
Construction_Occu 0.0154 0.0054 0.0047 0.0261 8 0.0047 
SomeHSorLess 0.0002 0.0001 0.0001 0.0003 9.85 0.0017 
Adults65nOver 0.0338 0.0039 0.0262 0.0415 75.08 <.0001 
Female 0.0148 0.0082 -0.0013 0.031 3.25 0.0714 
logPAHPOM 0.0104 0.0369 -0.0619 0.0828 0.08 0.7776 
Smoke 1.3842 0.685 0.0415 2.7268 4.08 0.0433 
LogPCP 0.0315 0.0466 -0.06 0.1229 0.46 0.4999 
Heat_Days 0.0023 0.0015 -0.0007 0.0052 2.24 0.1343 
BingeDrink 0.0062 0.7764 -1.5155 1.5279 0 0.9936 
Scale 1.5499 0 1.5499 1.5499 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
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Table B.9 Model 4.a: Analysis of maximum likelihood estimates South Carolina COPD 
deaths (2010-2014).a 
Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -6.5958 0.8162 -8.1954 -4.9962 65.31 <.0001 
Caucasian 0.0097 0.0049 0.0002 0.0192 3.97 0.0463 
Hispanic -0.0066 0.0034 -0.0134 0.0001 3.70 0.0545 
African_American 0.0030 0.0049 -0.0067 0.0126 0.36 0.5467 
Percent_Poverty -0.0029 0.0024 -0.0076 0.0017 1.52 0.2176 
MedianHHIncome -0.0003 0.0001 -0.0005 -0.0002 18.18 <.0001 
Construction_Occu 0.0078 0.0032 0.0015 0.0141 5.95 0.0147 
SomeHSorLess 0.0003 0.0001 0.0002 0.0005 16.74 <.0001 
Adults65nOver 0.0266 0.0021 0.0224 0.0307 160.52 <.0001 
Female 0.0155 0.0038 0.0080 0.0230 16.44 <.0001 
logPAHPOM 0.2342 0.0902 0.0574 0.4110 6.74 0.0094 
Smoke 2.5644 0.5433 1.4994 3.6293 22.27 <.0001 
LogPCP 0.0227 0.0366 -0.0490 0.0944 0.39 0.5348 
Heat_Days 0.0039 0.0013 0.0013 0.0065 8.93 0.0028 
BingeDrink -0.0834 0.7079 -1.4709 1.3040 0.01 0.9062 
Scale 1.6249 0.0000 1.6249 1.6249 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
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Table B.10 Model 4.b: Analysis of maximum likelihood estimates South Carolina lung 
cancer deaths (2010-2014).a 
Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -8.4356 0.7056 -9.8185 -7.0527 142.93 <.0001 
Caucasian 0.0115 0.0042 0.0032 0.0197 7.33 0.0068 
Hispanic -0.0051 0.0030 -0.0110 0.0008 2.84 0.0918 
African_American 0.0096 0.0043 0.0012 0.0180 5.07 0.0244 
Percent_Poverty -0.0052 0.0020 -0.0092 -0.0012 6.50 0.0108 
MedianHHIncome -0.0002 0.0001 -0.0004 -0.0001 11.89 0.0006 
Construction_Occu 0.0107 0.0028 0.0053 0.0161 14.99 0.0001 
SomeHSorLess 0.0002 0.0001 0.0001 0.0004 11.12 0.0009 
Adults65nOver 0.0244 0.0018 0.0209 0.0279 186.58 <.0001 
Female 0.0114 0.0032 0.0051 0.0178 12.37 0.0004 
logPAHPOM -0.0388 0.0783 -0.1921 0.1146 0.25 0.6204 
Smoke 1.9900 0.4644 1.0798 2.9001 18.36 <.0001 
LogPCP -0.0228 0.0307 -0.0830 0.0374 0.55 0.4580 
Heat_Days -0.0000 0.0011 -0.0022 0.0022 0.00 0.9945 
BingeDrink 0.3505 0.6019 -0.8292 1.5302 0.34 0.5603 
Scale 1.4718 0.0000 1.4718 1.4718 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
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APPENDIX C  
SUPPLEMENTARY TABLES ASSOCIATED WITH CHAPTER 4 
Table C.1 Model 1 descriptive statistics for NYC (2002-2006) 
Variable N N Miss Minimum Maximum Mean 
CT_Population 2217 0 0 24523 3612.214 
Caucasian 2193 24 0 100 44.74122 
Hispanic 2193 24 0 100 24.99567 
African_American 2193 24 0 100 28.15581 
Percent_Poverty 2168 49 0 100 20.58861 
MedianHHIncome 2217 0 0 188697 40056 
Construction_Occu 2159 58 0 100 7.188282 
Production_Occu 2159 58 0 100 11.76082 
SomeHighSchool 2171 46 0 100 16.77577 
Adults65nOver 2193 24 0 90 11.89184 
Male 2193 24 20 100 47.92832 
Female 2193 24 0 80 52.07187 
logPAHPOM 2195 22 -14.8739 -2.44459 -4.60907 
logTotalConc 2217 0 -5.47354 -1.98934 -4.22184 
Smoke 2217 0 0.15 0.23 0.17171 
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LogPCP 2217 0 -6.95396 -5.86918 -6.66923 
COPD_Death 586 1631 5 45 8.517065 
COPD_Death_r 2217 0 4 45 5.193956 
LC_Death 1124 1093 5 64 10.17349 
LC_Death_r 2217 0 4 64 7.129905 
aRecoded deaths based on single imputation adjustment =4. 
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Table C.2 Model 2 descriptive statistics for NYC (2004-2008) 
Variable N N Miss Minimum Maximum Mean 
CT_Population 2217 0 0 24523 3612.214 
Caucasian 2193 24 0 100 44.74122 
Hispanic 2193 24 0 100 24.99567 
African_American 2193 24 0 100 28.15581 
Percent_Poverty 2168 49 0 100 20.58861 
MedianHHIncome 2217 0 0 188697 40056 
Construction_Occu 2159 58 0 100 7.188282 
Production_Occu 2159 58 0 100 11.76082 
SomeHighSchool 2171 46 0 100 16.77577 
Adults65nOver 2193 24 0 90 11.89184 
Male 2193 24 20 100 47.92832 
Female 2193 24 0 80 52.07187 
logPAHPOM 2193 24 -5.66032 -2.51523 -4.45143 
LogTotalConc 2193 24 -4.99537 -2.06524 -4.0717 
Smoke 2217 0 0.15 0.23 0.17171 
LogPCP 2217 0 -6.95396 -5.86918 -6.66923 
COPD_Death 560 1657 5 41 8.351786 
COPD_Death_r 2217 0 4 41 5.099233 
LC_Death 1083 1134 5 61 10.10526 
LC_Death_r 2217 0 4 61 6.982409 
aRecoded deaths based on single imputation adjustment =4. 
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Table C.3 Model 3 descriptive statistics for NYC (2006-2010) 
Variable N N Miss Minimum Maximum Mean 
CT_Population 2217 1 0 24523 3612.214 
Caucasian 2193 25 0 100 44.74122 
Hispanic 2193 25 0 100 24.99567 
African_American 2193 25 0 100 28.15581 
Percent_Poverty 2168 50 0 100 20.58861 
MedianHHIncome 2217 1 0 188697 40056 
Construction_Occu 2159 59 0 100 7.188282 
Production_Occu 2159 59 0 100 11.76082 
SomeHighSchool 2171 47 0 100 16.77577 
Adults65nOver 2193 25 0 90 11.89184 
Male 2193 25 20 100 47.92832 
Female 2193 25 0 80 52.07187 
logPAHPOM 2193 25 -5.66032 -2.51523 -4.45143 
LogTotalConc 2193 25 -4.99537 -2.06524 -4.0717 
Smoke 2217 1 0.15 0.23 0.17171 
LogPCP 2217 1 -6.95396 -5.86918 -6.66923 
COPD_Death 563 1655 5 38 8.222025 
copd_death_r 2218 0 4 38 5.071686 
LC_death 1098 1120 5 67 9.852459 
lc_death_r 2218 0 4 67 6.897205 
aRecoded deaths based on single imputation adjustment =4. 
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Table C.4 Model 4 descriptive statistics for NYC (2010-2014) 
Variable N N Miss Minimum Maximum Mean 
CT_Population 2129 0 11.00 26588.00 3839.87 
Caucasian 2129 0 0.00 100.00 43.65 
Hispanic 2129 0 0.00 96.30 26.62 
African_American 2129 0 0.00 96.60 27.15 
Percent_Poverty 2114 15 0.00 91.80 18.23 
MedianHHIncome 2109 20 8694.00 232768.00 54747.31 
Construction_Occu 2111 18 0.00 70.00 7.22 
Production_Occu 2111 18 0.00 52.90 9.76 
SomeHSorLess 2117 12 0.00 85.90 21.25 
Adults65nOver 2129 0 0.00 82.60 78.27 
Male 2129 0 26.90 98.60 47.73 
Female 2129 0 1.40 73.10 52.27 
logPAHPOM 2129 0 -6.60 -5.38 -5.97 
Smoke 2129 0 0.15 0.23 0.17 
LogPCP 2129 0 -6.95 -5.87 -6.67 
COPD_Death 667 1462 5.00 48.00 8.42 
copd_death_r 2129 0 4.00 48.00 5.39 
LC_death 1139 990 5.00 67.00 9.38 
lc_death_r 2129 0 4.00 67.00 6.88 
aRecoded deaths based on single imputation adjustment =4. 
Table C.5 Model 2.a: Analysis of maximum likelihood estimates NYC COPD deaths 
(2004-2008).a 
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Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -10.7266 2.4639 -15.555 -5.897 18.95 <.0001 
Caucasian 0.0018 0.0011 -0.0004 0.004 2.62 0.1056 
Hispanic 0.0006 0.001 -0.0014 0.0025 0.33 0.5639 
African_American 0.0063 0.001 0.0043 0.0083 37.11 <.0001 
Percent_Poverty 0.002 0.002 -0.0019 0.006 1.02 0.3133 
MedianHHIncome 0 0 0 0 26.7 <.0001 
Construction_Occu 0.0118 0.004 0.004 0.0196 8.7 0.0032 
SomeHighSchool 0.0086 0.0031 0.0025 0.0147 7.71 0.0055 
Adults65nOver 0.0431 0.0023 0.0387 0.0475 365.29 <.0001 
Male 0.0406 0.0042 0.0324 0.0488 93.14 <.0001 
logPAHPOM -0.0209 0.0576 -0.1337 0.0919 0.13 0.7167 
Smoke 1.5991 1.7829 -1.8953 5.0936 0.8 0.3698 
LogPCP -0.158 0.2964 -0.7389 0.4229 0.28 0.594 
Cool_Days -0.0068 0.048 -0.1009 0.0873 0.02 0.887 
BingeDrink 0.9566 3.4456 -5.7967 7.71 0.08 0.7813 
Scale 1.2626 0 1.2626 1.2626 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
 
 
Table C.6 Model 2.b: Analysis of maximum likelihood estimates NYC lung cancer 
deaths (2004-2008).a 
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Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -13.3468 2.0264 -17.318 -9.375 43.38 <.0001 
Caucasian 0.0034 0.0009 0.0015 0.0052 13.11 0.0003 
Hispanic -0.0038 0.0008 -0.0055 -0.002 20.46 <.0001 
African_American 0.0032 0.0009 0.0015 0.0049 13.37 0.0003 
Percent_Poverty -0.0009 0.0017 -0.0044 0.0025 0.29 0.5907 
MedianHHIncome 0 0 0 0 1.35 0.2454 
Construction_Occu 0.01 0.0035 0.0032 0.0168 8.34 0.0039 
SomeHighSchool 0.0112 0.0027 0.0059 0.0165 17.43 <.0001 
Adults65nOver 0.0323 0.0019 0.0285 0.0361 277.01 <.0001 
Male 0.0183 0.0039 0.0106 0.026 21.81 <.0001 
logPAHPOM 0.1135 0.0478 0.0199 0.2071 5.65 0.0174 
Smoke 6.7111 1.4207 3.9266 9.4957 22.31 <.0001 
LogPCP 0.4044 0.2445 -0.0748 0.8835 2.74 0.0981 
Cool_Days 0.0855 0.0393 0.0084 0.1626 4.73 0.0297 
BingeDrink -2.7958 2.8498 -8.3814 2.7897 0.96 0.3266 
Scale 1.2433 0 1.2433 1.2433 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
 
 
Table C.7 Model 3.a: Analysis of maximum likelihood estimates NYC COPD deaths 
(2006-2010).a 
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Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -10.5153 2.4612 -15.339 -5.691 18.25 <.0001 
Caucasian 0.0016 0.0011 -0.0006 0.0038 2.12 0.1458 
Hispanic 0.0002 0.001 -0.0017 0.0022 0.05 0.823 
African_American 0.0056 0.001 0.0036 0.0076 29.86 <.0001 
Percent_Poverty 0.0015 0.002 -0.0025 0.0054 0.55 0.4583 
MedianHHIncome 0 0 0 0 26.62 <.0001 
Construction_Occu 0.0114 0.004 0.0036 0.0192 8.15 0.0043 
SomeHighSchool 0.0111 0.0031 0.005 0.0171 12.83 0.0003 
Adults65nOver 0.0415 0.0023 0.037 0.046 328.43 <.0001 
Male 0.0408 0.0042 0.0326 0.0489 96.05 <.0001 
logPAHPOM -0.0312 0.0576 -0.1441 0.0817 0.29 0.5878 
Smoke 1.0738 1.7844 -2.4235 4.5711 0.36 0.5473 
LogPCP -0.278 0.296 -0.858 0.3021 0.88 0.3476 
Cool_Days -0.019 0.048 -0.113 0.075 0.16 0.6922 
BingeDrink 2.129 3.4424 -4.6181 8.876 0.38 0.5363 
Scale 1.2568 0 1.2568 1.2568 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
 
 
Table C.8 Model 3.b: Analysis of maximum likelihood estimates NYC lung cancer 
deaths (2006-2010).a 
 179 
Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -11.1187 2.0043 -15.047 -7.1904 30.77 <.0001 
Caucasian 0.0029 0.0009 0.0011 0.0047 10.13 0.0015 
Hispanic -0.0038 0.0008 -0.0054 -0.0021 20.39 <.0001 
African_American 0.0028 0.0009 0.0011 0.0045 10.66 0.0011 
Percent_Poverty -0.0014 0.0017 -0.0047 0.002 0.63 0.4278 
MedianHHIncome 0 0 0 0 1.45 0.2279 
Construction_Occu 0.0128 0.0034 0.0061 0.0195 14.1 0.0002 
SomeHighSchool 0.0106 0.0027 0.0054 0.0158 15.97 <.0001 
Adults65nOver 0.0339 0.0019 0.0302 0.0376 316.91 <.0001 
Male 0.0196 0.0039 0.0119 0.0272 25.17 <.0001 
logPAHPOM 0.0972 0.0474 0.0044 0.1901 4.22 0.04 
Smoke 5.8436 1.4053 3.0893 8.5979 17.29 <.0001 
LogPCP 0.2391 0.2412 -0.2337 0.712 0.98 0.3216 
Cool_Days 0.0466 0.0389 -0.0296 0.1228 1.44 0.2304 
BingeDrink -1.0714 2.8143 -6.5873 4.4445 0.14 0.7034 
Scale 1.2227 0 1.2227 1.2227 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
 
 
Table C.9 Model 4.a: Analysis of maximum likelihood estimates NYC COPD deaths 
(2010-2014).a 
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Parameter Estimate Standard 
Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Square 
Pr > ChiSq 
Intercept -11.8488 2.1035 -15.971 -7.726 31.73 <.0001 
Caucasian 0.0020 0.0009 0.0002 0.0037 5.02 0.0250 
Hispanic -0.0009 0.0008 -0.0025 0.0006 1.44 0.2295 
African_American 0.0044 0.0008 0.0028 0.0060 29.34 <.0001 
Percent_Poverty 0.0010 0.0014 -0.0017 0.0038 0.55 0.4581 
MedianHHIncome -0.0000 0.0000 -0.0000 0.0000 0.07 0.7877 
Construction_Occu 0.0002 0.0026 -0.0050 0.0053 0.00 0.9479 
SomeHSorLess 0.0029 0.0016 -0.0002 0.0061 3.44 0.0635 
Adults65nOver 0.0398 0.0019 0.0361 0.0435 440.93 <.0001 
Male 0.0305 0.0045 0.0216 0.0393 45.19 <.0001 
logPAHPOM -0.3115 0.0916 -0.4910 -0.132 11.57 0.0007 
Smoke 1.6030 1.5875 -1.5084 4.7144 1.02 0.3126 
LogPCP -0.1455 0.2637 -0.6624 0.3715 0.30 0.5813 
Cool_Days -0.0003 0.0438 -0.0862 0.0856 0.00 0.9943 
BingeDrink 0.0145 2.9458 -5.7591 5.7881 0.00 0.9961 
Scale 1.0760 0.0000 1.0760 1.0760 
  
aDegrees of freedom (df) for all covariates = 1. Scale df = 0. 
 
 
Table C.10 Model 4.b: Analysis of maximum likelihood estimates South Carolina lung 
cancer deaths (2010-2014).a 
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Parameter Estimat
e 
Standar
d Error 
Wald 95% 
Confidence 
Limits 
Wald 
Chi-
Squar
e 
Pr > ChiS
q 
Intercept -8.4716 1.7657 -11.932 -5.0108 23.02 <.0001 
Caucasian 0.0029 0.0007 0.0015 0.0044 15.68 <.0001 
Hispanic -0.0035 0.0007 -0.0047 -0.0022 27.68 <.0001 
African_American 0.0025 0.0007 0.0011 0.0038 12.94 0.0003 
Percent_Poverty -0.0018 0.0012 -0.0041 0.0006 2.18 0.1398 
MedianHHIncome -0.0000 0.0000 -0.0000 -0.0000 8.71 0.0032 
Construction_Occ
u 
0.0061 0.0022 0.0018 0.0105 7.59 0.0059 
SomeHSorLess 0.0050 0.0013 0.0024 0.0076 13.76 0.0002 
Adults65nOver 0.0365 0.0016 0.0333 0.0396 527.12 <.0001 
Male 0.0078 0.0039 0.0000 0.0155 3.89 0.0486 
logPAHPOM -0.0839 0.0793 -0.2394 0.0715 1.12 0.2899 
Smoke 4.0288 1.3333 1.4156 6.6419 9.13 0.0025 
LogPCP 0.2930 0.2240 -0.1459 0.7320 1.71 0.1907 
Cool_Days 0.0251 0.0371 -0.0475 0.0977 0.46 0.4984 
BingeDrink -2.6457 2.4989 -7.5435 2.2520 1.12 0.2897 
Scale 1.0212 0.0000 1.0212 1.0212 
  
 
 
